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Abstract 
 
Background: Streptococcus pneumoniae is a human pathogen responsible for serious 
diseases such as pneumonia, septicaemia and meningitis. There are over 90 
pneumococcal serotypes, with serotype 1 being a major cause of invasive disease 
worldwide. Despite its high invasiveness, serotype 1 is rarely isolated during 
nasopharyngeal carriage. The aim of this study is to understand the various 
mechanisms that determine the pathogenicity of serotype 1.  
Methods: In vitro techniques were used to determine adhesion to and invasion of 
epithelial cells by serotype 1, and to assess its ability to avoid phagocytosis as well as 
to uncover the mechanisms involved. Furthermore, two in vivo models of infection in 
mice were used to assess serotype 1 virulence and ability to colonise and carry in the 
nasopharynx. Immunological techniques including flow cytometry and enzyme-linked 
immunosorbent assays were applied to determine the host immune responses to 
serotype 1. Furthermore, the gene expression of key virulence factors and metabolic 
pathways was studied in serotype 1 and compared to the less virulent serotype 2 
laboratory reference strain D39. 
Results: Serotype 1 is highly virulent, causing the death of 80-100% of infected mice 
by 48h post-infection when using an invasive pneumonia model. In a nasopharyngeal 
carriage model in mice, serotype 1 is able to establish colonisation, although at a lower 
density and for a shorter period of time than other serotypes. Serotype 1 is not able to 
induce an early recruitment of T regulatory cells or early production of the cytokines 
TGF-β1 and IL-10. The induction of these modulatory cells and cytokines is associated 
with maintenance of carriage and provides protection to the host during pneumococcal 
pneumonia. Therefore, the failure to induce immune-modulatory cytokines and 
regulatory T cells may lead to the clearance of serotype 1 in the nasopharynx and 
reduced protection against pneumococcal dissemination. Moreover, the gene 
expression analysis of key virulence factors and metabolic pathways showed that 
serotype 1 is less adapted to be a successful coloniser but is, in contrast, very successful 
at becoming invasive. 
Conclusions: The unique characteristics of the type 1 capsule are likely to influence 
the immune responses against this serotype; however, differences in the expression of 
non-capsular determinants may also have a key role in the invasiveness of serotype 1. 
Although serotype 1 is not successful at maintaining nasopharyngeal carriage, it is 
highly successful at becoming invasive. 
  
 
 
Acknowledgements 
I would like to express my sincere gratitude to my supervisors Prof. Aras Kadioglu 
and Dr. Dean Everett for their support throughout the past four years. Their vast 
knowledge in the pneumococcal area has guided me through my research allowing me 
to widen my knowledge in the subject and to produce this thesis. Moreover, I am 
immensely grateful for their guidance and encouragement during the ups and downs 
of my PhD study.  
I would like to thank my family who have worked very hard to give me the opportunity 
to get to this stage in my career, even if that meant living in a different country. They 
have all given me great moral support, and at times, I even got some “scientific advice” 
from my father. 
I would like to thank all my friends who have been there for me, especially when I 
needed a break, or even a few formatting lessons. You know who you are. 
Last but not least, I would like to thank all the members in the Kadioglu lab for helping 
me during all the stages of the PhD. I am very grateful for their technical support and 
for the great discussions we have had throughout the years, some of which have led to 
important experiments included in this thesis. However, I am the most grateful for their 
time and moral support during the many frustrating times. Again, you know who you 
are. 
I would like to finish by mentioning a Spanish saying that I have had to remember 
many times during the past four years: 
“La paciencia es la madre de la ciencia” 
  
  
 
 
Table of contents  
1. Introduction ............................................................................................................ 5 
1.1. Streptococcus pneumoniae ................................................................................ 5 
1.2. Epidemiology ..................................................................................................... 8 
1.3. Pneumococcal virulence factors ...................................................................... 10 
1.3.1. Polysaccharide capsule ............................................................................. 11 
1.3.2. Pneumolysin.............................................................................................. 15 
1.3.3. Choline-binding proteins (CBP) ............................................................... 20 
1.3.3.1. Pneumococcal surface protein A (PspA) ........................................... 21 
1.3.3.2. Choline –binding protein A (CbpA) .................................................. 22 
1.3.3.3 Autolysin ............................................................................................. 22 
1.3.4. Hyaluronate lyase (Hyl) ............................................................................ 23 
1.3.5. Neuraminidases ......................................................................................... 23 
1.3.6. PavA.......................................................................................................... 25 
1.3.7. Enolase ...................................................................................................... 26 
1.3.8. PsaA .......................................................................................................... 26 
1.3.9. Immunoglobulin A1 Protease ................................................................... 27 
1.3.10. Pili and sortases ...................................................................................... 28 
1.3.11. Gene expression of virulence factors ...................................................... 30 
1.4. Pneumococcal vaccines ................................................................................... 32 
1.4.1 Pneumococcal polysaccharide vaccines .................................................... 34 
1.4.2. Conjugate pneumococcal vaccines ........................................................... 35 
1.4.3. Serotype replacement ................................................................................ 37 
1.4.4. Potential vaccine candidates ..................................................................... 37 
1.5. Host immune response to pneumococcal infection ......................................... 40 
1.5.1. Immune responses during nasopharyngeal colonisation .......................... 40 
  
 
 
1.5.2. Immune responses during invasive pneumococcal disease ...................... 42 
1.6. The pneumococcus in animal models of infection .......................................... 46 
1.7. Pneumococcal Serotype 1 ................................................................................ 48 
1.7.1. Epidemiology of serotype 1 ...................................................................... 48 
1.7.2. Consequences of low carriage rates in serotype 1 distribution ................. 50 
1.7.3. Epidemiology of serotype 1 in Africa....................................................... 52 
1.7.4. Immune response to serotype 1 ................................................................ 53 
1.7.5. Serotype 1 in animal models of infection ................................................. 54 
1.8. Research aims .................................................................................................. 55 
 
2. Materials and Methods ........................................................................................ 58 
2.1. Pneumococcal bacterial strains ........................................................................ 58 
2.2. Confirmation of serotype 1 isolates by PCR ................................................... 60 
2.3. Determination of presence or absence of the pneumolysin gene ..................... 60 
2.4. Haemolytic assays............................................................................................ 61 
2.5. Growth curves .................................................................................................. 62 
2.6. Tissue culture ................................................................................................... 62 
2.7. Adhesion and invasion assays ......................................................................... 63 
2.8. Capsule thickness ............................................................................................. 64 
2.9. Opsonophagocytic killing assays ..................................................................... 65 
2.10. Complement deposition ................................................................................. 66 
2.11. Invasive pneumococcal disease model in mice ............................................. 67 
2.12. Nasopharyngeal carriage model in mice ........................................................ 69 
2.13. Assessment of long-term protection acquired during carriage ...................... 70 
2.14. Nasopharyngeal competition experiments in mice ........................................ 70 
2.15. Flow cytometry .............................................................................................. 71 
2.16. Cytokine analysis ........................................................................................... 72 
2.17. Determination of antibody levels in serum and nasal mucosa ....................... 72 
  
 
 
2.18. Capsule switch detection ............................................................................... 72 
2.19. RNA extraction .............................................................................................. 73 
2.20. Transcriptomic analysis ................................................................................. 74 
2.21. Statistical analysis .......................................................................................... 75 
 
3. In vitro characterisation of African serotype-1 pneumococcal isolates ........... 77 
3.1. Introduction ...................................................................................................... 77 
3.2. Serotype 1 confirmation by PCR ..................................................................... 78 
3.3. Determination of presence or absence of the pneumolysin gene by PCR. ...... 79 
3.4. Haemolytic assay ............................................................................................. 80 
3.5. Growth curves .................................................................................................. 83 
3.6. Adhesion and invasion assays ......................................................................... 84 
3.7. Capsule thickness ............................................................................................. 86 
3.8. Opsonophagocytosis killing assay ................................................................... 88 
3.9. C3 deposition ................................................................................................... 89 
3.10. Conclusions .................................................................................................... 90 
 
4: In vivo characterisation of the pathogenicity of pneumococcal serotype 1 
isolates during invasive pneumococcal disease ...................................................... 95 
4.1. Introduction ...................................................................................................... 95 
4.2. Virulence testing .............................................................................................. 95 
4.3. Virulence comparison between isolates from different geographic locations . 98 
4.4. Progression (time-line) of infection during invasive disease by serotype 1 .. 100 
4.5. Lung immune cellular profiling during invasive infection with serotype 1 .. 102 
4.6. Cytokine analysis of the lung during invasive infection by serotype 1 ......... 104 
4.7. Blood immune cellular profiling during invasive infection with serotype 1 . 106 
4.8. Cytokine analysis of serum during invasive infection by serotype 1 ............ 108 
4.9. Brain immune cellular profiling during invasive infection with serotype 1 .. 110 
4.10. Cytokine analysis of the brain during invasive infection by serotype 1 ...... 112 
  
 
 
4.11. Conclusions .................................................................................................. 114 
 
5. In vivo characterisation of pneumococcal serotype 1 isolates during 
nasopharyngeal carriage ....................................................................................... 119 
5.1. Introduction .................................................................................................... 119 
5.2. Pneumococcal serotype 1 during nasopharyngeal carriage in mice .............. 119 
5.3. Cellular profiling and cytokine analysis during nasopharyngeal carriage ..... 123 
5.3.1. Nasal associated lymphoid tissue (NALT) ............................................. 124 
5.3.2. Cervical Lymph nodes ............................................................................ 126 
5.3.3. Cytokine production during nasopharyngeal carriage ............................ 128 
5.4. Antibody production during nasopharyngeal carriage................................... 131 
5.4.1. IgA production ........................................................................................ 131 
5.4.2. Total IgG production .............................................................................. 132 
5.4.3. Antibody functionality in vitro ............................................................... 134 
5.4.4. Assessment of memory responses in vivo............................................... 136 
5.5. Capsule switch in serotype 1 during nasopharyngeal carriage ...................... 137 
5.6. In vivo competition experiments between serotypes ..................................... 139 
5.6.1. Co-infections with serotypes 1 and 6B ................................................... 140 
5.6.2. Co-infections with serotypes 1 and 19F ................................................. 142 
5.6.3. Host immune responses during co-colonisation ..................................... 144 
5.7. Conclusions .................................................................................................... 148 
 
6. Identification of orthologous genes that are differentially expressed between 
serotype 1 and the serotype 2 strain D39 during in vitro growth ...................... 153 
6.1. Introduction .................................................................................................... 153 
6. 2. In vitro growth phases................................................................................... 155 
6. 3. Details of mapping of RNA-seq reads .......................................................... 156 
6. 4. Gene expression of A42174 and D39 at different stages of growth ............. 158 
  
 
 
6.5. Functional category analysis during the five phases of growth ..................... 160 
6.5.1. Selection of functional categories ........................................................... 160 
6.5.2. Transport mechanisms ............................................................................ 165 
6.5.2.1. Bacterial secretion system ................................................................ 165 
6.5.2.2. ABC transporter ............................................................................... 166 
6.5.2.3. Phosphotransferase system............................................................... 167 
6.5.3. Metabolism of carbohydrates.................................................................. 168 
6.5.3.1. Fructose and mannose metabolism .................................................. 169 
6.5.3.2. Galactose metabolism ...................................................................... 170 
6.5.3.3. Starch and sucrose metabolism ........................................................ 171 
6.5.3.4. Glycolysis and gluconeogenesis ...................................................... 171 
6.5.3.5. Pyruvate metabolism ........................................................................ 172 
6.5.4. Biosynthesis ............................................................................................ 174 
6.5.4.1. Fatty acid biosynthesis ..................................................................... 174 
6.5.4.2. Peptidoglycan biosynthesis .............................................................. 175 
6.5.5. Two-component system .......................................................................... 176 
6.6. Analysis of gene expression of virulence factors in A42174 compared to D39
 .............................................................................................................................. 177 
6.6.1. Differential expression of virulence factors between A42174 and D39 . 179 
6.6.2. Capsule genes: cps2A, cps2B and cps2K. ............................................... 180 
6.6.3. Pneumolysin............................................................................................ 181 
6.6.4. Surface proteins ...................................................................................... 182 
6.6.4.1. Choline binding proteins: CbpA, CbpC, CbpD, CbpE, CbpG, PspA 
and LytA. ...................................................................................................... 182 
6.6.4.2. Pneumococcal surface adhesins: PsaB and PsaC. ............................ 185 
6.6.4.3. Surface exoglycosidases: NanA, NanB, BgaA and StrH. ................ 185 
6.6.4.4. Enolase ............................................................................................. 187 
6.6.4.5. Hyaluronidase lyase ......................................................................... 188 
  
 
 
6.6.4.6. Pneumococcal adherence and virulence factor A: PavA ................. 188 
6.6.5. Sortase A ................................................................................................. 190 
6.6.6. IgA protease ............................................................................................ 190 
6.6.7. Pyruvate oxidases ................................................................................... 191 
6.7. Conclusions .................................................................................................... 192 
 
7. Discussion ............................................................................................................ 197 
7.1. Introduction .................................................................................................... 197 
7.2. In vitro characterisation of serotype 1 ........................................................... 198 
7.2.1. Haemolytic activity ................................................................................. 198 
7.2.2. Adhesion and invasion ............................................................................ 199 
7.2.3. Capsule thickness .................................................................................... 201 
7.2.4. Opsonophagocytic killing assay ............................................................. 202 
7.2.5. Complement deposition .......................................................................... 202 
7.3. Serotype 1 during invasive disease ................................................................ 203 
7.3.1. Progression of infection .......................................................................... 203 
7.3.2. Host immune responses against invasive pneumococcal disease ........... 205 
7.4. Serotype 1 during nasopharyngeal carriage ................................................... 207 
7.4.1. Bacterial progression .............................................................................. 207 
7.4.2. Host immune responses to pneumococcal nasopharyngeal colonisation 208 
7.4.3. Serotype 1 during nasopharyngeal co-colonisation with other serotypes
 .......................................................................................................................... 210 
7.5. Gene expression of serotype 1 ....................................................................... 212 
7.6. Summary ........................................................................................................ 214 
7.7. Research limitations ....................................................................................... 216 
7.8. Future work .................................................................................................... 216 
 
8. References ........................................................................................................... 219 
  
 
 
9. Appendix ............................................................................................................. 252 
9.1. Appendix 1: Nasopharyngeal carriage by the serotype 1 strain C9174 ......... 252 
9.2. Appendix 2: Functional category analysis of the different growth phases .... 253 
9.3. Appendix 3: Absolute expression of virulence factors in D39 and A42174. 258 
 1 
 
Abbreviations 
APC = Allophycocyanin 
ATP = adenosine triphosphate 
BAB = Blood agar base 
BCA = Bicinchoninic acid assay 
BEAS-2B = Human bronchial-epithelial cell line 
BHI = Brain heart infusion 
Bp = Base pairs 
CAP = Community acquired pneumonia 
CBP = Choline-binding protein 
CD = Cluster of differentiation 
CDC = Cholesterol-dependent cytolysin 
CFU = Colony forming units 
CLN = Cervical lymph nodes 
CP = Capsular polysaccharides 
CPS = Capsule locus 
CSF = Cerebrospinal fluid  
DMEM = Dulbecco’s Modified Eagle’s Medium 
DMF = Dimethylformamide 
DMSO = Dimethyl sulfoxide 
DNA = Deoxyribonucleic acid 
DPBS = Dulbecco's phosphate-buffered saline 
ECM = Extracellular matrix 
EDTA = Ethylenediaminetetraacetic acid 
EEP = Early exponential phase 
ELISA = Enzyme-linked immunosorbent assay 
EMBL-EBI = European Bioinformatics Institute 
ESP = Early stationary phase 
Fc = Fragment crystallizable 
fcR = Fc receptor 
FCS = Foetal Calf Serum 
FI = Fluorescent intensity 
 2 
 
FITC = Fluorescein isothiocyanate 
HBSS = Hanks' Balanced Salt Solution 
HIV = Human immunodeficiency virus 
Hyl = Hyaluronidase lyate 
Ig = Immunoglobulin 
IL = Interleukin 
INF = Interferon 
IPD = Invasive pneumococcal disease 
IVIG = Intravenous immunoglobulin 
KC = Keratinocyte chemoattractant 
KEGG = Kyoto Encyclopedia of Genes and Genomes 
LEP = Late exponential phase 
LSP = Late stationary phase 
Lyt = Autolysin 
MEM = Minimum Essential Medium 
MEP = Mid-exponential phase 
MIP = Macrophage Inflammatory Protein 
MLST = Multi locus sequence type 
MHC = Major histocompatibility complex 
MRC = Medical Research Council 
NADH = Nicotinamide adenine dinucleotide 
NALT = Nasal associated lymphoid tissue 
Nan = Neuraminidase 
NCTC = National collection of type cultures  
NLRP3 = NOD-like receptor family pyrin domain containing 3 inflammasome 
OD = Optical density 
OPKA = Opsonophagocytic killing assay 
OR = Odds ratio 
PAGe1 = Pneumococcal African Genomic Consortium 1 
PavA = Pneumococcal adherence and virulence factor A 
PBS = Phosphate-buffered saline 
PCho = Phosphorylcholine 
PCR = Polymerase chain reaction 
PCV = Pneumococcal conjugate vaccine 
 3 
 
PE = Phycoerythrin 
PE/Cy7 = Phycoerythrin/Cyanine dye7 
pIgR = Polymeric immunoglobulin receptor 
PLNA = Pneumolysin deficient pneumococcus 
Ply = Pneumolysin 
PPV = Pneumococcal polysaccharide vaccine 
PsaA = Pneumococcal surface adhesin A 
PspA = Pneumococcal surface protein A 
PTS = Phosphotransferase system 
RNA = Ribonucleic acid 
RPMI = Roswell Park Memorial Institute medium 
Sec = Secretion systems 
SNP = Single nucleotide polymorphism 
SP = Streptococcus pneumoniae 
SpxB = Pyruvate oxidase 
Srt = Sortase 
SSA = Sub-Saharan Africa 
ST = Sequence type 
TGF = Transforming growth factor 
TLR = Toll-like receptor 
TNF = Tumour necrosis factor 
TOD = Time of death 
TPM = Transcripts per million 
UK = United Kingdom 
USA = United States of America 
WHO = World Health Organisation 
Xpt = Xanthine phosphoribosyltransferase 
ZPS = Zwitterionic polysaccharides 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction 
 
5 
 
1. Introduction 
 
 
1.1. Streptococcus pneumoniae 
Streptococcus pneumoniae, or the pneumococcus, is a Gram-positive, facultative 
anaerobic bacterium that is usually found in pairs (diplococcus), but can also be found 
singularly or forming short chains. As it is diploid in nature, it was for that reason that 
in 1920 Winslow and Broadhurst gave to it the original name of Diplococcus 
pneumoniae, which was later changed by Kauffman to Streptococcus pneumoniae in 
1974 [1-3]. 
The pneumococcus is often found as part of the “normal” nasopharyngeal flora. 
However it can also become pathogenic and, as such, it is a major pathogen for 
humans. The pneumococcus is the causative agent of severe infections such as 
pneumonia, meningitis and sepsis, but it is also responsible for relatively minor 
infections such as otitis media, bronchitis and sinusitis. 
S. pneumoniae causes invasive pneumococcal disease (IPD) mainly in children, the 
elderly and immune-suppressed people [4]. The pneumococcus is a leading cause of 
mortality and morbidity globally resulting in a huge burden to the already fragile health 
systems of developing countries and as such remains a major contributor to high 
childhood death rates in these countries, in particular in sub-Saharan Africa, where the 
incidence of pneumococcal disease is considerably higher (Figure 1) [5]. Furthermore, 
in year 2000 the number of deaths attributed to the pneumococcus in children under 5 
was approximately 826,000, 11% of those belonging to HIV positive children, with 
the highest mortality rates and case-fatality ratios found in sub-Saharan Africa and 
South East Asia [5].  
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In developed countries the pneumococcus is the most common cause of hospitalisation 
due to community acquired pneumonia (CAP), such as in the United Kingdom, where 
there is an average mortality rate of approximately 20%, but can reach 60% in the 
elderly [6].  
 
 
Figure 1. Rate of deaths caused by S. pneumoniae in children under the age of 5 [7]. 
 
 
Even though the pneumococcus can cause severe invasive diseases, it is commonly 
carried asymptomatically in the nasopharynx, which acts as the main reservoir for this 
pathogen. Carriage rates vary depending on age, geographic location, HIV status and 
serotypes that are being carried [8, 9]. Globally, between 30% and 70% of children 
under the age of five carry S. pneumoniae asymptomatically in their nasopharynx 
depending on geographical location [9-11], but the carriage rate is dramatically 
reduced in adults to less than 10% [10-12]. Not only does pneumococcal carriage occur 
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more often in children than in adults, but they are also more likely to have more new 
serotype acquisitions during the same period of time when compared to adults [8].  
The first important contact between the pneumococcus and the host is through 
nasopharyngeal colonisation, which is considered to be a prerequisite for invasiveness 
[13]. The pneumococcus is commonly carried asymptomatically in the nasopharynx 
of healthy adults; however, it can progress into serious diseases such as pneumonia, 
sepsis and meningitis (Figure 2) [13].    
 
 
Figure 2. Pathogenic route for Streptococcus pneumoniae infections [13]. 
 
 
According to previous studies, pneumococcal infection usually occurs after the 
acquisition of a new strain, and pneumococcal disease does not occur without prior 
nasopharyngeal carriage by the same strain [11, 13, 14]. Moreover, the nasopharynx 
acts as a reservoir for the pneumococcus, allowing the pathogen to easily spread within 
communities [12, 13, 15, 16].  Since nasopharyngeal carriage seems to be an inevitable 
step prior to invasiveness it is an area of high importance to study and understand the 
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interactions between the host and the pathogen and the mechanisms by which 
asymptomatic nasopharyngeal carriage can progress into invasive pneumococcal 
disease.   
 
1.2. Epidemiology 
There are more than 90 different pneumococcal serotypes which are characterised 
based on the chemical structure of their polysaccharide capsule. Even though most 
pneumococcal serotypes are capable of colonising the nasopharynx of healthy humans, 
there are some serotypes that are rarely found in carriage. The serotype distribution in 
carriage varies depending on age and geographical location. 
 
Europe USA Asia Africa 
6B, 6A, 19F,  
23F, 14 
6B, 6A, 19F,  
23F, 14 
6, 14, 15,  
19, 23 
6A, 6B, 13, 14, 
 15, 19F, 23F 
Table 1. Common serotypes causing nasopharyngeal carriage in different geographic locations. 
 
As observed in Table 1, the serotype distribution in Europe and USA is quite similar, 
with serotypes 6A, 6B, 19F, 23F and 14 being the most common serotypes [13, 17-
20]; serotypes 6, 14, 15, 19, and 23 the most common serotypes in Asia [13, 21-24]; 
and serotypes 6A, 6B, 13, 14, 15, 19F and 23F the most common serotypes in Africa 
[9, 13, 25-28]. Even though there is some variability, there are some serotypes, such 
as 6, 14, 19 and 23, that are consistently found among all geographical regions in high 
carriage rates, but also as the most common causes of invasive disease. However, there 
are other serotypes such as 1 and 5 that are rarely found in carriage, although they are 
common causes of invasive disease [29]. 
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Some studies have shown that there is a relationship between capsular type and ability 
to cause disease, with some serotypes highly associated with invasive disease and other 
serotypes highly associated with carriage [27]. Therefore, the virulence of an isolate is 
strongly associated with its capsule.  
The “invasive odds ratio” is used to quantify the virulence of a specific serotype. The 
ratio for serotype X is calculated using the formula ORx = (ad)/(bc) where a is the 
number of invasive isolates of a serotype X, b is the number of invasive isolates of 
other serotypes, c is the number of carried isolates of a serotype X, and d is the number 
of carried isolates from other serotypes [30].  
 
 Brueggemann 
et al. [27] 
Hanage 
et al. [31] 
Sa-Leao 
et al. [32] 
Shouval 
et al. [33] 
Kronenberg 
et al. [34] 
Rivera-
Olivero et 
al. [35] 
Study 
period (yrs) 
1994-2001 1995-1999 2001-2003 2000-2004 2002-2004 2006-2008 
Study area 
(country) 
UK Finland Portugal Israel Switzerland Venezuela 
Highly 
invasive 
serotypes 
1, 4, 14, 18C, 
7F, 9V, 19A 
6B, 14, 
18C, 19A, 
4, 7F, 9V, 
38 
1, 3, 4, 5, 
7F, 8, 9N, 
9L, 12B, 
14, 18C, 20 
1, 5, 12F, 
9V, 18C, 
19A, 19F 
1, 4, 5, 7F, 8, 
9V, 14, 19A 
1, 5, 7F, 18, 
3, 14, 19F 
Less 
invasive 
serotypes 
23F, 3, 6B, 
15B/C, 19F 
6A, 11A, 
35F, 3, 9N, 
10, 15, 19F, 
22, 23F 
6A, 6B, 
11A, 
15B/C, 
16F, 19F, 
23F, 34, 
35F, 37 
3, 6A, 6B, 
11A, 14, 
15A, 
15B/C, 21, 
23F, 35B 
3, 7, 10, 11, 
15, 19F, 23, 
6B, 9, 22, 
23F 
6A, 6B, 
19A, 23F 
 
Table 2. Invasive disease potential of different pneumococcal serotypes in different geographical 
locations based on the invasive odds ratio [29].  The serotypes in bold show the ones significantly 
different. 
 
As shown in Table 2, the serotypes that are highly invasive or less invasive can vary 
slightly depending on the geographical location, but some of the serotypes are 
consistently high or less invasive across countries [29]. The highly invasive serotypes, 
and therefore more related to invasiveness than carriage, are serotypes 1, 4, 5, 14, 18C 
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and 7F. On the other hand, the main serotypes that are more associated to 
nasopharyngeal carriage are types 23F, 6A, 6B and 19F [29]. 
Considering that certain serotypes are more invasive than others, it is clear that the 
polysaccharide capsule is an important factor in the virulence of the pneumococcus; 
however, there are other pneumococcal factors that have been shown to play key roles 
during invasive disease and also during nasopharyngeal carriage. 
 
1.3. Pneumococcal virulence factors 
The pneumococcus is an encapsulated bacterium; surrounded by a polysaccharide 
capsule, with a cell wall and cell membrane beneath. Even though the capsule is an 
important virulence factor there are proteins and enzymes located in and on the surface 
of the pneumococcus that also contribute to the virulence of this pathogen by either 
providing host immune evasion mechanisms or by actively interacting with the host 
[36].  
The pneumococcal genome is on average 2,088,534 bp [37]. Around 74% of the 
pneumococcal genome consists of genomic content that is present in all pneumococcal 
isolates (core genome), whilst the rest of the genome consists of genes present in a 
subset of isolates belonging to specific clonal lineages (accessory genome) [37, 38]. 
Many of the accessory genes are clustered in regions of three or more genes which are 
distributed along the pneumococcal genome; these regions are called islets or 
accessory regions [38].  
Through comparative genomic analysis it has been found that highly invasive isolates 
may lack some of the known bacterial virulence factors, suggesting a significant 
redundancy among virulence genes [39]. Having a better understanding of the different 
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virulence factors, their role during carriage and invasive disease and their expression 
during various stages of infection, can lead to the development of potential new 
vaccine candidates. The main pneumococcal virulence factors are shown in Figure 3 
and each factor will be discussed in turn. 
 
 
Figure 3. Selection of the main pneumococcal virulence factors: choline binding protein A 
(CbpA), pneumococcal surface proteins (PspA and PspC), autolysin (LytA), pneumococcal iron 
uptake ABC transporter (Piu), hyaluronidase lyase (Hyl), neuraminidases, sortases, pilus, 
enolases, pneumococcal surface adhesion (PsaA), pneumolysin, IgA1 proteases, and zinc 
metalloprotease B (ZmpB) [12]. 
 
 
 
1.3.1. Polysaccharide capsule 
The pneumococcal capsule is the outer layer of the pathogen and is usually formed by 
neutral or negatively charged chains of polysaccharides. In most serotypes, the 
capsular polysaccharides (CPs) are covalently attached to the peptidoglycan layer of 
the cell wall, as in other Gram positive bacteria [40, 41].  
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The capsule is a key virulence factor that allows the bacteria to evade the host immune 
system by protecting the bacteria against opsonophagocytosis [42], even though it also 
provides highly immunogenic antigens that can facilitate phagocytosis through the 
adaptive immune system, therefore giving protection against the pneumococcus [43]. 
The high immunogenicity in humans has led to the development of serotype specific 
vaccines. There are over 90 different structurally and serotypically distinct serotypes, 
and it is believed that the high diversity in pneumococcal serotypes is an evolutionary 
adaptation for an increased antigenic diversity imposed by the human immune system 
[44]. The geographical distribution of different serotypes is a result of the natural and 
vaccine-mediated immunity against the pneumococcus [45-51].  
Pneumococcal strains that belong to the same serotypes can be further divided in 
subgroups or clonal groups by differences in the sequences of 7 house-keeping genes; 
this method is known as Multi Locus Sequence Typing (MLST) [28]. The sequence 
typing of pneumococci has enabled researchers to study the evolution and expansion 
of clones within the same serotype. It is well known that recombination is the main 
source of genetic exchange in the pneumococcus [37], which can also include alleles 
from the seven house-keeping genes used for MLST [52].  
The majority of pneumococcal isolates produce a capsule, and this capsule can be 
detected using capsular type-specific antisera. Whilst most isolates can be classified 
according to their positive results during type-specific serological tests, a small 
proportion of isolates (0.5-2.2% recovered from sterile sites, and 10% recovered from 
non-sterile sites) show negative results during these tests, reflecting either a lack of 
capsule or the presence of a capsule that cannot be typed to any known serotype [53]. 
Those strains are known as non-typeables [53, 56]. Strains that do not produce a 
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polysaccharide capsule have been shown to be less virulent [56, 57], however some 
unencapsulated strains have been found to cause conjunctivitis [58, 59].  
The presence or absence of capsule in a pneumococcal strain can be preliminarily 
determined by the morphology of the colonies grown on a 5% blood agar plate: whilst 
an encapsulated strain has a mucoid and opaque appearance, an unencapsulated strain 
is flat and transparent (Figure 4) [42]. 
 
 
Figure 4. Colony morphology of the encapsulated serotype 2 strain D39 (A) and the un-
encapsulated serotype 2 strain R6 (B). 
 
 
The colony morphology differs in encapsulated and unencapsulated strains, however 
a flat and transparent colony is not always an indication of unencapsulation. Some 
pneumococcal serotypes have the ability to change the opacity of their colonies, being 
able to show at least three different phenotypes (Figure 5) [60]. Whilst the opaque 
colonies seem to be larger, mucoid and raised/domed, the transparent colonies appear 
smaller and more transparent in the centre, which is known as a bull’s eye. This ability 
of the pneumococcus to change the opacity of its colonies is reversible and it is known 
as phase variation [60]. 
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Figure 5. Different opacity phenotypes derived from a single isolate:                                                                                             
A) Transparent, B) Intermediate and C) opaque [60]. 
 
The transparent colonies have a similar morphology to the unencapsulated strains; 
however, these transparent colonies produce less capsular polysaccharide but more 
teichoic acid than the opaque colonies [57]. Furthermore, the increased production of 
teichoic acid affects the expression of choline-binding proteins, which are surface 
proteins that bind to the choline-containing teichoic acids. Choline binding proteins 
are associated with increased adherence; therefore, transparent variants have been 
shown to be better colonisers whilst opaque variants have been shown to be more 
virulent [57, 60, 61]. Since phase variation depends on production of capsular 
polysaccharides, a thicker capsule is associated with virulence whilst a thinner capsule 
is associated with adhesion and colonisation [60, 61]. 
The genes needed for the production of the pneumococcal capsule are clustered 
together in the cps locus [54], and it has been shown that this locus is in all serotypes, 
located in the same chromosomal location [62]. The cps locus consists of serotype-
specific genes that are surrounded by genes that are common to all serotypes [63]. 
Recombination during nasopharyngeal colonisation is the main source of genetic 
exchange in the pneumococcus; this genetic exchange can occur between different 
pneumococcal strains or between the pneumococcus and other bacterial species, such 
as other streptococcal species [64]. When recombination occurs between different 
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pneumococcal strains there can be exchange of genes within the cps locus, which can 
lead to the acquisition or loss of serotype-specific capsular genes leading to a change 
of the capsular serotype. As a result, these bacteria have a genetic background 
encoding a specific serotype, but a capsule locus of a different serotype [65]. This 
phenomenon is known as capsular switching. Capsular switching was first observed in 
1928 by Griffith [66], but has since been observed on repeated occasions [62, 65, 67-
69]. It is believed that capsular switching occurs regularly in the pneumococcus and it 
can alter the virulence potential of the bacteria [69-71]. Different studies have shown 
that although capsular type has an important effect on virulence, the complex 
interaction of capsular and non-capsular determinants have a synergistic effect on the 
final virulence potential of the pneumococcus [70, 71]. These observations suggest 
that the capsule has an effect on the accessibility and functionality of surface proteins; 
however, an altered expression of other genetic determinants may overcome the effect 
of the capsule on the accessibility and functionality of those surface proteins [70-72].   
In summary, the presence or absence of capsule, its thickness and its type can 
determine the virulence of a specific strain. However, even though the pneumococcal 
polysaccharide capsule is an important virulence factor there are other factors involved 
in the virulence of the pneumococcus. 
 
1.3.2. Pneumolysin 
Pneumolysin is a 53kDa protein that is composed of 471 amino acid residues and is 
synthesised by most pneumococcal isolates [73]. It is a member of the family of 
cholesterol-dependent cytolysins (CDC) that are synthesised by twenty different Gram 
positive bacteria [74]. These CDCs are pore-forming toxins that, at high 
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concentrations, lead to the disruption of cholesterol-containing membranes resulting 
in the lysis of the cell [75].   
Pneumolysin consists of four domains, of mainly β sheet structure. Domain 4 contains 
a conserved tryptophan-rich motif that is thought to interact with cholesterol, being 
therefore essential for cytolytic activity [76, 77, 78]. Whilst domain 4 is responsible 
for interaction with mammalian membranes, domain 3 is responsible for pore 
formation by insertion in the mammalian membrane (Figure 6) [79-81]. 
 
 
Figure 6. Pore formation on eukaryotic membranes by pneumolysin. Soluble monomer consists 
of 4 domains: domain 1 (blue), domain 2 (green), domain 3 (red) and domain 4 (yellow). The 
prepore is formed by the interaction of domain 4 with mammalian cells, whilst the pore forming 
activity relies on domain 3 [78]. 
 
 
As shown in Figure 6, pneumolysin is produced as a soluble monomer which binds to 
cholesterol-containing membranes and then oligomerises into a large ring-shaped 
assembly of around 40 subunits and 30nm diameter; this ring-shaped assembly, known 
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as a pre-pore assembly, can then punch a large hole in the target membrane leading to 
the lysis of the cell [82].  
Pneumolysin is a negatively charged toxin that is produced by the pneumococcus and 
stored in the cytoplasm instead of the membrane of the bacteria [74, 83]. In contrast to 
all other CDCs, pneumolysin lacks a signal peptide that allows the secretion of the 
protein via the type II pathway [84].  
Pneumolysin is released during the exponential growth phases of the pneumococcus, 
but its release is significantly increased during the stationary phase suggesting that 
pneumolysin is secreted due to the activity of autolysin [74, 83, 85]. Nonetheless, some 
observations suggest that there might be other secretion pathways that are autolysin-
independent and domain 2-dependent [86]. The two main observations that support the 
hypothesis of an autolysin-independent secretion pathway are: a) pneumolysin is 
detected in cultures during early stationary phase, when autolysis has yet not occurred 
[87], and most important b) the secretion of pneumolysin is not altered in the absence 
of autolysin [88]. Therefore, there may be an alternative unknown mechanism through 
which pneumolysin is released independently of bacterial lysis. Previous studies have 
shown that pneumolysin can be found bound to the cell wall during growth stages 
where autolysin is not occurring [89]. Moreover, pneumolysin released upon cell lysis 
is not able to reassociate with the cell wall of intact cells indicating that pneumolysin 
is release through an export system which is dependent on the domain 2 of 
pneumolysin [86].    
Since pneumolysin can punch holes in red blood cells the haemolytic activity levels of 
pneumolysin can be determined using an haemolytic activity assay where pneumolysin 
or bacterial lysates are incubated with red blood cells for a short period of time to 
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assess the lytic activity of different types of pneumolysin or different pneumococcal 
strains (Figure 7) [73].  
 
 
Figure 7. Example of haemolytic assay showing the different levels of lysis (A) and the absence 
of lysis (B) of red blood cells after incubation with 1:2 serially diluted pneumolysin and a 
negative control, respectively. 
 
 
 
Even though pneumolysin is present in virtually all pneumococcal isolates, some 
sequence types from serotypes 1, 7F and 8 have been found to produce pneumolysin 
expressing either low or undetectable levels of haemolytic activity [90]. Despite 
producing a low or non-haemolytic version of pneumolysin, these isolates are highly 
invasive, which suggests that the immunomodulatory properties of pneumolysin are 
independent of its cytolytic activity [90].  
At high concentrations pneumolysin is able to cause cell and tissue damage due to its 
ability to lyse cholesterol-containing membranes, but it also contributes to the 
pathogenesis of the pneumococcus at the early stages of the infection where the 
concentration of pneumolysin is low (Figure 8) [91].  
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Figure 8. Effect of pneumolysin at sub-lytic concentration in the host [92]. 
 
At low concentrations pneumolysin can induce apoptosis [93], antibody-independent 
activation of the classical complement pathway by binding to the Fc region of IgG [94, 
95], induction of pro-inflammatory reactions in immune cells [96], and TLR4-
independent activation of the NLRP3 inflammasome [97]. Previous studies have 
suggested that pneumolysin is able to activate TLR4 receptors [98, 99], mediating 
inflammatory responses in the host; however, more recent studies have cast doubt on 
this and have shown that pneumolysin is a potent activator of inflammatory responses 
in the absence of TLR4 activation [97, 100]. It is possible that bacterial 
lipopolysaccharide (LPS) contamination during the pneumolysin purification process 
from recombinant E.coli may be responsible for the activation of TLR4 [92]. 
 
A number of publications have demonstrated the role of pneumolysin in vitro and in 
vivo by using pneumolysin deficient mutants, such as PLN-A (pneumolysin deficient 
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D39, serotype 2), in murine models of infection [12, 101-103]. Pneumolysin-deficient 
pneumococci have significantly lower ability to adhere to respiratory epithelial cells 
and, even though it is able to colonise the nasopharynx of mice for a short period of 
time, it is found at a lower density and is rapidly cleared by the host [101, 102]. A high 
dose intra-nasal challenge usually leads to high numbers of pneumococci in the lung 
and subsequently blood and therefore death of the mouse; however, in the absence of 
pneumolysin bacterial clearance is increased in the lung and this leads to a prolonged 
survival of the mice [103].  
Pneumolysin has pro-inflammatory effects that lead to the release of IL-8, IL-1α, IL-
1β, TGF-β1, TNF-α and the production of IL-6 [92, 97, 104]. Moreover, pneumolysin 
has been shown to be a potent activator of the inflammasome, which plays a key role 
in anti-pneumococcal immunity by promotion of IL-1 and IL-17A responses [97, 92, 
100, 105]. Although cytokine activation by pneumolysin should be detrimental to the 
pneumococcus, it has been shown otherwise: pneumolysin enhances bacterial 
dissemination by increasing tissue permeability due to tissue damage caused by 
uncontrolled production of pro-inflammatory cytokines [102, 106, 107].  
Therefore, pneumolysin is an important virulence factor in the invasiveness of the 
pneumococcus and in its ability to colonise the nasopharynx.  
 
1.3.3. Choline-binding proteins (CBP) 
The pneumococcal cell wall is composed of peptidoglycan, teichoic acid, lipoteichoic 
acid and phosphorylcholine (PCho) [108]. There is a series of surface-exposed proteins 
that are anchored to the cell wall through the PCho [36, 109]. 
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As observed in Figure 9, there are a large number of choline binding proteins, but not 
all of them are produced by all of the pneumococcal strains [109]. The number of CBPs 
can range between 10 (serotype 2, strain R6; the unencapsulated derivative of D39) 
and 15 (serotype 4 strain TIGR4) [108]. The function of the more abundant and 
important choline-binding proteins is discussed further. 
 
 
Figure 9. Choline Binding Proteins anchored to the cell wall of the pneumococcus: LytA, LytB, 
LytC, CbpA, CbpD, CbpE, CbpG, PspA, PcpA, CbpF, CbpH and CbpI [109]. 
 
 
1.3.3.1. Pneumococcal surface protein A (PspA)  
The pneumococcal surface protein A is a CBP that is located in the cell wall of the 
pneumococcus and has a molecular weight that can vary from 67 to 99 kDa [110]. 
PspA is a highly variable protein and this variability is determined by the N-terminal 
module, whilst the C-terminal module enables the protein to anchor to the 
pneumococcal cell wall [36]. It is believed that the exposed negatively charged 
extreme of the protein prevents the binding of C3 to the pneumococcus, therefore 
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inhibiting complement-mediated opsonisation which leads to a reduction in 
phagocytosis of the pneumococcus by the host [111]. 
 
1.3.3.2. Choline –binding protein A (CbpA) 
Also known as pneumococcal surface protein C (PspC), SpaA and PbcA, the CbpA 
consists of 665 amino acid residues and is an adhesion protein that connects the 
teichoic and lipoteichoic acids from the pneumococcal cell wall to glycoconjugates 
from human cells [12]. This protein is connected to the cell wall though the C-terminal 
module, whilst the N-terminal module provides the binding site to the human cells.  It 
is considered to be the most important adhesion molecule in the pneumococcus 
because it is responsible for the adhesion and invasion of the bacteria into the epithelial 
cells of the nasopharynx, lungs and endothelial cells [112]. CbpA adheres to epithelial 
cells by binding to an extracellular domain of the polymeric immunoglobulin receptor 
(pIgR) which is responsible for the transport of secretory IgA to the surface of 
nasopharyngeal epithelial cells. Through this mechanism, pneumococci can use the 
human cellular machinery to be translocated across epithelial cells into the 
bloodstream [113].  
 
1.3.3.3 Autolysin 
Autolysins are a group of enzymes responsible for the degradation of the 
peptidoglycan layer of the cell wall of bacterial organisms [12]. There is a variety of 
autolysins, but the best characterised member of this group is the pneumococcal LytA 
amidase, which cleaves the N-acetylmuramoyl-L-alanine bond of the peptidoglycan 
leading to the lysis of the bacteria [114]. The molecular structure of LytA is composed 
of two different domains: the C-terminal domain which binds the enzyme to the cell 
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wall, and the N-terminal domain which is the functional part [36]. The activity of LytA 
leads to cell lysis and therefore cell death, but it is also involved in cell wall growth 
and turnover [115, 116]. LytA is an important virulence factor because, by lysing the 
cell wall, it facilitates the release of the cytoplasmatic contents of the bacteria, which 
includes the important cytolysin pneumolysin [12, 83, 117]. Different experiments 
with mice have shown that LytA deficient pneumococcal strains are less virulent than 
their parent wild type strains in both intraperitoneal and intranasal challenge models 
[118-121].  
 
1.3.4. Hyaluronate lyase (Hyl) 
Hyaluronate lyase is a surface protein found in a variety of pathogens and its function 
is to breakdown mammalian hyaluronic acid by cleaving the 1,4-glycosidic linkage 
between N-acetyl-β-D-glucosamine and D-glucuronic acid residues [122]. Hyaluronic 
acid is found in mammalian connective tissue and extracellular matrix, and is involved 
in different biological processes such as cell migration and differentiation, wound 
healing and inflammation [36, 85]. The activity of hyaluronidases increases the 
permeability of mammalian tissues therefore increasing the accessibility of the 
pneumococcus to those tissues [36]. As a result of this, the pneumococcus has an 
increased ability to colonise mammalian tissues and to translocate between different 
tissue niches [85].  
 
1.3.5. Neuraminidases 
Neuraminidases, also known as sialidases, cleave terminal sialic acid from host 
glycans located in body fluids and cell surfaces, such as glycolipids, glycoproteins and 
cell-surface oligosaccharides [36]. By doing this, neuraminidases alter the host cell 
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surface, which can lead to an increased susceptibility to pneumococcal colonisation, 
and also releases sugars as carbon and energy sources that are beneficial for the growth 
of bacteria [123]. Three different neuraminidases have been identified in the 
pneumococcus: NanA, NanB and NanC [124]. The NanA gene (nanA) is found in the 
core genome and is therefore found in all pneumococcal strains [125]. While the genes 
encoding NanB and NanC are found in the accessory genome which means that they 
and are not found in all pneumococcal strains [38]. Both NanA and NanB, the most 
well characterised neuraminidases, are secreted proteins, but NanA possesses an 
LPxTG motif present in the C-terminal module, which allows it to bind to the cell wall 
[38, 124, 126]. The different types of neuraminidases have different biological 
properties and different molecular sizes, suggesting variations in their efficacy 
depending on what tissue they are colonising [119]. Supporting this idea is evidence 
that NanC is more commonly detected in strains isolated from cerebrospinal fluid 
(CSF) than in those isolated from nasopharyngeal carriage [125]. Several studies have 
shown that NanA contributes to all the processes that contribute to pneumococcal 
infection: colonisation, dissemination into the lungs [107], sepsis [127] and passage 
across the blood-brain barrier [128]; but there are contradictory studies that have found 
no significant role for NanA, although these studies have come from one laboratory 
and not from several groups as is the case for studies that support an important in vivo 
role for neuraminidases [129, 130].  Experiments performed using NanA and NanB 
mutants, nanA∆ and nanB∆ respectively, show that these proteins are key factors for 
adherence to cultured epithelial cells, which suggests an important role during 
colonisation [123, 127]. In a similar way to pneumolysin, purified neuraminidase is 
toxic for mice but can also confer some degree of protection against pneumococcal 
infection [131]. 
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1.3.6. PavA 
The pneumococcal adhesion and virulence A (PavA) protein is a surface adhesin that 
binds to one of the components of the extracellular matrix (ECM); fibronectin, through 
heparin binding domains [132]. Fibronectin acts as a link between pathogens and 
integrins from host epithelial cells [133]. It has been shown that in other Gram-positive 
bacteria, like Streptococcus pyogenes, the presence of proteins binding to fibronectin 
plays an important role in adherence to epithelial cells and invasion of host cells [132-
135]. The use of pneumococcal PavA deficient mutants in a murine sepsis model has 
shown a reduction in virulence in the absence of PavA [132]. During a long term 
nasopharyngeal colonisation model it was observed that in the absence of PavA, the 
pneumococcus is cleared from the nasopharynx over time, suggesting that PavA has 
an important role during colonisation [136]. In an invasive pneumonia model, where 
infection develops into pneumococcal pneumonia and subsequently progresses into 
septicaemia and death of mice in 80-100% of the cases, the PavA mutant was unable 
to seed into blood and therefore progress into septicaemia and host death. Instead, the 
PavA deficient pneumococcus was able to remain in the lung causing a chronic 
pneumococcal infection without being cleared [136]. In a meningitis model, where the 
infection is introduced through an intracisternal injection, the number of bacteria 
recovered from brain and blood after an infection with PavA deficient pneumococcus 
was consistently lower than in an infection with PavA-producing pneumococcus and 
there was decreased mortality in infections with the PavA mutant [133, 136]. These 
studies suggest that PavA is a key factor during nasopharyngeal colonisation and 
translocation of the pneumococcus between compartments due to its role in adherence 
and invasion to host cells [136]. Even though PavA is known to bind to fibronectin, it 
does not so exclusively, as PavA mutants still retain 50% fibronectin-binding activity 
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[133]. One of the other proteins able to bind to fibronectin is PavB [137]. During 
pneumonia, mice infected with PavB deficient pneumococci exhibit longer survival 
times and a delay in transmigration to the lungs when compared to wildtype 
pneumococcus infected mice [137]. Whilst PavB deficient pneumococci show reduced 
adherence to epithelial cells in vitro, which correlates to the observed decrease in 
bacterial numbers during a nasopharyngeal carriage model, no differences were 
observed in virulence during a meningitis model. These observations suggest that 
PavB is an important virulence factor only in upper respiratory tract infections [137].  
 
1.3.7. Enolase 
Enolase is a pneumococcal surface protein of 47kDa which binds to human plasmin 
and plasminogen, has α-enolase activity and is needed for viability [138]. The serine 
protease plasmin, the activated form of the glycoprotein plasminogen, plays a crucial 
role in fribrinolysis (dissolving blood clots), homeostasis and degradation of the 
extracellular matrix (ECM) [139-141]. It is thought that enolases open the plasminogen 
molecule conformation leading to an enhanced plasmin generation which gives the 
bacteria an efficient proteolytic activity that targets plasmin substrates in the host 
(fibrin, fibronectin, thrombospondin, laminin, and von Willebrand factor) [142]. 
Binding of the pneumococcus to circulating plasminogen also enhances bacterial 
attachment to host cell surfaces which has been shown to increase virulence in a mouse 
model [143, 144]. 
 
1.3.8. PsaA 
PsaA is a metal ion-binding lipoprotein that, alongside PsaB and PsaC (an ATP 
binding protein that releases ions into the cytoplasm and an integral membrane protein 
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that transfers the ions in and out, respectively), composes the ABC tranporter for Mn2+ 
or Zn2+ uptake in S. pneumoniae [145]. Manganese is an element that has been shown 
to be essential for the growth and survival of the pneumococcus by acting as a cofactor 
for a large number of enzymes [146, 147]. Whilst the pneumococcus needs manganese 
to maintain cellular functions, large concentrations of this element can be toxic, which 
results in the need to have mechanisms, such as the ABC transporter, to carefully 
regulate intracellular manganese homeostasis [145, 148]. Zinc competes with 
manganese for the binding site on the ABC transporter inhibiting its acquisition [149].  
PsaA is located on the surface of all known pneumococcal serotypes, and not only is 
part of the ABC transporter, but can also act as an adhesin [150, 151]. Some studies 
performed with PsaA deficient pneumococcus have shown that in the absence of PsaA 
there is a reduction in virulence and nasopharyngeal colonisation in vivo and a 
reduction in adherence to epithelial cells in vitro [152].  
 
1.3.9. Immunoglobulin A1 Protease 
Streptococcus pneumoniae produces a protease that specifically cleaves human serum 
IgA1 and secretory IgA. IgA is an immunoglobulin that plays an important role in 
mucosal immunity by inhibiting adhesins and toxins, and enhancing pathogen 
clearance [153, 154]. The immunoglobulin A1 protease is an enzyme that cleaves a 
proline-threonine bond in the hinge region of the immunoglobulin, which results in the 
formation of intact Fc and Fab fragments [153, 155]. Since the Fab fragments alone 
are not able to bind to antigen, the activity of IgA1 protease leads to antibody 
inactivation eliminating the protective role of IgA, making the presence of IgA1 
protease an important factor in the pathogenesis of S. pneumoniae [153, 155].  
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1.3.10. Pili and sortases 
Pili or fimbriae are long structures composed of associated protein subunits called 
pilins or fimbrins that are assembled by sortases [156, 157]. Pili were firstly thought 
to be characteristic of Gram-negative bacteria until they were first observed in Gram-
positive bacteria in 1968 [158]. Since then, a wide range of Gram-positive bacteria 
have been found to express pili including S. pneumoniae [159].  
In the pneumococcus the pili are approximately 3nm in diameter with a length that can 
vary between 0.1 and 5 µm, and can be visualised only using immunoelectron 
microscopy (Figure 10) [156].  
 
 
Figure 10. Immunoelectron microscopy of the main pilus component in S. pneumoniae (RrgB) 
[160]. 
 
 
In all Gram-positive bacteria, the genes encoding pilus proteins (i.e. RrgB) and 
sortases are clustered in the same genetic locus and they are transcribed in the same 
direction, indicating that they are part of an operon [160].  
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There are two important sortases in Gram-positives: sortase D (SrtD) and sortase A 
(SrtA). SrtD is responsible for the polymerisation of pili, whilst SrtA is responsible for 
the anchoring of the pili to the cell wall (Figure 11) [157].  
 
 
Figure 11. Formation of pili via the sortase-assembly mechanism: sortase D is responsible for 
the binding of different pilins (green and blue boxes), whilst sortase A is responsible for the 
anchoring of the pilus to the cell wall [157].  
 
In S. pneumoniae two different pathogenicity islands have been found to contain pili 
genes, the widely known PI-1 (rlrA islet) and the PI-2 [38]. Not all pneumococcal 
isolates express pili however. The rlrA pilus islet is present in genetically related 
pneumococcal strains preferentially associated, but not only, with the carriage 
associated serotypes 6B, 9V, 19F and 35B [38, 161]. On the other hand, PI-2 is 
associated with serotypes 1, 2, 7F, 19A and 19F [38]. Since these pathogenicity islands 
are flanked by inverted repeats, which are characteristic of mobile genetic elements, 
isolates containing pili can be found globally; however, pili are present in 
approximately 30% of invasive pneumococcal isolates [38, 160, 162, 163]. 
Pili appear to be very important in the interaction of the pneumococcus with the host 
epithelial cells. The pilin subunits RrgA encoded by the pathogenicity islet rlrA acts 
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as an adhesin which binds to respiratory cells: RrgA deficient pneumococcus show 
reduced adherence to epithelial cells, whilst an overexpression of RrgA shows increase 
adherence [156]. 
Non-piliated isolates have been shown to be less virulent than piliated isolates in 
pneumonia and bacteraemia models of infection in mice. Moreover, it was observed 
that pilus expression enhances adherence to lung epithelial cells and piliated isolates 
were able to out-compete non-piliated isolates in nasopharyngeal colonisation models 
in mice. In addition, it was also shown that pili can stimulate host inflammatory 
responses by inducing IL-6 and TNF production [159]. 
 
1.3.11. Gene expression of virulence factors 
The expression of many pneumococcal genes is influenced by external stimuli [164]. 
Furthermore, it has been shown that the gene expression of virulence factors change 
during the different in vitro growth stages of the pneumococcus [164]. Genes encoding 
proteins responsible for the biosynthesis of the polysaccharide capsule, fatty acid 
biosynthesis and cell division have been shown to be down-regulated during the 
stationary phase when compared to the exponential phase [164], while genes encoding 
for neuraminidases, proteases and heat shock proteins were found to be up-regulated 
during the stationary phase [164]. These observations suggest that the expression of 
specific genes change during different growth phases of the pneumococcus, where 
genes involved in growth and division are up-regulated during the exponential growth 
phase, when the pneumococcus is growing quickly. 
In vivo studies of pneumococcal gene expression have been extensively done using 
microarrays, although the gene expression of only a small range of serotypes has been 
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studied, with the serotype 2 strain D39 being the most commonly used [165-169]. 
Studies of in vivo pneumococcal gene expression were mainly focused on the 
expression of genes encoding Ply, CbpA, PspA, PsaA, Cps2A, NanA and SpxB [167, 
168]. Those studies showed that the expression of different genes vary during an intra-
peritoneal infection where psaA and cps2A were highly up-regulated during the early 
hours of infection, whilst the up-regulation of ply and pspA occurred in later stages of 
the infection. In contrast, no differences were observed in the expression of cbpA 
throughout the course of infection [168]. Although gene expression in vitro varies 
when compared to in vivo infections, it was shown that genes up-regulated during in 
vivo infection, were also more expressed in vitro when compared to other virulence 
factors [168]. 
Other studies have investigated the differential expression of specific virulence factors 
in different sites of infection (i.e. nasopharynx, lungs and blood); these studies showed 
that although some genes are up-regulated in all infection sites, some are mainly 
expressed in the nasopharynx [167]. These observations emphasise the idea that certain 
proteins are important during nasopharyngeal carriage, others are important for 
invasiveness and others have an important role during both nasopharyngeal carriage 
and invasive disease. 
Gene expression is an important tool to understand the pathogenesis of S. pneumoniae; 
however, little is known about the effect of differential gene expression in the 
differences observed in pathogenesis of different serotypes. Therefore, the study of 
differential gene expression between different serotypes may help elucidate the 
mechanisms through which some serotypes are more invasive than others. 
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Differential gene expression of key pneumococcal virulence factors will be discussed 
further in Chapter 6. 
 
1.4. Pneumococcal vaccines 
In 1880, S. pneumoniae was independently isolated in New Orleans and Paris by 
George M. Sternberg and Louis Pasteur respectively, and it was later recognised in 
1881 in two separate publications, to be the principal cause of pneumonia, meningitis 
and bacteraemia [3, 170-172]. The first person to demonstrate humoral immunity in 
rabbits following pneumococcal infection was Albert Fränkel, who in 1886, observed 
that rabbits that had recovered from a pneumococcal infection were resistant to 
reinfection [3]. Between 1895 and the 1940s, anti-pneumococcal serum was 
commercially available through the H.K. Mulford catalogue [3, 173]. During the early 
1900s efforts were made to purify and concentrate type-specific antiserum, which was 
then used to treat patients resulting in a reduction in mortality cases [173- 176].  
Also during the early 1900s a different type of approach was taken in the war against 
pneumococcal infections: immunisation with whole-cell killed pneumococcal 
vaccines [3]. Sir Almroth E. Wright, a British physician, performed a series of clinical 
trials during the 1910s to test the efficacy of whole-cell killed pneumococcal vaccines, 
in which they were using circulating strains in their whole cell preparations, but not 
considering serotype-specificity [177]. In 1916-17, Oswald T. Avery and Alphonse R. 
Dochez isolated the pneumococcal polysaccharide capsule which allowed the 
pneumococcus to be classified by serotypes.  
Development of the ‘quellung reaction’ by Franz Neufeld, a method in which 
antibodies from sera exposed to previous pneumococcal infection bind specifically to 
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subsets of pneumococcal capsules, along with the realisation of serotype-specificity 
(Figure 12), led to the development of serotype-specific whole-cell killed 
pneumococcal vaccine  [3, 178, 179].  
 
 
Figure 12. Pneumococcus positive (A) and negative (B) for the ‘quellung reaction’. Serotype-
specific anti-capsular antibodies bind to the pneumococcal capsule allowing its visualisation; the 
capsule appears to swell due to the increased surface tension [180].  
 
 
In 1927, Oscar Schiemann and Wolfgang Casper discovered the immunogenicity of 
the polysaccharide capsule, whilst in 1929, Avery conjugated pneumococcal 
polysaccharides to proteins to improve immunogenicity [3, 181, 182]. 
Between the 1930s and the 1970s, various pneumococcal polysaccharide vaccines 
(PPVs) were developed and tested, until 1977, when a 14-valent PPV license was 
approved [3]. PPV14 targeted 70-80% of invasive pneumococcal disease in the US 
and was indicated for people above 50 and for anyone older than 2 with certain 
underlying health conditions [3, 183, 184]. The need for protection against a wider 
range of serotypes resulted in the development of the PPV23 in 1983, which covered 
approximately 87% of pneumococcal bacteraemic disease in the US [185]. 
Chapter 1: Introduction 
 
34 
 
Polysaccharide vaccines have been shown to protect more efficiently against 
bacteraemia than pneumonia, but they protect more against pneumonia than 
nasopharyngeal carriage [186-188].  
 
1.4.1 Pneumococcal polysaccharide vaccines 
Pneumococcal polysaccharide vaccines, such as the PPV23, have been shown to be 
highly immunogenic in adults, unfortunately children under five years of age are 
unable to produce a significant increase in antibody after vaccination [186, 189, 190].  
The capsular polysaccharide is poorly immunogenic in children because it produces 
antibodies through T-cell-independent mechanisms [12]. T cell independent 
mechanisms produce an immune response that is not long-lasting, and boosters do not 
increase its duration of protection [190, 191]. Children under the age of 2 have an 
immature immune system which makes the polysaccharide vaccines not effective in 
that age group. Moreover, it was observed that PPV23 was not able to enhance herd 
protection due to its reduced effect in nasopharyngeal carriage [190]. The inefficiency 
of polysaccharide vaccines in children, a group at high risk of invasive pneumococcal 
disease, and its inability to provide “herd immunity” led to the development of 
vaccines in which the capsular polysaccharides were conjugated to a protein 
(diphtheria carrier protein) to increase the immunogenic effect of the vaccine in 
children; conjugated vaccines activate a T-cell dependent antibody response [3, 192]. 
The first pneumococcal conjugated vaccine to be licensed in the US was PCV7, which 
came in 2000, thirteen years after the first protein-conjugated vaccine to be licensed: 
the vaccine against Haemophilus influenzae type b [3].  
In summary, the limitations of polysaccharide vaccines are: lack of immunogenicity 
in small children, transient efficiency in the healthy elderly, lack of efficiency in the 
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frail elderly, failure to induce mucosal immunity and low impact on nasopharyngeal 
carriage which results in low herd protection [192]. Nonetheless, PPV23 is, together 
with PCV13, currently recommended to all adults over the age of 65 in the US [190, 
193]. 
 
1.4.2. Conjugate pneumococcal vaccines 
In the US, before the introduction of the first pneumococcal conjugate vaccine (PCV7), 
there were around 65,000 cases of invasive pneumococcal disease (IPD) annually. Of 
these cases, 25% occurred in children under five, and 80% of those cases were caused 
by serotypes covered by PCV7 [194, 195]. Shortly after the introduction of PCV7 into 
the US, there was a reduction in cases of IPD; even though there was a higher reduction 
in the incidence of cases covered by PCV7-types (94%), there was also an overall 
reduction of cases by all serotypes (45%) [194]. Interestingly, it was observed that this 
reduction in IPD cases was not only seen amongst vaccinated children, but also 
amongst unvaccinated children and adults, which suggests that vaccination with 
conjugate vaccines provides herd protection [194, 196, 197].  
Pneumococcal conjugate vaccines have been shown to reduce nasopharyngeal carriage 
and therefore transmission [198]. However, an increase in IPD cases caused by 
serotypes not included in the 7-valent vaccine (i.e. serotype 19A) highlighted the need 
of developing new vaccines with broader serotype coverage [3, 194]. Since PCV7 was 
first developed, two more pneumococcal conjugate vaccines have been licensed, 
PCV10 and PCV13, whilst PCV15 is currently being developed for licensure [199]. 
Serotypes 1 and 5 were included in PCV10 and PCV13 because they cause 
approximately 10% of IPD cases globally, a number that goes up to a third of the cases 
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in some developing countries [200]. Nonetheless, the efficacy of PCV10 and PCV13 
against those serotypes has been shown to be limited [192, 193].  
Serotype distribution varies between countries, and even though PCV7 is highly 
effective in some countries, in some developing countries it only provides 25% 
coverage against IPD-causing strains [201]. Therefore, the development of PCV10 and 
PCV13 should further reduce the paediatric IPD mortality rates in developing 
countries, where the incidence of pneumococcal disease is higher [202-204]. Recent 
studies have been evaluating the effect of PCV10 and PCV 13 showing a reduction in 
invasive disease caused by serotype 19A since the introduction of PCV13 [205]. 
Furthermore, there was a reduction in invasive disease in developing countries, such 
as Brazil and Peru, after the introduction of PCV10 and PCV13 [206-208].  
A summary of the serotype coverage and the year of introduction of the main 
pneumococcal vaccines can be found in Table 3. 
 
Vaccine 
 
Serotype coverage Year/place of introduction 
PPV14 1, 2, 3, 4, 5, 6A, 7F, 8, 9N,  
12F, 18C, 19F, 23F, 25F 
1977 USA 
PPV23 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 
12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 
22F, 23F, 33F 
1983 USA 
PCV7 4, 6B, 9V, 14, 18C, 19F, 23F 2000  (infants) USA and Europe 
PCV10 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F 2009  (infants) Europe 
PCV13 1, 3, 4, 5, 6A, 6B, 7F, 9V,  
14, 18C, 19A, 19F, 23F 
2010 (infants) in USA and Europe 
2011 (adults) in USA and Europe 
Table 3. Main pneumococcal vaccines, serotype coverage and years of introduction (3). 
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1.4.3. Serotype replacement 
Conjugate vaccines effectively reduce the risk of carriage and transmission of 
serotypes covered by the vaccines. In contrast, the risk of carriage and transmission of 
serotypes not covered by the vaccines has increased, resulting in a higher incidence of 
IPD caused by non-vaccine-covered serotypes [198]. Globally, the main serotypes 
responsible for IPD are 1, 5, 6A, 6B, 14, 19F and 23F, with serotypes 1, 5 and 6A not 
included in the first PCV, as previously mentioned [200, 209]. 
The serotype distribution profile of the pneumococcus has fluctuated over time due to 
factors such as changes in socio-economic conditions, demographic changes, 
introduction of antibiotics, adaptations by the pneumococcus and most importantly: 
the introduction of vaccines [210, 211]. After the introduction of PCV7 an increase of 
IPD cases by non-PCV7-covered serotypes was observed in different countries, most 
of this increase being attributable to serotype 19A which is now included in PCV13 
[49, 200, 212- 217]. The fact that IPD cases by non-vaccine-covered serotypes increase 
after the introduction of a vaccination program suggests that developing vaccines with 
higher serotype coverage will constantly be needed. Unfortunately, the development 
of conjugated vaccines that cover all or most of the serotypes is not feasible due to the 
reduced cost-effectiveness [192, 218]. For that reason, the current research towards 
new vaccines is focusing on the development of vaccines based on broadly 
representative, serotype-independent and highly-conserved pneumococcal antigens 
[192].  
 
1.4.4. Potential vaccine candidates 
The current approach for new-generation vaccines is the development of non-
polysaccharide antigens that are common in most pneumococcal serotypes [201]. 
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These new vaccines are: protein vaccines, DNA vaccines, and whole-cell vaccines 
with low-level expression of capsular polysaccharides [192, 218]. Currently, the more 
developed potential vaccines are protein vaccines.  
Many of the pneumococcal virulence factors have been suggested as potential vaccine 
candidates (Table 4); however, PspA, PsaA and pneumolysin are the leading 
candidates [219]: recent publications show that PspA conjugated to a flagella protein 
is able to enhance immunity against pneumococcal infections in mice [220]; 
immunisation studies with PsaA showed increased protection against carriage; 
pneumonia and bacteraemia in mice [221-223]; and previous immunisation studies in 
mice have shown increase protection against invasive disease after immunisation with 
pneumolysin [131, 73].  
Even though these proteins can individually enhance immunity against the 
pneumococcus, it has been shown that in combination, this immunity is increased 
[224-226].   
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Protein Ligand 
Pneumococcal surface adhesin A (PspA) E-cadherin 
 
Pneumococcal surface protein C (PspC) 
Polymeric Ig receptor 
FH domain of complement factor H 
Vitronectin 
Choline-binding protein E (CbpE) Plasminogen 
α-Enolase Plasminogen 
Fibronectin-binding protein A (PfbA) Fibronectin and plasminogen 
Pneumococcal adherence and virulence 
factors A and B (Pav A/B) 
Fibronectin and plasminogen 
Polyhistidine triad (Pht) proteins Unknown 
Pneumococcal serine-rich repeat protein 
(Psrp) 
The intermediary filament protein 
PcpA Uncertain 
Pneumococcal pili PI-1 and PI-2 Collagen, fibronectin and laminin 
Type IV pilus DNA 
Neuraminidases A and B (Nan A/B) Expose cryptic adhesion sites on target 
cells 
Pneumococcus-specific glycosyl 
hydrolase 25 (GHIP) 
Exposes cryptic adhesion sites on 
target cells 
Hyaluronate lyase (SpnHL) Hydrolyses extracellular matrix 
NADH oxidase Contactin 4, chondroitin 4, 
sulphotransferase, laminin 
Pneumococcal protein endopeptidase O 
(PepO) 
Plasminogen and fibronectin 
Zinc metalloproteinase B (ZmpB) Collagen IV 
Cell wall-associated serine protease (PtrA) Collagen IV 
Autolysin A (LytA) Promotes autolysis and release of Ply 
Pneumolysin (Ply) Facilitates invasion via pore-forming 
activity and activates NLRP3 
inflammasome 
Table 4. Pneumococcal proteins with vaccine potential [192]. 
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1.5. Host immune response to pneumococcal infection 
As previously described, the pneumococcus is a common commensal of the 
nasopharynx of healthy humans, however asymptomatic colonisation can progress into 
invasive disease depending on different factors such as viral infections, age, 
pneumococcal serotype or most importantly, host susceptibility [227]. The main risk 
groups for IPD are children, the elderly and the immunocompromised, which suggests 
that an impaired host immune system leads to increased progression of pneumococcal 
nasopharyngeal carriage into invasive disease [12, 13]. In children, the immaturity of 
the immune system leads to poor immunogenesis and therefore reduced protection 
against the pneumococcus [186, 189, 190]. In the elderly, the increased susceptibility 
to pneumococcal disease is due to a variety of age-related changes in the immune 
system [92]: reduced cough reflex [228], reduced responsiveness by macrophages and 
monocytes to TLR ligands [229], defects in innate immune chemotaxis [230], impaired 
dendritic cell function [231], reduced T cell responses [232], and reduced B cell 
antibody production [233]. 
Due to the high incidence of pneumococcal carriage in the population, there is high 
exposure of the respiratory mucosa to the pneumococcus [92]. For that reason, humans 
have developed a plethora of innate and acquired, humoral and cellular immune 
responses to the pneumococcus [92].  
 
1.5.1. Immune responses during nasopharyngeal colonisation 
The nasopharynx is usually where the first encounter with the pneumococcus occurs; 
for that reason, the host immune responses taking place in the nasopharynx influence 
the clearance or persistence of carriage and its potential progression into invasive 
disease [92]. Asymptomatic carriage is not only beneficial to the pathogen, but also to 
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the host where it provides a natural boosting mechanism to sustain protective immunity 
against disease in adults [92, 234]. However, a dysregulation in the balance between 
immune tolerance and inflammatory responses could lead to the development of 
invasive disease [92, 104, 235]. 
As observed in Figure 13, the host has resistance mechanisms to detect and eliminate 
invading pathogens; however, some of these resistance mechanisms can also cause 
damage in the host through inflammation. For that reason, the optimal immune 
response is determined by the fine balance between efficient pathogen clearance and 
acceptable levels of inflammation [235]. 
 
 
Figure 13. Host resistance and tolerance defence strategies during infection [235]. 
 
 
Previous studies have shown that S. pneumoniae induces active transforming growth 
factor (TGF)-β1 and T regulatory cells in the nasopharynx of mice during the early 
stages of colonisation, an induction that is crucial for prolonged pneumococcal 
carriage [104]. Moreover, elevated levels of T regulatory cells and Interleukin-10 (IL-
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10) in the nasal associated lymphoid tissue (NALT) has been associated with 
persistence of pneumococcal carriage [236]. In summary, pneumococcal induction of 
TGF-β1, IL-10 and T regulatory cells in the nasopharynx limits the production of pro-
inflammatory cytokines reducing tissue damage and providing an immune-tolerance 
mechanism that allows prolonged pneumococcal carriage [92, 104, 236]. In the 
absence of TGF-β1, IL-10 and T regulatory cells induction the pneumococcus is 
cleared and nasopharyngeal carriage is prevented [104]. Since nasopharyngeal 
carriage is a pre-requisite for invasiveness it would be acceptable to consider 
nasopharyngeal carriage as unfavourable for the host; however, there is a production 
of anti-pneumococcal antibodies during carriage that protects the host from invasive 
disease [92, 237]. 
 
1.5.2. Immune responses during invasive pneumococcal disease 
Anti-pneumococcal antibodies are produced during asymptomatic nasopharyngeal 
carriage, with IgM and IgG being the most common types produced in serum, and IgA 
the most common type produced in mucosal surfaces [92, 234, 238-242]. These 
antibodies act as a protective mechanism against invasive disease; however, other host 
immune mechanisms are also involved in the clearance of the pneumococcus during 
invasive disease [92]. 
Pneumococci can descend from the upper respiratory tract (nasopharynx) to the lower 
respiratory tract (lungs) by aspiration of respiratory secretions; however, the lungs 
have been adapted to restrict bacterial growth by producing enzymes, such as 
lysozyme and surfactant proteins, capable of killing external pathogens [92]. 
Normally, alveolar macrophages are able to phagocytose pathogens and to maintain a 
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non-inflammatory state by producing anti-inflammatory mediators such as TGF-β and 
IL-10 [92, 104].  
 
 
Figure 14. Phagocytosis process [243]. 
 
As observed in Figure 14, phagocytes such as macrophages and neutrophils, ingest 
pneumococci through an opsonin-dependent mechanism in which pneumococci have 
been opsonised by immunoglobulin or complement and are detected by the phagocytes 
through the Fc receptor (FcR) or the complement receptor (CR) respectively [13, 92]. 
The complement system is a collection of soluble proteins present in blood and other 
body fluids that are responsible for opsonisation of invading organisms, acting as early 
protection during infection [92, 243]. It is organised into three different pathways 
depending on how the activation is initiated: the lectin pathway (initiated by mannose-
binding lectin and ficolins which bind to carbohydrate structures on microbial 
surfaces), the classical pathway (initiated by the recognition by C1q of microbial 
surfaces or antibodies already bound to the surface of the pathogen) and the alternative 
pathway (initiated by spontaneous hydrolisis of C3 which can then bind to bacterial 
surfaces) [243]. When activated, these pathways cleave the complement protein C3 
into its active form C3b, which acts as an active opsonin stimulating phagocytosis by 
neutrophils and macrophages through the complement receptor (CR) [92, 243]. The 
complement system also leads to the lysis of pathogens via formation of a membrane-
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attack complex (MAC) which disrupts the bacterial cell membrane causing lysis. 
However, the pneumococcus produces a phosphoglycerate kinase that acts as a 
complement inhibitor by inhibiting the formation of the membrane attack complex 
(MAC) [244]. 
Mouse models of infection have shown the importance of complement in the immunity 
against the pneumococcus; mice with genetic deficiencies in all three complement 
pathways have shown increased susceptibility to pneumococcal infections [92, 245-
247]. 
 
Figure 15. Mechanisms of complement identification of S. pneumoniae and the bacterial factors 
that prevent complement activation. The mechanisms of initiation by S. pneumoniae are 
indicated at the top and major immune effects of complement activation are shown in the light 
blue boxes. The S. pneumoniae factors interfering with complement activity are shown in 
coloured balloons at their recognized sites of action [92]. 
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As shown in Figure 15, the complement system is able to recognise the pneumococcus 
through recognition of: phosphocholine from the cell wall, antibody bound to surface 
antigens, capsular polysaccharide and components of selected serotypes [92]. 
However, the pneumococcus has developed mechanisms to inhibit complement 
activation. Some of the inhibition mechanisms found in the pneumococcus are: 
capsule, which although it can be recognised by some complement proteins it can also 
reduce susceptibility to complement by blocking access to surface protein antigens 
[248-250]; the pneumococcal surface protein PspA, which inhibits C1q binding and 
therefore inhibits the classical pathway [329, 330]; and the pneumococcal PspC, which 
is able to inhibit both the alternative and the classical pathways by binding to factor H 
and C4BP respectively [251, 252]. 
 
Both macrophages and neutrophils are phagocytes involved in the clearance of the 
pneumococcus during infection; whilst macrophages are present in healthy lungs 
aiding to control bacterial growth, neutrophils are recruited during pneumonia via 
inflammatory cytokine recruitment [92, 253]. During the early stages of pneumonia 
the host needs to rely on innate immune responses and memory immune responses 
[92]. In mice, neutrophils start to accumulate in the lungs between 12 and 16 hours 
post-infection which coincides with a period of rapid bacterial growth occurring after 
a decline in bacterial numbers [254]. The interaction of the pneumococcal surface with 
Toll-like receptor 2 (TLR2), an innate immune receptor present on the surface of 
mammalian cells, leads to cytokine secretion (TNF-α, IL-1, IL-6, IL-8, IL-10, IL-12 
and IL-17) which is responsible for pneumococcal clearance in the lung [92, 255, 256]. 
At this stage, if the infection is not contained the pneumococcus can cause IPD by 
translocating into the blood and causing bacteraemia [92].  
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1.6. The pneumococcus in animal models of infection  
The pneumococcus is a human-adapted commensal pathogen; however, many 
vertebrates like mice, ferrets and even Zebra fish can be infected with pneumococci, 
and reproduce many aspects of invasive human disease [38].  
The most common animal used to study the pathogenesis of the pneumococcus is the 
mouse due to: a) the genomes of many mouse strains have been sequenced and 
therefore their genome can be manipulated to create knock-out or transgenic animals 
[257], b) there is a variety of well-characterised strains with varying susceptibilities to 
pneumococcal disease [258, 259], c) there is a variety of anti-mouse antibodies and 
other immunological resources available for immunological studies in mice, and d) 
there is a number of well-defined models that mimic human pneumococcal disease 
[260]. 
There are two types of mouse strains: inbred and outbred. Inbred mice, such as 
BALB/c and CBA mice, offer reproducibility of responses, which provides a more 
uniform phenotype during colonisation and infection [260]. Outbred mice on the other 
hand, offer phenotypic diversity which mimics the natural variation in the human 
population of immune responses during nasopharyngeal colonisation and infection 
[260]; for that reason outbred mice were used in this study.  
In animal models of infection there is a large variation in the outcome of disease 
depending on the dose, the administration route, the mouse strain, the pneumococcal 
strain and even the sex of the mice [261].  For that reason, it is important to use the 
same variables throughout one specific study to allow comparability between 
experiments. Two well characterised mouse models of infection were used during this 
study: the invasive pneumonia and nasopharyngeal carriage models [254, 238]. 
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Pneumococcal serotype 2 (strain D39) is a commonly used laboratory strain, with a 
large amount of mechanisms of pathogenesis and host immune responses to 
pneumococcal infection based on studies done using D39 [107, 121, 238, 254, 258, 
260, 262-265]. Published data using the invasive pneumonia model used in this study, 
showed that all mice intra-nasally infected with 106 bacteria in a 50µl volume of PBS 
showed signs of disease by 24h post-infection, and had become moribund by 48h post-
infection [254]. Furthermore, in published data which established the nasopharyngeal 
model used in this study, D39 was able to sustain stable colonisation in the 
nasopharynx of mice intra-nasally infected with 105 bacteria for a minimum of 28 days 
(Figure 16) [238].  
 
 
Figure 16. Density of nasopharyngeal colonisation by D39 expressed as Log CFU/mg of total 
homogenised nasopharynx [238]. 
 
 
Since these models have been well-characterised, the virulence as well as the density 
and duration of nasopharyngeal colonisation of D39 can be used as a reference to 
compare and study the virulence and nasopharyngeal colonisation patterns of other 
strains and serotypes. 
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1.7. Pneumococcal Serotype 1 
Serotype-1 was one of the first serotypes to be identified [266]. It has a zwitterionic 
capsular polysaccharide (ZPS), which differs from other pneumococcal serotypes 
[267]. Whilst most polysaccharide capsules are either neutral or negatively charged, 
the zwitteronic capsule is charged both negatively and positively. The serotype-1 
capsule has a trisaccharide repeating unit with one positive charge and two negative 
charges (Figure 17) [268].   
 
,  
Figure 17. Differences in the structure of the polysaccharide repeating unit of different 
pneumococcal serotypes [269]. 
 
1.7.1. Epidemiology of serotype 1 
Pneumococcal serotype 1 is known for being a major cause of invasive disease, 
especially in developing countries, and a high proportion of the population affected by 
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it are young adults under the age of 30, in contrast to other serotypes that mainly affect 
children and the elderly [270-272].  
Serotype 1 causes common pneumococcus-associated diseases such as pneumonia, 
bacteraemia, meningitis and otitis media; but it is also found causing other uncommon 
diseases like empyema and peritonitis [269]. Empyema is an accumulation of pus and 
bacteria in the pleural space (space between the lung and the inner surface of the chest 
wall) that can occur after bacterial pneumonia, trauma, lung abscesses or surgery 
[273].  Approximately half of the patients with pneumonia develop fluid in the pleural 
space, with 5-10% of these developing empyema [274]. Empyema is a serious 
complication of pneumonia that can develop into necrosis, cavitation, or fistulas in the 
thoracic cavity [275]. Pneumococcal serotype 1 is the main cause of empyema in 
children and it is a common cause in adults. The incidence rates of empyema have 
increased in recent decades, which is thought to be a result of the introduction of 
pneumococcal vaccines and consequent serotype replacement [275].  
What makes serotype 1 special is that, unlike other serotypes, it is rarely found in 
nasopharyngeal carriage [269, 270]. In a study dating from 1937, it was observed that 
around 22% of pneumococcal pneumonia cases in children, and 33% in adults, were 
caused by serotype 1 isolates, whilst only 2% of the isolates found in carriage were 
serotype 1 [276]. Since then, many studies have observed the same pattern [22, 277-
280]. The fact that nasopharyngeal carriage with serotype 1 seems to be much lower 
than invasive disease suggests that serotype 1 has a high attack rate, which means that 
the probability of carrying it is low, but once it is carried, there is a high probability of 
developing invasive disease [281]. 
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Even though nasopharyngeal carriage with serotype-1 is rare, there are reports where 
serotype-1 carriage has been observed [30, 282]. Moreover, in closed communities and 
during outbreaks when serotype-1 isolates are found causing nasopharyngeal carriage, 
the probability of finding other individuals carrying serotype 1 is higher [283-205]. 
This suggests that serotype-1 is able to colonise the nasopharynx and spread amongst 
close contacts, but the duration of colonisation is short when compared to other 
serotypes [269].  
 
1.7.2. Consequences of low carriage rates in serotype 1 distribution 
The low duration and density of carriage by serotype 1 results in less genetic diversity 
due to low chances of horizontal gene transfer, which occurs mainly during 
nasopharyngeal carriage [269, 270].  Furthermore, low genetic diversity results in 
distinctive geographic differences in serotype-1 clones [281]. A clone (or Sequence 
Type) is a group of isolates with identical multilocus sequence type (MLST) allelic 
profile, which is determined by 7 house-keeping genes (ddl, spi, recP, aroE, gdh, gki 
and xpt) [286].  
A study of the clonal diversity of 488 serotype-1 isolates from 27 different countries 
(including 11 in Africa) showed clear differences in the geographic distribution of each 
clone (Figure 18) [270]. The serotype 1 isolates studied clustered into four distinct 
lineages: a) lineage A containing isolates form Europe, South America and Oceania; 
b) lineage B containing isolates from Africa; c) lineage C containing isolates from 
South America; and d) lineage D containing isolates from Asia [270]. 
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Figure 18. Phylogeography of the 488 pneumococcal serotype 1 isolates. Maximum-likelihood 
phylogenetic tree based on the whole genome SNPs of serotype 1 isolates annotated with country 
of origin. The colour of each isolate indicates the continent of origin: red, Africa; orange, Asia; 
green, Europe; blue, South America (the Brazilian group is highlighted by a circle, the 
Argentinian and Peruvian isolates are highlighted by a star); purple, Oceania. Specific lineages 
referred to in the text are labelled: A (lineage A, Europe, South America & Oceania), B (lineage 
B, Africa), C, (lineage C, South America), D (lineage D, Asia). Note that Asian isolates are 
present in all of the lineages [270]. 
 
In the same study, the phylogeography of serotype 1 within Africa was analysed, 
showing that the African isolates clustered into 6 different clades with a high level of 
geographical structure [270]. Within the African isolates, 2305 orthologous genes 
were identified, with 59% of these genes found in all isolates (therefore belonging to 
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the core genome) and 37% found in at least two isolates (therefore belonging to the 
accessory genome). The remaining genes were unique to single isolates [270]. The 
high percentage of genes not shared between all African serotype 1 isolates suggest 
that the accessory genome may reflect host-specific selective pressures between 
regions and may therefore explain differences in disease severity between regions 
[270]. Moreover, European serotype 1 ST306 isolates have been shown to produce 
non-haemolytic pneumolysin due to mutations found in the pore-forming region of the 
protein [287]. These observations suggest that the pathogenesis of serotype 1 isolates 
from different geographic regions should be studied differently due to the genetic 
differences observed between isolates from different origins which may lead to 
differences in virulence and pathogenicity. 
 
1.7.3. Epidemiology of serotype 1 in Africa 
The incidence of invasive disease caused by serotype 1 can vary in time; there are 
periods of low incidence of serotype-1 invasive disease followed by periods of high 
incidence, or outbreaks [269]. In most serotypes, different sequence types can coexist 
at the same time, while in serotype 1 pre-existing clones are constantly being replaced 
by new clones [269, 270, 288, 289].  
Serotype 1 is the most common cause of pneumococcal meningitis in the African 
meningitis belt [290, 291, 292]. The African meningitis belt region is an area in Africa 
with a high incidence of meningitis disease which include a total of 26 nations (Figure 
19) [292, 293].   
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Figure 19. African meningitis belt [293]. 
 
As previously mentioned, serotype 1 is one of the capsular types included in the 
conjugated vaccines currently being used (PCV10 and PCV13); however, the efficacy 
of these vaccines against serotype 1 has been shown to be limited [192, 294]. Hence, 
the study of the pathogenic mechanisms of African serotype 1 is of key importance to 
understand the factors responsible for the mortality and morbidity caused by serotype 
1 in the developing countries of Sub-Saharan Africa. 
 
1.7.4. Immune response to serotype 1  
Pneumococcal polysaccharide capsule is presented to B cells on the cell surface of 
antigen presenting cells, probably through complement receptors, which leads to a T-
cell-independent response leading to the production of antibodies in individuals over 
the age of 2 [269]. In contrast, the type 1 capsular polysaccharide is able to associate 
to the major histocompatibility complex II (MHC II) allowing recognition by CD4+ T 
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cells and differentiation into Th1 (producing INF-γ) and Th17 cells (producing IL-
17A) (Figure 20) [269, 295-297].  
 
Figure 20. Immune response to pneumococcal serotype 1 capsule compared to other 
serotypes[269]. 
 
However, capsular type 1 is particularly resistant to opsonisation and complement 
deposition and moreover, CD4+-dependent immunity has been shown to be reduced in 
mice when using protein-conjugated immunisation and hence could be the reason why 
PCV10 and PCV13 are not as efficient against serotype 1 as against other capsular 
types [269, 192, 294]. 
 
1.7.5. Serotype 1 in animal models of infection 
Previous studies have shown serotype 1 to induce a low immune response and be less 
virulent than other serotypes in mouse models of infection. However, the isolates used 
in these studies were ST228, ST306, ST227 and ST304 isolates, all of which belong 
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to lineage A, which includes isolates from Europe, North America and Australia (Table 
5) [270, 281, 295, 298-301].  
 
Europe, North America 
and Australia 
Africa and Israel Chile 
ST306, ST617, ST228, 
ST227, ST304, ST305 
ST217, ST303, ST614, 
ST612, ST613, ST618, 
ST3081 
ST615, ST611, ST616, 
ST300 
Table 5. Geographic location of the most common sequence types from serotype 1 [281]. 
 
 
In one study, the isolate used belonged to ST217 (the most common sequence type 
from lineage B, which includes isolates form Africa), although the partially resistant 
inbred mouse strain C57BL/6 was used. [295, 300, 301]. More recently, a study 
showed that a serotype 1 ST618 isolate from the Gambia, was highly virulent in a 
mouse model of bacteraemia where the mice were infected intra-venously [302]. 
 
1.8. Research aims 
The incidence of invasive disease caused by serotype 1 isolates ranges from 10% in 
developed countries up to 30% in some developing countries. These observations 
together with the reduced efficacy of the pneumococcal conjugate vaccine against 
serotype 1 highlights the importance of understanding the various mechanisms that 
determine the pathogenicity of this serotype.  
Furthermore, the high genetic diversity observed between serotype 1 isolates across 
the world suggests that isolates from different geographic locations may be 
phenotypically quite different and hence observations based on one lineage may not 
be applicable to other lineages. To this end, as most of the studies to determine 
virulence and host immune responses during serotype 1 infections have been done 
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using isolates from lineage A (Europe, North America and Australia) the aim of this 
thesis was to study isolates from lineage B (Africa), which includes major disease 
causing sequence types, of which ST217 is the most common. As Sub-Saharan Africa 
bears the heaviest burden of pneumococcal disease across the world and serotype-1 is 
the major invasive disease causing serotype, the overall aim of this study was to 
determine the mechanism of pathogenesis and host immune interactions of African 
serotype 1 isolates belonging to ST217.  
 
  
 
 
 
 
 
 
 
Materials and methods 
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2. Materials and Methods 
 
All the reagents used were from Sigma Aldrich® (St. Louis, USA) unless stated 
otherwise. 
 
2.1. Pneumococcal bacterial strains 
The Streptococcus pneumoniae isolates used in this project were representative 
isolates from the blood of patients with sepsis, from the cerebrospinal fluid of patients 
with meningitis, from lung aspirates of patients with pneumonia or from the 
nasopharynx of asymptomatic individuals. The isolates from Malawi were collected 
for ongoing studies at two different locations: the Queens Elizabeth Central Hospital 
in Blantyre (the leading state-run hospital in Malawi based in the economic capital, 
Blantyre), and the Karonga district of Malawi (located in the rural Northern Region of 
Malawi). The isolates from The Gambia were provided by the MRC Unit which store 
isolates collected from different areas in the country. The data available for these 
isolates can be found in Table 6. In some experiments, the strain D39 serotype 2 of S. 
pneumoniae (NCTC 7466) and its unencapsulated R6 isotype were used as a control. 
Two non-serotype 1 isolates were used for competition experiments alongside 
serotype 1 isolates; the serotypes chosen were 6B and 19F, which are commonly found 
in asymptomatic carriage. 
For long-term storage the isolates were maintained in bead stocks (MicrobankTM, Pro-
Lab, Bromborough, UK) at -80°C, and streaked out onto 5% Horse Blood agar plates 
(Oxoid, Basingstoke, UK) when needed. After incubating the plates overnight at 37°C, 
alpha-haemolytic and optochin resistant colonies were observed. During most of the 
experiments, liquid bacterial stocks were used. The stocks were obtained by incubating 
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a streak of colonies from a blood plate in 20% BHI serum (Oxoid) at 37°C for 10-12h, 
and were then kept at -80°C for long-term storage. The stocks were ready to be used 
in the experiments after checking the purity and concentration of the stocks using the 
Miles and Misra method [303].  
 
 
Table 6. List of pneumococcal isolates used in this study. 
Sample ID 
Carriage
/ 
Invasive 
Blood/ 
pneumonia/ 
CSF/Naso 
ST Location Year Age Serotype 
Child
/ 
Adult 
A41626 Invasive Blood 217 Blantyre 2006 54 1 adult 
A42174 Invasive Blood 217 Blantyre 2006 30 1 adult 
A47864 Invasive Blood  Blantyre 2007 37 1 adult 
B11510 Invasive CSF 217 Blantyre 2005 42 1 adult 
B13969 Invasive CSF 217 Blantyre 2006 38 1 adult 
B17099 Invasive CSF 217 Blantyre 2007  1 adult 
C9471 Invasive CSF 217 Blantyre 2004 3 1 child 
C10305 Invasive CSF  Blantyre 2004 3 1 child 
C10827 Invasive CSF  Blantyre 2004 9 1 child 
D25796 Invasive Blood 217 Blantyre 2004 8 1 child 
D48309 Invasive Blood 217 Blantyre 2008 4.8 1 child 
D42785 Invasive Blood  Blantyre 2007 10 1 child 
MLAB7062 Carriage Naso  Blantyre 2006  NT adult 
W000168 Carriage Naso  Karonga 2008 26 1 adult 
W001477 Carriage Naso  Karonga 2009 16 1 child 
W001640 Carriage Naso  Karonga 2009 6w 1 child 
W001641 Carriage Naso  Karonga 2009 4 1 child 
W002818 Carriage Naso  Karonga 2009 2 1 child 
W004030 Carriage Naso  Karonga 2010 2 1 child 
W004737 Carriage Naso  Karonga 2010 10w 1 child 
L001564 Invasive Blood  Karonga 2010 29 1 adult 
PNI 830 Invasive Pneumonia 217 The 
Gambia 
2009 45 1 adult 
SVT 23946 Carriage Naso 217 The 
Gambia 
2006 12 1 child 
D33275 Carriage Naso 9533 Malawi   6B  
19F Carriage Naso 177 Europe   19F  
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2.2. Confirmation of serotype 1 isolates by PCR 
The Malawian isolates were confirmed to be serotype-1 by amplification of the WchC 
gene by colony PCR. Individual colonies grown overnight in 5% Blood Agar plates 
were picked and placed in DNase free water to be lysed. PCRs were performed using 
a Techne Flexigene thermal cycler (Therem, Stone, UK) and using ReadyMixTM Taq 
PCR Reaction Mix according to the manufacturer’s instructions.  
The sequence of the forward primer used for this PCR was 5’-
CTAATGCTAAATTAATCTTAGG-3’, whilst the sequence of the reverse primer was 
5’-ATTTCATCTCCCTTGATAAACG-3’. This primer amplifies a 401bp fragment.  
The thermocycling conditions for this PCR are shown in Table 7. 
The presence or absence of the WchC gene was determined by separation of the DNA 
fragments using a 1% agarose gel electrophoresis. 
 
Step Temperature Time 
Initial Denaturation 95°C 5 min 
35 cycles 95°C 
50°C 
72°C 
30 sec 
30 sec 
1 min 
Final extension 72°C 10 min 
Hold 15°C  
Table 7. Thermocycling conditions for the serotype-1 capsule PCR. 
 
 
2.3. Determination of presence or absence of the pneumolysin gene 
The presence of the pneumolysin gene in the Malawian isolates was also determined 
by colony PCR by amplifying the ply gene. PCRs were performed using a Techne 
Flexigene thermal cycler and using ReadyMixTM Taq PCR Reaction Mix according to 
Chapter 2: Materials and methods 
 
61 
 
the manufacturer’s instructions. The sequence of the forward primer used for this PCR 
was 5’- GTCGCAAGCATTCTCCTCTC-3’, whilst the sequence of the reverse primer 
was 5’- GGCTGATTTCGCTGAACAAG-3’. This primer leads to the amplification 
of a 1501bp fragment. The thermocycling conditions for this PCR are shown in Table 
8. 
The presence or absence of the ply gene was determined by separation of the DNA 
fragments using a 1% agarose gel electrophoresis. 
 
Step Temperature Time 
Initial Denaturation 95°C 5 min 
35 cycles 95°C 
50°C 
72°C 
30 sec 
30 sec 
1 min 
Final extension 72°C 10 min 
Hold 15°C  
Table 8. Thermocycling conditions for the pneumolysin PCR. 
 
 
2.4. Haemolytic assays  
The haemolytic activity of the different Malawian isolates was determined using a 
modified version of a method published by James C. Paton in 1983 [73, 90]. The 
bacterial isolates were grown in BHI to late exponential phase (OD500 < 1) and then 
lysed by treatment with 0.1% sodium deoxycholate. The total protein of the lysates 
was determined using the BCA Protein Assay Kit (Thermo Scientific, Loughborough, 
UK). Approximately 85µg of total protein was used for the determination of the 
haemolytic activity of each isolate by making serial dilutions of the lysates and 
incubating them with a 4% suspension of sheep red blood cells (Oxoid). After a 30min 
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incubation at 37°C the suspension was centrifuged at 3000g for 5min and the OD540 of 
the supernatants was measured to determine the haemolytic activity. This experiment 
was performed in triplicate. 
 
 
2.5. Growth curves  
The OD550 of 200µl of a suspension of 10
3CFU/ml bacteria in 20% BHI serum was 
determined every 30min for a total of 15h using a BMG Labtech FLUOstar OMEGA 
microplate reader (BMG Labtech, Aylesbury, UK)..  
 
2.6. Tissue culture 
The cell lines used for this study were the human bronchial-epithelial cells BEAS-2B 
(ATCC® CRL-9609™), the human nasopharyngeal epithelial cells Detroit-562 
(ATCC® CCL-138™) and the promyelocytic leukaemia human cell line HL-60 
(ATCC® CCL-240™). 
The BEAS-2B is an adherent cell line that was maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 5% inactivated Foetal Calf Serum 
(FCS) and 1% Penicillin-Streptomycin solution. The cells were kept in horizontal 
75cm2 flasks at 37°C and 5% CO2 until confluent. Once confluent, approximately 
every 2-3 days, the cells were split into a new flask after being detached using 5ml of 
1xTripsin/EDTA. The Detroit-562 is also an adherent cell line and was maintained in 
Minimum Essential Medium Eagle (MEM) supplemented with 10% FCS and 1% 
Penicillin-Streptomycin solution. This cell line was kept under the same conditions as 
the BEAS-2B and the cells were split after incubation with 5ml 1xTrypsin to induce 
the detachment of the cells from the flask. 
Chapter 2: Materials and methods 
 
63 
 
The HL-60 cell line was maintained in suspension in RPMI-1640 Phenol Red free 
medium (Invitrogen, Thermo Scientific, Loughborough, UK) supplemented with 20% 
FCS. The cells were kept in vertical 75cm2 flasks at 37°C and 5% CO2, and the media 
was changed every day. This cell line was used for opsonophagocytic killing assays, 
for which the cells had to be differentiated into polymorphonuclear lymphocytes 
(neutrophils) by incubating 2x105cells/ml in 100ml of medium with 750µl of 
dimethylformamide (DMF) for 4 days. For opsonophagocytic killing assay the 
viability of the cells after differentiation needed to be above 90%, which was 
determined with trypan blue. 
 
2.7. Adhesion and invasion assays 
The adhesion and invasion assays were performed using the lung epithelial cells 
BEAS-2B and the nasopharyngeal epithelial cells Detroit-562 following a modified 
version of a protocol published by Paton in 1996 [152]. 
Approximately 105 cells were seeded in 24 well plates and grown in their appropriate 
media (DMEM for BEAS-2B, and MEM for Detroit-562) in the presence of FCS and 
antibiotics. The cells were grown at 37°C and 5%CO2 until confluent, approximately 
48h after seeding. Frozen stocks of known concentrations of bacteria were used for 
this assay. The bacteria were pelleted down and re-suspended in the appropriate 
medium (with FCS but without antibiotics to a final concentration of 106CFU/ml. One 
ml of the bacterial suspension was added to the seeded cells after those had been 
washed 3 times with PBS (Oxoid). The 24 well plates were then incubated for 2h at 
37°C and 5% CO2. For each experiment two 24 well plates were used, one of them to 
assess the adherence of the bacteria to the surface of the cells, the other one to assess 
the invasion of the bacteria into the cells. 
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After 2h of incubation both plates were washed 5 times with PBS to remove the 
bacteria that were not adhered or invading. In the plate designated to determine the 
invasion of the bacteria 1ml of medium with FCS and 5ug of penicillin was added to 
each well and incubated at 37°C and 5%CO2 for a further 2h. For the plate designated 
to assess adhesion, 100µl of 1xTrypsin/EDTA were added to each well and the plate 
was incubated for 10min at 37°C and 5% CO2. Once the cells were detached they were 
lysed by incubating them for 10min in 1ml of 0.05% Triton X-100 media with FCS. 
Finally, the viable bacterial number was determined using the Miles and Misra method, 
by serially diluting the sample and incubating the dilutions overnight on 5% BAB 
plates at 37ºC [303].  
After the extra 2 hours of incubation with penicillin, the cells in the plate used to 
determine the invasion were washed 3 times with PBS to remove the penicillin. After 
the washes with PBS the cells were detached and lysed as with the plate designated to 
determine bacterial adhesion. The viable bacterial numbers were determined using the 
Miles and Misra method [303]. The number of adhered bacteria was determined by 
subtracting the number of invading bacteria (invasion plate) to the total number of 
bacteria (adhesion plate). 
These experiments were performed in triplicate on three independent days and controls 
without bacteria and without cells were used every time.  
 
2.8. Capsule thickness 
The bacterial capsule thickness was determined using a modified version of the FITC-
dextran exclusion method originally published by Gates in 2004 [304, 305]. This 
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method consists of measuring the zone of exclusion of FITC-dextran which correlates 
with capsule size. 
Briefly, a single colony from an overnight culture on 5% BAB plates was incubated 
for approximately 8-12 hours at 37°C in 10ml of BHI to mid-log phase. The bacteria 
were then sub-cultured to again, a mid-log phase. Finally, 2µl of 200kDa FITC-dextran 
(Thermo Scientific) was added to 10µl of the culture and pipetted onto a microscope 
slide. The slides were observed using a Nikon Eclipse 80i fluorescence microscope 
(Nikon, Kingston Upon Thames, UK). At least 100 individual bacteria were analysed 
for each sample using the ImageJ software. These experiments were kindly done by 
Laura Jacques, a PhD student in the lab. 
 
2.9. Opsonophagocytic killing assays 
The opsonophagocytic killing assay with HL-60 cells is used to determine the ability 
of different bacterial strains to avoid phagocytosis by human neutrophils, and is also 
used to determine the opsonising ability of different serums against different bacteria. 
The assay used in this study is a modification of the protocol published by Romero-
Steiner in 2003 [306].    
Frozen bacterial stocks of known concentration were washed in PBS and re-suspended 
to a final concentration of 105CFU/ml in HBSS (Invitrogen). 10µl of the bacterial 
suspension (103 bacteria) were incubated with 20µl of opsonin for 30min at 37°C and 
shaking at 175rpm. The opsonin used differed in each assay, being either serum 
obtained from naïve or infected mice, or pooled human IgG (IVIG, Grifols 
Therapeutics, New York, USA). During the opsonisation time the neutrophils were 
prepared by centrifugation at 250g for 10min and re-suspending them in 1ml DPBS-/- 
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(Invitrogen). The concentration of the cells was determined using a Neubauer chamber 
and trypan blue, being adjusted to a final concentration of 1.125x107cells/ml. After 
opsonisation 40µl of the neutrophils suspension (4x105 neutrophils) were added to the 
bacteria, followed by 10µl of baby rabbit complement (Invitrogen). The cells were 
then incubated for 45min at 37°C and shaking at 175rpm. Finally, 10µl of the 
suspension were plated out onto 5% BAB plates and incubated overnight to determine 
the number of viable bacteria.  
The controls used in this assay include bacteria only, bacteria with neutrophils, bacteria 
with opsonin, bacteria with complement, bacteria with neutrophils and opsonin, 
bacteria with opsonin and complement, and bacteria with neutrophils and complement. 
The experiments were done in triplicate on three independent days.   
 
2.10. Complement deposition 
The complement deposition assay is an assay where human serum is added to the 
bacteria and the deposition of C3 on the surface of the bacteria is determined by flow 
cytometry. The human serum used in this experiment was a pool from different healthy 
individuals. Thiazol orange was used as a bacterial stain to be able to gate and select 
live bacterial cells during the flow cytometry acquisition. The C3 deposition on the 
bacteria was determined using a mouse-anti-human C3 antibody (Abcam, Cambridge, 
UK) and an anti-mouse-APC antibody  (Clone m2a-15F8) (eBiosciences, Hatfield, 
UK).  
Briefly, a 5ml suspension of 105CFU/ml in BHI was made using bacterial frozen 
aliquots of known concentration. The bacterial suspension was centrifuged at 3350g 
for 10min after allowing the bacteria to re-activate for 15min at 37°C. The bacterial 
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pellet was re-suspended in 5ml PBS and the suspension was equally distributed in 3 
eppendorf tubes. All tubes were centrifuged and the bacterial pellet was re-suspended 
with 100µl of 20% serum diluted in PBS and 1% Gelatine Veronal Buffer. After an 
incubation of 30min at 37°C and 5% CO2 the bacteria were washed with 900µl of PBS 
and centrifuged at 17,000g for 3min. The pellet of the first two tubes was re-suspended 
in 100µl of PBS whilst in the third tube it was re-suspended with 100µl of mouse-anti-
human C3 (1:300 dilution in PBS). The bacteria were again incubated for 30min at 
37°C and 5% CO2 followed by another wash with 900µl of PBS. After centrifugation 
at 17,000 for 3min the pellets of the first and second tubes were re-suspended again in 
100µl of PBS whilst in the third tube the pellet was re-suspended with 100µl of anti-
mouse-APC (1:400 dilution in PBS). The bacteria were then incubated at 4°C for 
30min in the absence of light. After the incubation the bacteria were washed twice 
with 900µl and a further 100µl of PBS. Finally, 5µl of Thiazol orange (1:1000 dilution 
in PBS) was added to tubes two and three before the samples were analysed using the 
BD Accuri™ C6 flow cytometer (BD Biosciences, Oxford, UK). The first two tubes 
were used as controls whilst the third tube was used to determine the mean 
fluorescence intensity, used to determine C3 deposition. These experiments were 
performed in triplicate on three independent days. 
 
2.11. Invasive pneumococcal disease model in mice 
The induction of IPD in mice was carried out following the protocol previously 
described by Kadioglu in 2000 and 2002 [102, 254]. The experiments were performed 
at the University of Liverpool following the Home Office guidelines for animal 
procedures. 
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Seven to ten week old female MF1 outbred mice (Charles River, Margate, UK) were 
temporally anaesthetised with 2.5% (vol/vol) isoflurane (Abbott, Chicago, USA) over 
oxygen delivered at a rate of 1L/min. The bacteria were administered intra-nasally in 
a 50µl volume of sterile PBS at a concentration of approximately 106CFU/ml. The 
bacterial dose was prepared using frozen aliquots of known concentration. 
The mice were monitored and signs of disease recorded. The illness chart classifies 
mice as normal, hunched, piloerect, lethargic, moribund or dead. Each level of illness 
was scored as not present, present or strongly present. Mice were culled by CO2 
asphyxiation and cervical dislocation at pre-established specific time points or when 
showing signs of lethargy, as established by the Home office licence.  
Blood was collected in heparinised tubes by tail-bleeding at different time points and 
by cardiac puncture at time of death. The bacterial load in blood was determined using 
the Miles and Misra method [303]. For some experiments the collection of serum was 
required. In these cases a minimum of 500µl of blood were collected by cardiac 
puncture in the absence of heparin and the tube was left to rest for either 30min at 
room temperature or overnight at 4°C. The blood was then centrifuged for 10min at 
2,000g and the serum was collected and stored at -20°C for future analysis. 
Lung, nasopharyngeal tissue and brain were obtained for bacterial load determination. 
The tissues were collected in sterile PBS, weighted and homogenised by mechanical 
disruption using a T10 ULTRA-TURRAX® homogeniser (IKA®, Staufen, Germany). 
After homogenisation 20µl of the samples were serially diluted in PBS, plated onto 
5% BAB plates and incubated overnight at 37°C. When necessary, the remaining 
sample was centrifuged at 300g for 5min to pellet down the cells and the supernatants 
were stored at -20°C for future cytokine analysis. 
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When the tissues were required for cellular profiling using flow cytometry they were 
mashed and sieved using 40µm cell strainers (Corning, New York, USA) instead of 
homogenised by mechanical disruption. The cells were then ready to be stained or 
ready to be re-suspended in freezing media (75% RPMI, 15% FCS and 10% DMSO) 
and stored at -80°C for future analysis.  
 
2.12. Nasopharyngeal carriage model in mice 
The induction of pneumococcal nasopharyngeal carriage in mice was performed 
following the method previously described by Richards in 2010 [238]. The 
experiments were done at the University of Liverpool following the Home Office 
guidelines for animal procedures. 
Seven to ten week old female MF1 outbred mice (Charles River) were temporally 
anaesthetised with 2.5% (vol/vol) isoflurane (Abbott) over oxygen delivered at a rate 
of 1L/min. The mice were infected intra-nasally with 10µl of sterile PBS containing 
approximately 105CFU/ml of bacteria. The bacterial dose was made using frozen 
stocks of known concentration. 
The mice very rarely developed any sign of disease, therefore they were culled at pre-
established time points by CO2 asphyxiation followed by cervical dislocation.  
For bacterial load determination and cytokine analysis blood, lung, brain and 
nasopharyngeal tissue were collected at time of death and processed following the 
same guidelines as for the invasive mouse model. Serum was obtained as previously 
described and used for antibody and cytokine analysis. The cervical lymph nodes 
(CLN) and the nasal-associated lymphoid tissue (NALT) were collected in PBS, 
mashed and sieved through a 40µm cell strainer for flow cytometry analysis. 
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2.13. Assessment of long-term protection acquired during carriage 
In order to assess the long term protection induced during nasopharyngeal carriage 
with serotype 1 isolates, twenty 7-10 week old female MF1 outbred mice (Charles 
River) were infected with the bacteraemia isolate and then re-infected 21 days later 
with the same isolate. The mice were infected with 105 bacteria in 10 µl of sterile PBS 
and let to rest for 21 days before infecting them again with another 105 bacteria in 10µl 
of sterile PBS. The doses, as for the nasopharyngeal carriage model, were done using 
frozen stocks of known bacterial concentration. The re-infection was performed 21 
days after the first infection to ensure that most of the bacteria from the first infection 
had been cleared. The mice were then culled 0, 1, 3 and 7 days post re-infection.  
The nasopharynx was collected for bacterial load determination and for cytokine 
analysis. The cervical lymph nodes and the nasal-associated lymphoid tissue were 
collected in PBS, mashed and sieved for flow cytometry analysis. 
 
 
2.14. Nasopharyngeal competition experiments in mice 
Competition experiments were performed in mice to assess the ability of different 
serotypes to out-compete one another during nasopharyngeal carriage. In order to do 
this, 7-10 week old female MF1 outbred mice (Charles River) were infected with 105 
bacteria in 10µl of sterile PBS and were left to rest for 7 days until the second infection 
with a different serotype. The time between infections was 7 days in order to allow the 
first introduced serotype to establish colonisation before the addition of the second 
serotype.  
For bacterial number determination blood, lung, brain and nasopharyngeal tissue were 
collected at different time points and processed as previously described. After bacterial 
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number determination, the nasopharyngeal tissue was harvested and the supernatant 
was used for cytokine analysis. Serum was collected as previously described and used 
for antibody and cytokine analysis. The cervical lymph nodes and the nasal-associated 
lymphoid tissue were collected in PBS, mashed and sieved for flow cytometry 
analysis. 
2.15. Flow cytometry 
Lungs, cervical lymph nodes, brain, and nasal-associated lymphoid tissue were 
collected in PBS, mashed through cell strainers and centrifuged for 5min at 300g, as 
previously described. After centrifugation the pellets were re-suspended in freezing 
media and stored at -80ºC for future staining and acquisition. For the lung cells, the 
pellet was treated with 10% red blood cell lysis (BD Biosciences) for 5min in order to 
remove the red blood cells from the cell suspension. The blood was also treated with 
red blood cell lysis and stored at -80ºC for future staining and acquisition. 
For staining and acquisition the samples were thawed and washed twice with PBS 
before being incubated with purified anti CD16/CD32 Fc blocking antibody 
(eBiosciences) for 10min at 4ºC. Following the incubation with Fc blocking antibody, 
cell surface markers were stained using a combination of monoclonal antibodies 
conjugated with FITC, PE, PECy7 and APC fluorochromes (Biolegend, London, UK). 
An intracellular monoclonal antibody against Fox P3 was also used for staining T 
regulatory cells (Biolegend). The panels used in this study can be seen in Table 9. The 
samples were acquired using a BD FACSCaliburTM flow cytometer (BD Biosciences) 
and analysed using FlowJo vX.0.6. 
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Panel 1 Panel 2 
APC - CD45 (immune cells) 
Clone I3/2.3 
APC – F4/80 (macrophages) 
Clone BM8 
PE – FoxP3 (T regulatory cells) 
Clone FJK-16S 
PE – CD19 (B cells) 
Clone eBio1D3 
PE/Cy7 - CD4 (T cells) 
Clone GK1.5 
PE/Cy7 – Gr1 (neutrophils) 
Clone RB6-8C5 
FITC – CD3 (T cells) 
Clone 17A2 
FITC – CD45 (immune cells) 
Clone 30-F11 
Table 9. Staining panels used for flow cytometry. 
 
2.16. Cytokine analysis 
Levels of cytokines from the nasopharynx, lungs, brains and serum of mice were 
determined using enzyme-linked immunosorbent assays (ELISA). Commercially 
available kits from eBiosciences were used for all cytokines except for MIP-2 and KC, 
which were purchased from Sigma and Invitrogen respectively. The levels of KC, 
MIP-2, IL-1β, IL-10, IL-6, IL-17A, TGFβ, TNFα, and INFγ in the nasopharynx of 
mice carrying pneumococcus were determined following manufacturer instructions. 
The levels of IL-6, IL-17A, MIP-2, INFγ and TNFα were determined from lungs, brain 
and serum of mice with invasive pneumococcal disease. 
 
2.17. Determination of antibody levels in serum and nasal mucosa 
Enzyme-linked immunosorbent assays (ELISAs) were used to determine the levels of 
total IgG from serum and IgA from the nasal mucosa following manufacturer 
instructions (eBiosciences).  
 
2.18. Capsule switch detection  
The determination of capsule switching events during nasopharyngeal co-colonisation 
was studied during a competition experiment in which serotype 6B was introduced 3 
days after a carriage infection with the serotype 1 bacteraemia isolate (A42174). Ten 
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isolates were recovered as controls from the nasopharynx of mice on day 3 post-
infection with serotype 1, but before the introduction of the 6B isolate. A further 300 
single isolates were obtained from the nasopharynx of co-colonised mice at days 1, 3 
and 7 post 6B introduction. The phenotypic determination of the capsule type of 46 of 
the 300 isolates was performed using serotype 1 specific latex antisera (Immulex™, 
Statens Serum Insitut, Copenhagen, Denmark). The genotypic determination of the 
capsule type of those 46 isolates was done by sequencing the xanthine 
phosphoribosyltransferase (xpt) housekeeping gene (accession number: Q8RJS3), 
which has different alleles for the serotypes 1 and 6B, allowing differentiation. 
 
2.19. RNA extraction 
Growth curves of the serotype 2 strain D39 and the serotype 1 strain A42174 from 
bacteraemia were performed by inoculating 250ml of BHI with 2.5x106 bacteria and 
incubating them at 37ºC in a water bath. Samples were taken every hour to determine 
the optical density (OD500). This experiment was done in triplicates and plotted to 
determine the five phases of growth: early exponential phase (EEP), mid-exponential 
phase (MEP), late exponential phase (LEP), early stationary phase (ESP) and late 
stationary phase (LSP).  
Ribonucleic acid (RNA) from each growth phase was stabilised to avoid sacrificing 
the integrity of the RNA by incubating the bacteria with a solution of 5% phenol 
(Invitrogen) and 95% ethanol for a minimum of 30min in ice. Following stabilisation, 
the RNA was extracted using a phase separation method using TRIzol® (Invitrogen) 
[307]. Briefly, the cells were centrifuged and re-suspended in TRIzol® to allow 
bacterial lysis. The lysed bacteria were mixed with chloroform to separate the RNA 
from DNA, lipids and proteins. Once the aqueous phase was collected (RNA), the 
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sample was washed and the RNA was precipitated using ethanol. Finally, the RNA 
was re-suspended in DNase/RNase free distilled water (Invitrogen). The RNA 
extraction was done in an RNase-free area and using RNase-free materials to avoid 
RNA degradation. 
The quantity of RNA was determined using the Qubit® Fluorometer (Thermo 
Scientific). A 2100 Bioanalyzer (Agilent Technologies, Stanta Clara, USA) was used 
to assess the quality of the RNA: if the RNA is not degraded two bands should be 
observed, if the RNA is degraded the two bands disappear into a smear. Once 
confirmed that the RNA was not degraded the samples were sent to Vertis 
Biotechnologie AG (Freising, Germany) for Illumina NextSeq 500 sequencing 
(Illumina). 
Different methods were used to optimise the RNA extraction from bacteria infecting 
different tissues of mice, but no method was found to provide RNA of good enough 
quantity and quality.  
The growth curves and RNA extraction for the serotype 2 strain D39 were kindly done 
by Reham Yahya, a PhD student in the lab. 
 
2.20. Transcriptomic analysis 
The raw sequencing data was sent from Vertis Biotechnologie AG in FastQ format. 
The genomes were annotated by another PhD student in the lab, Chrispin Chaguza. 
Assembly of the sequence reads was performed using Velvet and SPADes assembly 
programs. The resulting contigs of the genomes were then ordered by ABACAS and 
annotated using a combination of the RATT and PROKKA prokaryotic annotation 
pipelines. Orthologous genes between the A42174 (EMBL-EBI Accession number: 
ERS353646) and the D39 strains (Genebank Accession number: NC_008533) were 
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identified using CD-HIT. The mapping of the RNA-Seq reads against the annotated 
genomes to infer transcripts was done by Dr. Karsten Hokamp at Trinity College, 
Dublin, as previously described [308]. Finally, the expression analysis of the 
transcriptome was done in collaboration with Prof. Jay Hinton (University of 
Liverpool) using the GeneSpring 7.3 software (Agilent Technologies).  
 
2.21. Statistical analysis 
The GraphPad Prism 5® software was used to create all the graphs shown in this thesis 
and to do the statistical analysis of the results. The individual tests used are explained 
in the figure legends. 
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3. In vitro characterisation of African serotype-1 pneumococcal 
isolates 
 
3.1. Introduction  
Phylogeographic analysis based on whole genome sequencing of Streptococcus 
pneumoniae serotype 1 isolates has led to the conclusion that serotype 1 clusters into 
four distinct lineages, each of which is associated with a single continent [270]. 
Different isolates from different continents have been shown to be phenotypically 
different during infection [270, 287]. This difference in pathogenicity highlights the 
importance of analysing isolates forming different lineages separately. Across sub-
Saharan Africa, serotype 1 remains one of the most common causes of invasive 
pneumococcal disease, causing approximately 20% of invasive pneumococcal disease 
cases in Sub-Saharan Africa and the African meningitis belt [290-292, 309, 310]. The 
high propensity for this serotype to cause invasive disease across the continent 
highlights the need for understanding how it causes disease and its genotypic and 
phenotypic characteristics which contribute to its pathogenesis.  
The Pneumococcal African Genomic Consortium 1 (PAGe1) is a consortium funded 
by the Bill and Melinda Gates Foundation that focuses on the genomic analysis of 
pneumococcal serotype 1 isolates across Africa. This consortium is currently analysing 
more than 900 sub-Saharan serotype 1 genomes to understand the molecular 
mechanisms of pathogenesis of this highly invasive pneumococcal serotype. ST217 is 
one of the most prevalent serotype 1 sequence types found in Africa [295, 300, 301]. 
For that reason, a group of 20 different Malawian serotype 1 ST217 isolates were 
selected as representatives of different infection sites (nasopharynx, blood and CSF) 
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to link the genomic analysis of the 900 sub-Saharan serotype 1 isolates to their in vitro 
and in vivo phenotypic characteristics. 
In vitro experiments were used to determine the phenotype of serotype 1 pneumococci 
using 3 experimental designs: a) by determining the role of pneumolysin on the 
virulence of serotype 1 ST217, b) by assessing the ability of ST217 isolates to adhere 
and invade human cells and c) by assessing the ability of ST217 to evade the host 
immune system. 
 
3.2. Serotype 1 confirmation by PCR 
To ensure all the isolates selected for this study were indeed serotype 1, all the isolates 
were analysed for the presence or absence of the wchC gene. The product of the wchC 
gene is a putative acetyltransferase responsible for the acetylation of the type 1 capsule 
[311]. All the isolates were positive for the presence of this gene (Figure 21).  
To subsequently validate the PCR results, with one exception, all isolates were 
confirmed to be serotype 1 in silico through whole genome sequencing. The only 
exception was the MLAB7602 isolate which was later confirmed as non-typeable by 
full genome sequencing. Non-typeable isolates are considered to be encapsulated 
bacteria that have lost their capsule through the loss of either the whole capsule operon 
or a selection of genes inside the operon [53]. Since this isolate was positive for the 
wchC gene by PCR we hypothesised that this isolate could have been a serotype 1 
isolate before losing the capsule or that it had acquired the whcC gene by 
recombination [65].  
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Figure 21. PCR for the wchC gene, representative of a serotype 1 capsule, shown as presence or 
absence of the 401bp gene product. 
 
 
3.3. Determination of presence or absence of the pneumolysin gene by PCR.  
Pneumolysin has been found to be produced by approximately 99% of all 
pneumococcal serotypes, including serotype 1 [312]. Across Europe, ST306 is the 
most common sequence type associated with serotype 1, while the ST217 strain is 
commonly found in sub-Saharan Africa. The type and levels of production of 
pneumolysin has been shown to be different between clones, with ST306 producing a 
non-haemolytic form of pnumolysin [287]. Since pneumolysin is a major virulence 
factor for pneumococcal pathogenesis, a PCR was performed to detect the presence or 
absence of the pneumolysin gene (ply) in all 20 ST217 isolates used in this thesis. All 
the Malawian isolates had the pneumolysin gene present (Figure 22). 
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Figure 22. PCR for the pneumolysin gene, shown as the presence or absence of the 1501bp gene 
product. 
 
3.4. Haemolytic assay 
In order to determine the level of production of the active pneumolysin (PLY) protein, 
the haemolytic activity of pneumolysin produced by ST217 isolates was compared to 
the haemolytic activity of the pneumolysin produced by the control isolates using a 
well-established haemolytic assay [73]. The D39 isolate was used as a positive control 
whilst its isogenic pneumolysin deficient mutant (PLN-A) and the non-haemolytic 
ST306 strain B915 were used as negative controls. 
The haemolytic activity is shown in Figure 23 as the OD540 after 30min incubation of 
different dilutions of the bacterial lysate with a 4% Sheep Red Blood Cell solution. 
These results clearly demonstrate that the haemolytic activities for all the isolates were 
broadly similar at the first dilution but differences between isolates began to emerge 
at 1:2 dilution. A one way ANOVA test was used to analyse the differences between 
all serotype 1 isolates at 1:2 dilution (Figure 24).  
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Figure 23. Haemolytic activity of all serotype 1 isolates shown as mean OD540 ± SEM of the 1:2 
dilutions of bacterial lysates after incubation with a 4% red blood cell solution.  The 
bacteraemia isolates are shown in red, the meningitis isolates are shown in blue and the carriage 
isolates are shown in green. This experiment was performed in triplicate on three independent 
days. 
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Figure 24. Levels of haemolytic activity of all serotype 1 isolates compared to the haemolytic 
activity of the serotype 2 D39 at dilution 1:2 shown as mean OD540 ± SEM. Black: D39 control, 
red: bacteraemia isolates, blue: meningitis isolates and green: carriage isolates. ***P-
value<0.005 when analysed using a one-way ANOVA test. 
 
Only one isolate had a significantly lower haemolytic activity when compared to the 
other isolates; the isolate was C9471, which was isolated from the cerebrospinal fluid 
of a 3 year old child. Since no significant difference in the level of haemolytic activity 
was observed across the entire set of 20 isolates selected for this study, with the 
exception of C9471, only three representative isolates were selected for further in vitro 
phenotypic investigations representing adult bacteraemia (A42174), adult CSF 
(B13969) and child carriage (W004030).  
To ensure validity of results, the low haemolytic serotype 1 ST217 isolate (C9471) 
was selected for direct comparison to the 3 study isolates demonstrating no observable 
differences in the in vivo carriage model of infection. These results can be seen in 
Section 9.1. 
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3.5. Growth curves 
To determine the fitness of the different bacterial isolates used, a growth rate 
experiment was undertaken to compare the growth kinetics of the serotype 1 isolates 
to the well characterised laboratory serotype 2 strain D39 by growing the different 
bacteria in 20% BHI-serum for 15h and determining the OD550 every 30min.  
 
Figure 25. Growth curves of the bacteraemia, meningitis and carriage serotype 1 isolates and 
the serotype 2 D39 shown as mean OD550 ± SEM of bacterial cultures determined every 30 
minutes during a 15 hour incubation in 20% BHI-serum. This experiment was done in triplicate 
on three independent days and no significant differences were observed. 
 
As observed in Figure 25, all the isolates followed the same pattern of growth: there is 
a static period of time in which the isolates do not grow mainly due to adjustment to 
the new environment; this phase is also known as the lag phase [328]. Following 
adaptation to the culture media the isolates begin to replicate in a phase known as the 
exponential phase [328]. The final bacterial growth phase is known as the stationary 
phase, where the bacteria stop replication due to the exhaustion of available nutrients, 
and also due to the increasing accumulation of waste products and toxic metabolites 
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that are detrimental to bacterial growth. Following the stationary phase the bacteria 
start to die due to the prolonged lack of nutrients [328]. 
The doubling times for each bacteria was determined using the OD550 values obtained 
from the growth curve: 50min for the bacteraemia isolate A42174 and 1h for the 
meningitis isolate B13969, the carriage isolate W004030 and the serotype 2 control 
strain D39. In summary, no significant differences were observed in the growth 
patterns of the serotype 1 isolates and the serotype 2 control strain D39. 
 
3.6. Adhesion and invasion assays 
To assess the ability of the serotype 1 isolates to adhere to and invade human 
nasopharyngeal epithelial cells (Detroit-562) and human broncho-alveolar epithelial 
cells (BEAS-2B), adhesion and invasion assays were performed. Two controls were 
used in these experiments: the first control was the serotype 2 strain D39 in order to 
be able to compare the adherence and invasion of the serotype 1 isolates to a well-
studied pneumococcal strain. The second control was the non-typeable MLAB7062 
pneumococcal strain obtained from Malawi to be able to compare the adhesion and 
invasion of the serotype 1 isolates to a non-encapsulated wild-type pneumococcal 
strain.  
Figure 26a clearly demonstrates that all the pneumococcal isolates used were able to 
adhere to nasopharyngeal epithelial cells (Detroits-562), but the percentage of 
adhesion varied between isolates. No significant differences were observed between 
the D39 strain and the serotype 1 isolates when analysed by ANOVA, but there was a 
significant difference in adhesion of D39 and the serotype 1 isolates when compared 
to the non-typeable strain MLAB7062, for which the adherence levels were much 
higher than for the rest of the isolates (*P-value<0.05, ***P-value<0.005 ****P-
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value<0.0001). Figure 26b shows that some invasion was observed with the non-
typeable isolate and the meningitis isolate (B13969), although the level of invasion 
was not consistently observed throughout independent experimental repetitions, it 
does suggest that the non-typeable isolate and the meningitis isolate might be better at 
tissue invasion than the rest of the isolates studied. Furthermore, the levels of invasion 
were independent of the number of adhered bacteria suggesting that invasion was 
determined by the bacterial strain and not by the number of adhered bacteria.  
 
 
Figure 26. Adhesion and invasion levels of serotype 1 isolates in the Detroit-562 cell line shown as 
mean CFU ± SEM of adhered bacteria per ml of media with an initial inoculum of 106 
bacteria/ml. Invasion is also shown as a percentage of adhered bacteria. These experiments were 
performed in triplicate on three independent days. *P-value<0.05, ***P-value<0.005 and ****P-
value<0.001 when compared to the MLAB7062 control using a one-way ANOVA. 
 
When the broncho-alveolar epithelial cells (BEAS-2B) were used no adhesion or 
invasion was detected for the D39 strain or the serotype 1 isolates. The only strain able 
to adhere or invade this cell line was the non-typeable strain MLAB7062 (Figure 27a 
and 27b). The MLAB7062 was significantly more able to adhere to the BEAS-2B cells 
when compared to the rest of the isolates (*P-value<0.05), but no significant 
differences were seen for invasion due to the low levels observed. 
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Figure 27. Adhesion and invasion levels of serotype 1 isolates in the BEAS-2B cell line shown as 
mean CFU ± SEM of adhered bacteria per ml of media with an initial inoculum of 106 
bacteria/ml. Invasion is also shown as a percentage of adhered bacteria. These experiments were 
done in triplicate on three independent days. *P-value<0.05 when analysed using a one-way 
ANOVA. 
 
3.7. Capsule thickness 
A major virulence factor of S. pneumoniae is the polysaccharide capsule, which 
provides protection against opsonophagocytosis by the host immune system. The 
thickness of the capsule can vary between isolates and at different stages of infection. 
An increase in the capsule thickness can lead to an increased protection against the 
host immune system, whilst a reduced capsule thickness can lead to an increased 
ability to adhere to epithelial and endothelial host cells [57, 60, 61]. Therefore by 
measuring the capsule thickness it is possible to determine the relative ability of the 
isolate to evade the host immune system and its potential ability to adhere and cause 
colonisation.  
The capsule thickness of the serotype 1 isolates was determined using a FITC-dextran 
exclusion method and a one-way ANOVA for statistical significance (Figure 28a).  
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Figure 28. a) Capsule thickness of the serotype 1 isolates directly from frozen stocks shown as 
the mean area of a minimum of 100 individual bacterium ± SEM. The encapsulated D39 strain 
and the unencapsulated R6 strain were used as controls. b) Streptococcus pneumoniae serotype 1 
isolate stained using the FITC-dextran method. ***P-value<0.005 and ***P-value<0.001 when 
analysed using a one-way ANOVA. 
 
The FITC-dextran exclusion method requires the total surface area of the bacterium to 
be stained with FITC-dextran and then measured and used to compare the thickness of 
the capsule of different isolates (Figure 28b). This method is based on the premise that 
pneumococci are generally uniform in their size, therefore any size differences 
observed using this method is attributable to differences in capsule thickness. This 
method is used to measure the size of individual pneumococci not found forming 
chains. The area, and therefore capsule thickness, measurements showed no 
differences between the bacteraemia (A42174) and the meningitis (B13969) isolates, 
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but the carriage isolate (W004030) had a significantly thicker capsule than the other 
two serotype 1 isolates (***P-value>0.005). 
 
 
3.8. Opsonophagocytosis killing assay 
In order to assess the ability of the serotype 1 isolates to evade phagocytosis an 
opsonophagocytosis killing assay (OPKA) was performed in which the bacteria were 
opsonised using intravenous IgG (IVIG) and then incubated with baby rabbit 
complement and HL-60 derived neutrophils. This experiment was performed using the 
bacteraemia and the meningitis isolates and the D39 strain as a control. This 
experiment was not done on the carriage strain due to a sudden reduced availability of 
HL-60. A high variability in the activity of different batches of differentiated HL-60 
cells was the reason why the carriage strain was not further tested during 
opsonophagocytic killing assays.  
 
Figure 29. Percentage of IVIG-opsonised bacteria killed by differentiated human neutrophils 
(HL-60) shown as mean ± SEM. This experiment was done in triplicates on three independent 
days. *P-value<0.05 when analysed using a one-way ANOVA. 
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As observed in Figure 29, there were no significant differences in phagocytic killing 
of the different serotype 1 isolates, but both serotype 1 isolates were significantly less 
susceptible to phagocytic killing than the serotype 2 D39 strain with approximately 
80% killing of D39 and 30-50% killing of the serotype 1 isolates (*P-value<0.05).  
 
 
3.9. C3 deposition 
The activation of the host complement system leads to the deposition of complement 
protein C3 on the surface of the pneumococcus resulting in recruitment of phagocytes 
and the phagocytosis of the pathogen [243]. As C3 deposition is closely associated 
with successful opsonisation and phagocytosis of bacteria, it is important to determine 
the levels of C3 deposition on different pneumococcal strains to potentially correlate 
with differences in phagocytosis between isolates. As observed in Figure 30, the three 
serotype 1 isolates had similar levels of C3 deposition and although all 3 strains had 
lower C3 deposition levels than the control serotype 2 (D39) strain, this difference was 
not statistically significant. The reduced levels of C3 deposition on the surface of 
serotype 1 might explain the reduced killing of the serotype 1 isolates observed in the 
opsonophagocytic killing assays (Figure 29). The results are shown as fluorescent 
intensity (FI), and were analysed using a one-way ANOVA. 
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Figure 30. C3 deposition on the surface of serotype 1 isolates and the D39 control strain shown 
as the mean fluorescent intensity ± SEM. These experiments were done in triplicate on three 
independent days. No significant differences when analysed using a one-way ANOVA. 
 
 
 
3.10. Conclusions 
In vitro experiments were performed to characterise the pathogenic phenotype of 
serotype 1 isolates obtained from cases of bacteraemia (A42174), meningitis (B13969) 
or carriage (W004030) to assess possible differences in the pathogenesis related to the 
site of isolation. Experiments that tested bacterial fitness, capsule thickness, adherence 
and invasion of host respiratory tissue, resistance to phagocytic killing and 
complement deposition were performed on all 3 serotype isolates and on the serotype 
2 strain D39, which was used as a phenotype comparator. The experiments clearly 
showed that serotype 1 isolates are phenotypically different from the serotype 2 strain 
D39.  
The haemolytic activity of 20 different serotype 1 isolates from bacteraemia, 
meningitis and carriage was initially tested to try to find isolates with non-haemolytic 
pneumolysin; however, only one strain was found to produce a significantly less 
haemolytic pneumolysin. However, the level of haemolysis was not as low as the 
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ST306 and it had no effect on the pattern of carriage when compared to other serotype 
1 isolates with a higher haemolytic activity.  
Since no significant differences were found between the haemolytic activity of the 
different serotype 1 isolates, with the exception of the already mentioned C9471 
isolate, one isolate from each infection type (bacteraemia, meningitis and carriage) 
was selected for further investigations.  
Growth curves were performed to assess possible differences in the growth rates of the 
three serotype 1 isolates. It was observed that all the isolates had similar patterns of 
growth, although the meningitis isolate was slower during growth when compared to 
the serotype 2 strain D39 and the other serotype 1 isolates. 
Adherence and invasion of the pneumococcus is a key ability needed to cause 
nasopharyngeal carriage and to progress into invasive disease. For that purpose, 
adhesion and invasion assays were performed using a human nasopharyngeal 
epithelial cell line and a human broncho-epithelial cell line to assess the ability of the 
serotype 1 isolates to adhere and invade those cells. All serotype 1 strains, as well as 
the control strain D39, were able to adhere to the nasopharyngeal epithelial cells, but 
not to the broncho-epithelial cells. Adherence of approximately 0.06% of D39 bacteria 
to broncho-epithelial cells has previously been reported; however, the total 
concentration of bacteria and the bacteria:cell ratio used in this study were different 
[313]. Whilst approximately 2x107CFU/ml were used in the published study, only 
106CFU/ml were used in this study. Moreover, the ratio bacteria:cell was 40:1 in the 
published study, a ratio of 20:1 was used for this study. These differences in the 
experimental procedures might explain the low adherence of the pneumococcus to 
BEAS-2B.  
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The main finding from the adhesion and invasion assays was that the meningitis isolate 
was the only isolate, excluding the non-typeable control MLAB7062, able to invade 
the nasopharyngeal epithelial cells. Moreover, the percentage of invading bacteria 
relative to the adhered number of bacteria was significantly higher in the meningitis 
isolate (14.3%) than in the non-typeable isolate (0.04%). These finding suggest that 
the meningitis isolate might be a better invader and therefore might be more able to 
translocate from the nasopharynx to the brain by invasion of the nasopharyngeal 
epithelial tissue.  
The analysis of the capsule thickness of the serotype 1 isolates showed no differences 
in the capsular thickness of the bacteraemia and the meningitis isolates when compared 
to D39. Nonetheless, the carriage strain showed to have a thicker capsule than the other 
two serotype 1 isolates and the control strain D39. These observations contradict the 
hypothesis that a reduction in the thickness of capsule is an adaptation of the 
pneumococcus during nasopharyngeal carriage to improve adhesion to epithelial cells 
and to avoid the activation of immune responses. However, no significant differences 
were observed between the adhesion of the carriage strain to nasopharyngeal epithelial 
cells (Detroit-562) when compared to the other serotype 1 strains. These observations 
suggest that although absence of capsule does increase the adhesion ability of the 
pneumococcus, as observed with the non-typeable MLAB7062 strain, small 
differences in capsule thickness might not affect adhesion ability providing that a 
minimum capsule thickness is present.  
The main clearance mechanism of the pneumococcus is through phagocytosis, 
therefore opsonophagocytic killing assays were performed on the serotype 1 isolates 
and the control strain D39 to assess the ability of serotype 1 to avoid phagocytosis by 
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host cells. No differences were observed between the percentage of killing of the 
bacteraemia and the meningitis serotype 1 isolates; however, a higher percentage of 
killing was observed in the control strain D39. Considering that phagocytosis occurs 
after opsonisation of the pneumococcus, the levels of C3 deposition of the serotype 1 
and the control strain D39 were determined. It was observed that D39 had a higher 
complement deposition on its surface than the serotype 1 isolates, which could explain 
the higher killing of this isolate during the opsonophagocytic killing assays when 
compared to the serotype 1 isolates. 
These in vitro experiments suggested that serotype 1 might be more adapted to avoid 
phagocytosis by reducing the C3 deposition on its surface. Moreover, the adhesion and 
invasion assays suggested that the meningitis isolate may be more invasive than the 
bacteraemia and the carriage isolates.  
The next step was assessing whether the phenotypic differences observed between the 
serotype 1 isolates in vitro contributes to phenotypic differences during 
nasopharyngeal carriage and invasive disease by assessing their performance in vivo. 
In the next chapter, mouse models of infection will be used to determine the virulence 
of these isolates and to better understand the mechanisms of infection of African 
serotype 1 isolates. 
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4: In vivo characterisation of the pathogenicity of pneumococcal 
serotype 1 isolates during invasive pneumococcal disease 
 
4.1. Introduction 
Animal models have been widely used to study infections caused by Streptococcus 
pneumoniae, but whilst certain serotypes have been extensively studied, relatively 
little is known about the pathogenicity of serotype 1 in vivo. The majority of published 
work is based on infections caused by the serotype 2, strain D39, which in an invasive 
pneumonia model is able to cause the death by 48h of 80-100% of mice infected intra-
nasally, although this effect can be mouse strain dependent [254]. Serotype 1 is known 
to have a high attack rate, causing the majority of invasive disease outbreaks in Sub-
Saharan Africa, while being rarely found in carriage [269, 270]. To understand the 
mechanisms of serotype 1 infection, its virulence was determined using a well-
established in vivo pneumonia model [254]. The same model was also used to study 
the host immune responses to serotype 1 invasive infections. 
 
4.2. Virulence testing 
The virulence of each of the serotype 1 isolates was determined by infecting 10 mice 
with either isolates that caused bacteraemia, meningitis or were recovered from 
carriage (Figure 31). The mice were culled either when they became lethargic or five 
days post-infection, which was considered as having survived the infection. Of the 
mice infected with the 3 serotype 1 isolates, 90% to 100% of them started to show 
signs of disease 24h post-infection and all became lethargic between 24h and 48h post-
infection. Mice infected with the meningitis isolate were all dead by 29h post infection, 
whereas 10% of the mice infected with the bacteraemia or the carriage isolates were 
able to survive. Furthermore, by the time the mice infected with the meningitis isolate 
Chapter 4: Invasive disease 
96 
 
had died, only 10% and 30% of mice infected with the carriage and the bacteraemia 
isolates respectively had succumbed to the infection indicating that the development 
and progression of disease was significantly faster with the meningitis isolate. Despite 
this earlier difference though, 90% of mice infected with either the bacteraemia or the 
carriage isolate succumbed to infection within 48h post-infection. In summary, the 
meningitis isolate was significantly more virulent than the bacteraemia and the 
carriage isolates, but no significant differences were observed between the bacteraemia 
and carriage isolates (*P-value<0.05 and ***P-value<0.005). The data was analysed 
using the Log-Rank test analysis, which is used for the comparison of survival curves. 
 
 
Figure 31. Percentage survival of MF1 mice infected with the bacteraemia (A42174), the 
meningitis (B13969) and the carriage (W004030) isolates (n=10). *P-value<0.05 and ***P-
value<0.005 when analysed using the Log-Rank test. 
  
The blood, lungs, nasopharynx and brain of each mouse were collected to determine 
the number of bacteria present in each tissue at the time of death.  
As observed in Figure 32a, there were no significant differences in the numbers of 
bacteria found in the nasopharynx and the brain of mice infected with the different 
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serotype 1 isolates. However, the bacterial load in the lungs of mice infected with the 
meningitis isolate was significantly higher than in the mice infected with the 
bacteraemia or carriage isolates (***P-value<0.005 and ****P-value<0.001 
respectively) when analysed using a two-way ANOVA. Figure 32b shows the number 
of bacteria in blood at 24h post-infection, and at the time of death. The values for the 
mice that survived are highlighted with a circle.  
 
Figure 32. a) Bacterial CFU per mg of nasopharynx, lung and brain tissue of MF1 mice at time 
of death post pneumococcal infection shown as mean ± SEM (n=10). b) Bacterial CFU per ml of 
blood in MF1 mice at 24h post-infection and at time of death (TOD) shown as mean ± SEM 
(n=10). The surviving mice are highlighted with a circle. *P-value<0.05, ***P-value<0.005 and 
****P-value<0.001 when analysed using a two-way ANOVA. 
Chapter 4: Invasive disease 
98 
 
These results indicate that although pneumococci were able to translocate into blood 
in the mice infected with the bacteraemia isolate (A42174), the number of bacteria in 
blood 24h post-infection was much lower in the mice that survived than in the mice 
that eventually succumbed to the infection. Furthermore, the mouse was able to clear 
the infection from the lungs by 96h post-infection, which is when the experiment was 
terminated. The mouse infected with the carriage isolate (W004030) that survived the 
infection had no bacteria in the blood 24h post-infection, which suggests that this 
mouse was able to clear the infection from the lung before the bacteria were able to 
translocate into the blood. 
 
Although the mice infected with the carriage isolate (W004030) had lower number of 
bacteria in the blood 24h post-infection this difference was not statistically significant 
when analysed using a two-way ANOVA. However, the mice infected with the 
meningitis isolate had significantly higher number of bacteria in blood at time of death 
than those infected with the carriage isolate (*P-value<0.05). No differences were 
observed between the bacteraemia and the meningitis isolate or between the 
bacteraemia and the carriage isolate.  
 
4.3. Virulence comparison between isolates from different geographic locations 
As previously mentioned, whole genome sequencing analysis has shown that serotype 
1 isolates cluster into four distinct lineages, with each lineage predominantly 
associated with a single continent [270]. Further phylogeographic analysis determined 
that African serotype 1 isolates cluster together with the isolates from the same country 
of origin [270].  
In order to determine possible virulence differences between isolates of the same 
sequence type but from a different geographic location the virulence of an invasive 
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ST217 isolate isolated from the lung aspirate of a pneumonia patient from The Gambia 
(PNI830) was determined and compared to the virulence of the ST217 bacteraemia 
isolate (A42174) from Malawi. No significant differences were observed in the 
survival of mice infected with either the Malawian or the Gambian ST217 isolates 
(Figure 33a), or in the bacterial numbers in the nasopharynx, lungs, brain or blood at 
time of death of mice infected with either the Malawian or the Gambian isolates 
(Figure 33b). The data was analysed using a Log-Rank test and a two-way ANOVA 
test respectively. 
 
Figure 33. a) Percentage survival of MF1 mice infected with the ST217 bacteraemia strain 
(A42174) from Malawi (Figures 11 and 12), and the ST217 pneumonia strain (PNI830) from The 
Gambia (n=10). b) CFU per mg of tissue or ml of blood of the same MF1 mice infected with the 
ST217 bacteraemia strain (A42174) from Malawi, and the ST217 pneumonia strain (PNI830) 
from The Gambia (n=10) at time of death shown as mean ± SEM. No significant differences 
were observed when analysed using the Log-Rank test and a two-way ANOVA, respectively. 
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4.4. Progression (time-line) of infection during invasive disease by serotype 1 
Based on the results from the in vivo virulence testing experiments where no major 
differences between the carriage and the bacteraemia isolates were observed (Section 
4.2), only the meningitis and the bacteraemia isolates were selected for further 
investigation, in order to investigate further any possible differences between these 
two isolates.  
To determine the timeline of infection, 45 mice were intra-nasally infected with 
106CFU of the bacteraemia isolate and 45 mice were infected with 106CFU of the 
meningitis isolate. Of those, five mice from each group were culled 15 minutes after 
the infection, and ten mice were culled at each of the following time-points post-
infection 3h, 6h, 12h, and 24h to assess the progression of the infection (Figure 34). 
As shown in Figure 34, the infection patterns for both isolates were very similar and 
followed the same patterns as the serotype 2 strain D39 [254]. Moreover, no significant 
differences were observed between the two isolates at any time-point and in any tissue 
when analysed using a two-way ANOVA test. For both isolates, there was no major 
variation of bacterial numbers in the nasopharynx throughout the infection, although a 
slight increase in number was observed between 12h and 24h post-infection. The 
number of bacteria in the lungs increased during the first 6h of the infection until they 
started declining around 12h post-infection, only to go back up by 24h post-infection. 
The decline in bacterial numbers in the lung correlated with the seeding of bacteria 
into blood. Although the mean CFU values for the bacterial isolate in blood were 
higher than for the meningitis isolate at 12h post-infection, this was not statistically 
significant. Finally, no major differences were observed in the seeding of bacteria into 
the brain, which did not occur until 24h post-infection. Although not significant, the 
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number of bacteria in the brain of mice infected with the meningitis isolate was slightly 
higher than in those infected with the bacteraemia isolate.  
 
Figure 34. CFU per mg of nasopharynx (a), lung (b), brain (d) and per ml of blood (c) of MF1 
mice infected with the bacteraemia isolate (A42174) at times +15min, 3h, 6h, 12h and 24h post-
infection shown as mean ± SEM (n=10). Five mice were used for time +15mins and 10 mice were 
used for the rest of the time-points. No significant differences were observed when analysed 
using a two-way ANOVA. 
 
 
In summary, no significant differences were observed in the progression of infection 
caused by the bacteraemia or the meningitis isolate. These findings suggest that ST217 
serotype 1 isolates might follow similar patterns of infection leading to similar 
pathogenic outcomes over similar time-periods. For that reason, only one of the 
isolates was selected for further analysis to understand the mechanism of serotype 1 
invasive disease. The isolate selected was the bacteraemia isolate (A42174). 
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4.5. Lung immune cellular profiling during invasive infection with serotype 1 
The cellular profiling of the lung of 5 MF1 mice infected with the bacteraemia isolate 
(A42174) was determined at different stages of infection using flow cytometry. The 
number of leukocytes (a), B cells (b), T cells (c), T regulatory cells (d), neutrophils (e) 
and macrophages (f) present in the lung are shown in the following figure:  
 
Figure 35. Cellular profiling in the lung of MF1 mice during an invasive infection caused by the 
bacteraemia isolate (A42174) at times +15min, 3h, 6h, 12h and 24h post-infection shown as mean 
± SEM (n=5). *P-value<0.05 and **P-value<0.01 when analysed using a one-way ANOVA. 
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The CD45 marker was used to gate leukocytes, therefore excluding erythrocytes and 
platelets, from the rest of the lung cells. Approximately 105 cells from the whole lung 
were detected to be leukocytes and this number did not change significantly throughout 
the course of the infection (Figure 35a).  
There were between 105 and 106 B cells (CD19+) in the lung at time +15mins post-
infection (Figure 35b). Three hours post-infection the number of B cells in the lung 
were reduced to just below 105 and remained at similar levels throughout the course 
of infection. A one-way ANOVA test showed a significant difference between time 
+15mins and 3h post-infection, but no other significant differences were observed (*P-
value<0.05). The number of T cells (CD3+/CD4+) and T regulatory cells 
(CD4+/FoxP3+) didn’t change throughout the duration of the experiment (Figure 35c 
and 35d). The number of T cells and T regulatory cells in the whole lung was 
approximately 104 and 103 cells respectively. 
The number of macrophages (F4/80+) were stable at a range of 103 to 104 during the 
first 24h of the infection with serotype 1 (Figure 35f). On the other hand, the number 
of neutrophils in the lung of infected mice varied throughout the duration of infection 
(Figure 35e). There were below 105 neutrophils in the lung 15 minutes post-infection, 
with numbers decreasing during the first 6 hours of infection. The lowest number of 
neutrophils was reached 6h post-infection, where the number of neutrophils varied 
between 102 and 105 depending on the mouse. In later stages of infection the number 
of neutrophils significantly increased to approximately 105 cells per lung. The number 
of neutrophils 3h and 6h post-infection were significantly lower when compared to 
24h post-infection when compared using a one-way ANOVA test (*P-value<0.05 and 
**P-value<0.01). 
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 4.6. Cytokine analysis of the lung during invasive infection by serotype 1 
Cytokine levels in the lungs of MF1 mice infected with serotype 1 were determined at 
different stages of infection. This analysis was done on the same lungs used for cellular 
profiling (Figure 35). A selection of cytokines involved in host immune responses 
against bacterial infection was analysed: IL-6, TNF-α, MIP-2 (IL-8), IL-17 and INF-
γ. The changes in cytokine levels during infection are shown in the following figure: 
 
Figure 36. Cytokine analysis of the lung of MF1 mice during an invasive infection caused by the 
bacteraemia isolate (A42174) at times +15mins, 3h, 6h, 12h and 24h post-infection shown as 
mean ± SEM (n=5). *P-value<0.05 when analysed using a one-way ANOVA. 
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As observed in Figure 36a the levels of IL-6 were virtually 0pg/ml throughout most of 
the infection, except 24h post-infection, when there was a significant increase to 400-
500pg/ml coinciding with neutrophil influx (*P-value<0.05). The data was analysed 
using a one-way ANOVA. IL-6 is secreted by macrophages and T lymphocytes, but 
the levels of those cell types were not increased, as observed in Figure 35. IL-6 is 
required for neutrophil influx, therefore the increase in IL-6 levels 24h post-infection 
relates to the increased number of neutrophils found in the lung 24h post-infection.  
The levels of TNF-α followed a similar pattern than IL-6; there were low levels of the 
cytokine throughout the infection followed by a significant increase in TNF-α 24h 
post-infection (Figure 36c). TNF-α is a cytokine mainly produced by macrophages and 
is involved in cellular apoptosis and immune regulation and is an indication of 
inflammation. Therefore an increase in the levels of TNF-α 24h post-infection is a sign 
of the inflammation developed in the lung when the bacterial numbers are as high as 
104cfu/mg of lung (Figure 34).   
There were no significant changes in the levels of IL-17, INF-γ and MIP-2 throughout 
the course of infection (Figures 36b, 36d and 36e). The levels of IL-17 were 
approximately 0pg/ml at the start of the infection and increased gradually, although 
not statistically significantly, between 3h and 6h post-infection. IL-17 is responsible 
of recruiting neutrophils to the site of infection, therefore an increase of this cytokine 
6h post-infection could be related to the neutrophil influx observed after 6h. The levels 
of INF-γ and MIP-2 remained constant at approximately 100pg/ml and 400pg/ml 
respectively. 
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4.7. Blood immune cellular profiling during invasive infection with serotype 1  
The cellular profiling of the blood during an invasive infection in mice infected with 
the bacteraemia serotype 1 isolate (A42174) was determined at times +15mins, 3h, 6h, 
12h and 24h post-infection. The mice used for the cellular profiling of the blood were 
the same mice used for the cellular profiling and cytokine analysis of the lung. The 
percentage of leukocytes (a), B cells (b), T cells (c), T regulatory cells (d), neutrophils 
(e) and macrophages (f) present in the blood of five mice per time point are shown in 
Figure 37.  
The percentage of leukocytes in blood was, as expected, very high. At time +15mins, 
approximately 80% of the cells were leukocytes and this percentage increased during 
the course of infection (Figure 37a). In the last time-points, 12h and 24h, the 
percentage of leukocytes was between 90% and 100%.    
The percentage of B cells was slightly decreased between time +15mins and 3h post-
infection, going from 50-60% to 20-40%; however, this difference was not significant 
(Figure 37b). By 6h post infection the percentage of B cells had returned to the initial 
levels (50-60%) and remained consistent for the rest of the infection. 
Approximately 20% of the leukocytes in the blood were T cells at the beginning of the 
infection (Figure 37c). An increase in the percentage of T cells was observed at the 
early stages of infection, which was followed by a steady decline reaching the low 
percentage of 5-10% by 12h post-infection. The decrease in T cells between 3h and 
12h post-infection was statistically significant when analysed using a one-way 
ANOVA test (*P-value<0.05). The percentage of T cells remained at approximately 
10% during the last hours of infection. Less than 10% of the T cells observed at time 
+15min were T regulatory cells (Figure 37d). The percentage of T cells that were 
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FoxP3+ (T regulatory cells) was significantly increased throughout the course of 
infection from less than 10% to a range of 10-60% at 12h post-infection (*P-
value<0.05). 
 
 
Figure 37. Cellular profiling in blood of MF1 mice during an invasive infection caused by the 
bacteraemia isolate (A42174) at times +15min, 3h, 6h, 12h and 24h post-infection shown as mean 
± SEM (n=5). *P-value<0.05 and **P-value<0.01 when analysed using a one-way ANOVA. 
Chapter 4: Invasive disease 
108 
 
The percentage of neutrophils at time +15min was approximately 20%, which 
gradually declined to 0-15% by 6h post-infection (Figure 37e). During the last hours 
of the infection the percentage of neutrophils significantly increased reaching its peak 
at 24h post-infection at 30-60% (**P-value<0.01). 
The percentage of monocytes in blood was consistently low throughout the course of 
infection (Figure 37f). At time +15mins the percentage of monocytes was 
approximately 0%. This percentage was significantly increased 3h later to 
approximately 5%, with the exception of an outlier that reached approximately 15%. 
The percentage of macrophages remained between 0% and 5% for the rest of the 
infection. 
 
4.8. Cytokine analysis of serum during invasive infection by serotype 1 
The level of selected cytokines in serum of the same MF1 mice used for the cellular 
profiling of the lung and blood, and the cytokine analysis of the lung was determined 
during the course of infection at times +15min, 3h, 6h, 12h and 24h post-infection. 
The cytokines selected were the same set that were studied in the lung: IL-6, IL-17, 
TNF-α, INF-γ and MIP-2 (Figure 38). 
The sera of mice from each time-point were pooled due to the small volume of serum 
available from each mouse and the large quantity of sample required for each ELISA 
test. For that reason, a single data set was obtained for each time-point resulting in the 
inability to perform a statistical test.  
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Figure 38. Cytokine analysis of the serum of MF1 mice during an invasive infection caused by 
the bacteraemia isolate (A42174) at times +15min, 3h, 6h, 12h and 24h shown as mean ± SEM 
(n=5). No statistical test available for this experiment. 
 
 
 
The levels of IL-6 and TNF-α were close to 0pg/ml throughout most of the course of 
infection, until time-point 24h where the levels of both cytokines increased to 
approximately 500pg/ml (Figures 38a and 38c), similarly to what occurs in the lung. 
Contrary to the observation in the lung, the levels of MIP-2 in serum followed the same 
pattern as IL-6 and TNF-α: the levels of MIP-2 were low throughout most of the course 
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of infection until 24h post-infection when the levels reach 1000-1200pg/ml indicating 
high levels of inflammation probably due to the increased number of bacteria in blood 
which induce a release of MIP-2 from blood endothelial vessels (Figure 38e and Figure 
34). 
IL-17 followed a similar pattern in serum as it did in the lungs. There were 
approximately 100-150pg/ml of cytokine in serum at the start of the infection and an 
increase was observed at 6h post-infection, when there was approximately 300pg/ml. 
During the last stages of infection, the levels of IL-17 decreased and reached the initial 
levels of 100-150pg/ml. Therefore, IL-17 probably acted as an early inductor of 
neutrophils, being itself induced by the presence of bacteria in blood 6h post-infection 
(Figure 34). The levels of IL-17 12h post-infection were zero, which was probably due 
to an error in during the detection process, considering that there were a minimum of 
100pg/ml at any other given time-point. 
No INF-γ was detected in serum throughout the course of infection.   
 
4.9. Brain immune cellular profiling during invasive infection with serotype 1 
The same panel of antibodies was used to study the cellular profiling of the brain 
during an invasive infection in MF1 mice with the bacteraemia serotype 1 isolate 
(A42174). This analysis was done on the brain of the same mice used for the cellular 
profiling and cytokine analysis of the lung and the blood.  
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Figure 39. Cellular profiling in the brain of MF1 mice during an invasive infection caused by the 
bacteraemia isolate (A42174) at times +15mins, 3h, 6h, 12h and 24h post-infection shown as 
mean ± SEM (n=5). *P-value<0.05 and **P-value<0.01 when analysed using a one-way ANOVA.  
 
As observed in Figure 39, the number of leukocytes in the brain was very low, never 
exceeding 104cells/tissue throughout the duration of the infection; however, there was 
an increase in leukocytes between time 3h and 12h post-infection (Figure 39a). Due to 
the low number of leukocytes it was not possible to detect any T cells or T regulatory 
cells. Approximately 101 of the leukocytes were B cells at the beginning of the 
infection, a number that went up to 103cells 3h post-infection and remained at that 
level for the rest of the infection (Figure 39b). Due to the variability between mice, the 
increase of B cells when compared to time +15min was only considered significant at 
12h post-infection when analysed using a one-way ANOVA test (*P-value<0.05). 
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Approximately 103 of the leukocytes at time +15min were neutrophils (Figure 39c). 
The number of neutrophils in the brain of infected mice remained constant throughout 
the course of infection.  
However, the number of leukocytes observed to be F4/80+ (microglial cells), was 
approximately 103cells/tissue at the beginning of the infection, a number which 
decreased between +15min and 3h post-infection only to increase to the original levels 
by 6h post-infection (Figure 39d). The percentage of microglial cells in the brain of 
mice infected with the bacteraemia serotype 1 isolate was significantly higher 6h and 
12h post-infection than at time 0h when analysed using a one-way ANOVA test (*P-
value<0.05 and **P-value<0.01).  
 
4.10. Cytokine analysis of the brain during invasive infection by serotype 1  
The levels of IL-6, IL-17, TNF-α, INF-γ and MIP-2 were determined in the brains of 
MF1 mice infected with the bacteraemia serotype 1 isolate (A42174) (Figure 40). The 
analysis was done on the same mice used for the cellular profiling of the lung, blood 
and brain, and cytokine analysis of the lung and serum.  
No IL-6 and TNF-α were detected at the start of the infection (Figure 40a and 40b). 
The levels of these cytokines in the brain did not change throughout the course of the 
infection, remaining at 0pg/ml. 
The levels of MIP-2 at the start of the infection were 200-400pg/ml (Figure 40e). Even 
though there was a reduction in this cytokine between time 0h and 3h post-infection, 
this was not significant when analysed using a one-way ANOVA. The levels of MIP-
2 remained constant for the rest of the infection at a concentration of 100-300pg/ml. 
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Similarly to MIP-2, the levels of INF-γ remain constant throughout the course of 
infection, with the numbers ranging between 0 and 100pg/ml (Figure 40d). On the 
other hand, the levels of IL-17 were between 0pg/ml and 50pg/ml at the start of the 
infection, which were increased 3h post-infection to 25-200pg/ml (Figure 40b). After 
the peak in IL-17 levels at 3h post-infection, there was a gradual reduction of this 
cytokine in the brain (*P-value<0.05). The data was analysed using a one-way 
ANOVA test. 
 
Figure 40. Cytokine analysis of the brains of MF1 mice during an invasive infection caused by 
the bacteraemia isolate (A42174) at times +15min, 3h, 6h, 12h and 24h shown as mean ± SEM 
(n=5). *P-value<0.05 when analysed using a one-way ANOVA. 
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4.11. Conclusions 
An in vivo model of invasive pneumococcal pneumonia was used to study the 
pathogenicity and host interactions of serotype 1. Initially, isolates from different 
sources (carriage, meningitis and bacteraemia) were used to determine potential 
differences in virulence between isolates. It was observed that 90-100% mice infected 
with serotype 1, independently of the isolate used, developed septicaemia leading to 
the death of the mouse. Although most mice succumbed to the infection in the first 
48h, the survival time of the mice infected with the meningitis isolate was significantly 
reduced when compared to mice infected with the bacteraemia or the carriage isolates. 
Bacterial numbers in different tissues were determined at time of death, showing no 
significant differences in numbers in the nasopharynx or the brain. However, the 
number of bacteria in the lungs was significantly higher in mice infected with the 
meningitis isolate when compared to the other two isolates. No differences were 
observed in the bacterial load in blood 24h post-infection; on the contrary, more 
bacteria were detected in blood at time of death of mice infected with the meningitis 
isolate when compared to the carriage isolate. No differences were observed between 
the bacteraemia and the meningitis isolate, or between the bacteraemia and the carriage 
isolate.  
No significant differences were observed in the virulence of the bacteraemia and the 
carriage isolates, and for that reason the bacteraemia and the meningitis isolates were 
used to further study the progression of serotype 1 infections.  
When bacterial numbers were determined in different tissues at specific pre-
determined time-points (+15min, 3h, 6h, 12h and 24h) no differences were observed 
between the bacteraemia and the meningitis isolate suggesting that the progression of 
infection for the two isolates was similar. Therefore, further experiments were 
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performed to understand the pathogenicity of serotype 1 isolates focusing on just the 
bacteraemia isolate. Those experiments included flow cytometry to determine the 
cellular profiling of different tissues during invasive disease with serotype 1, and 
cytokine analysis to understand the host immune responses to serotype 1 infections.   
The cellular profiling of the lung showed no significant changes during the timecourse 
of infection with the exception of a small reduction in B cells in the first three hours 
post infection and a variation in the number of neutrophils. There was a small reduction 
in the number of neutrophils in the lung during the first hours of infection followed by 
an increase during the last stages of infection. This suggests that during the initial 
stages the host is using the neutrophils in the lung to try to control the infection by 
phagocytosis. In the final stages of infection, the number of bacteria in the lungs 
increase. An increase in neutrophils is usually required to try to control the infection; 
however, the increase of neutrophils was not enough to control the infection in this 
case. The lack of early activation of immune cells suggests that serotype 1 has a 
mechanism of immune evasion to avoid clearance. Moreover, there was no activation 
of T regulatory cells, which is observed in other serotypes, which suggests a lack a 
protective immunity leading to uncontrolled tissue damage [386]. The increase in 
neutrophils at the final stages of infection was likely to be due to an early increase in 
IL-17 observed 6h post-infection and an increase in IL-6 observed 24h post-infection. 
Moreover, there was an increase in TNF-α at 24h post-infection which was probably 
used as a mechanism to induce neutrophil influx and to immune-modulate to reduce 
inflammation. Increased IL-6 led to an increase in activated macrophages, but not in 
the total number of macrophages. The levels of INF-γ and MIP-2 in the lungs remained 
constant throughout the course of infection. 
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In blood, there was a small increase in leukocytes during the infection. A reduction of 
T cells was observed, but the percentage of T cells found to be T regulatory cells 
increased throughout the infection. An increase was observed in macrophages and 
neutrophils in the early stages of infection and at the late stages of infection 
respectively. An increase in IL-6, TNF-α and MIP-2 in blood was probably due to the 
increased numbers of T cells, macrophages and neutrophils which coincided with the 
appearance of the first bacteria in blood. There was also an increase in IL-17 by 6h 
post-infection in blood, which coincided with the translocation of the first bacteria into 
blood, which is probably responsible for the increase number of neutrophils observed 
after 6h post-infection. No differences were observed in the levels of INF-γ in blood. 
The translocation of bacteria from the blood to the brain occurs between 12h and 24h 
post-infection; no pneumococci were found in the brain 12h post-infection, but by 24h 
post-infection there were between 0 to 102 bacteria per mg of tissue. As observed in 
the cellular profiling study and the cytokine analysis of the brain, no immune responses 
are induced during pneumonia or even during sepsis in the brain. The brain is 
considered to have limited pathogen-specific immune responses due to the lack of a 
lymphatic system which would allow the migration of immune cells [314]. However, 
there was a decrease of microglial cells during the first three hours of infection only to 
increase to the original levels by 6h post-infection. An increase in the levels of IL-17 
observed 3h post-infection might explain the increase of microglial cells observed 
between 3h and 6h post-infection. No changes were observed in the levels of IL-6, 
TNF-α, INF-γ and MIP-2. This observation suggests that the immune responses in the 
brain are limited, with microglial cells being the main innate cell type. The number of 
bacteria in the brain remained close to zero until 24h post-infection, at which point the 
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brain is not able to generate a strong immune response due to the large damaged caused 
in other organs during sepsis.  
In summary, the invasive pneumonia model of infection using serotype 1 isolates 
clearly demonstrated that there were no major differences in virulence between niche 
specific serotype 1 isolates. The cellular profiling and cytokine analysis during 
infections with serotype 1 shows that due to the fast progression of infection the 
adaptive immune system is not involved in controlling the infection; therefore, the 
innate immune system is the only defence against pneumococcal invasive disease in 
naive mice. However, the immune responses to serotype 1 infection seem to be delayed 
when compared to other serotypes, which reflects in the increased virulence of 
serotype 1 [386].  
It is well documented that serotype 1 is rarely detected during carriage, yet it is highly 
invasive. Therefore the next step was to study the ability of serotype 1 to be carried in 
the nasopharynx of the mice. The nasopharyngeal carriage model was used to study 
the patterns of colonisation by serotype 1.   
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5. In vivo characterisation of pneumococcal serotype 1 isolates 
during nasopharyngeal carriage 
 
 
5.1. Introduction 
The pneumococcus is a common commensal of the nasopharynx of healthy individuals 
although some serotypes, like serotype 1, are rarely found during nasopharyngeal 
carriage. Carriage is considered a pre-requisite for invasive disease, therefore low 
carriage rates would suggest low invasiveness. Contradictorily, serotype 1 is one of 
the main causes of pneumococcal invasive disease, accounting for approximately 20% 
of the cases in sub-Saharan Africa, despite very low carriage rates [269, 270]. These 
observations have led investigators to question whether serotype 1 is able to establish 
stable nasopharyngeal colonisation or whether serotype 1 can carry for the same 
duration and at the same density as other serotypes. The nasopharyngeal carriage 
mouse model was used in this study to study the carriage pattern of serotype 1 isolates 
in mice. 
 
5.2. Pneumococcal serotype 1 during nasopharyngeal carriage in mice 
The bacteraemia (A42174), the meningitis (B13969) and the carriage (W004030) 
serotype 1 strains were used in the carriage model of infection in which mice were 
infected with 105 bacteria of either strain. The infection was performed intra-nasally 
in a total volume of 10μl, allowing the bacteria to stay only in the nasopharynx without 
seeding into the lungs. Three mice per strain were culled straight after the infection 
(day 0) and five more were culled at each time-point on days 1, 3, 7 and 14 post-
infection. The bacterial numbers per mg of nasopharynx were determined and are 
shown in Figure 41. 
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Figure 41. Nasopharyngeal carriage with serotype 1 isolates. Pneumococcal CFU per mg of 
nasopharyngeal tissue of MF1 mice infected with the bacteraemia (A42174), meningitis 
(B13969) and carriage (W004030) isolates at days 0, 1, 3, 7 and 14 post-infection shown as 
median value (a) and CFU of individual mice (b). Three mice were used for the day 0 control, 
and five mice were used for the rest of the time-points. No significant differences were observed 
when analysed using a two-way ANOVA. 
 
As observed in Figure 41, the number of bacteria in the nasopharynx of mice on day 0 
ranged between 101 and 102CFU/mg of tissue. One day post-infection the number of 
bacteria increased approximately half a log for the bacteraemia and the meningitis 
isolate and approximately one log for the carriage isolate. On day 3 post-infection the 
nasopharyngeal bacterial numbers reached their peak at approximately 103CFU/mg of 
tissue and started declining after that point to be almost cleared by day 14 post-
infection. Although the carriage strain was found at a slightly higher density during 
days 1, 7 and 14, the differences were not significant when analysed using a two-way 
ANOVA, probably due to the large variation between mice infected with the same 
strain. Since there were no significant differences in the patterns of colonisation 
between the different strains only the bacteraemia and the meningitis isolates were 
used for further investigation. 
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Although the number of bacteria in the nasopharynx of mice infected with either the 
bacteraemia or the meningitis isolates was close to zero at 14 days post-infection, it 
was necessary to extend the experiment beyond 14 days to see if there would be any 
recovery of pneumococcal numbers post day 14. For that reason the same experiment 
was repeated and bacterial numbers were assessed at 0, 1, 3, 7, 14 and 21 days post-
infection. The bacterial numbers for each individual mouse and the median for each 
time point and for each strain is shown in Figure 42. The same pattern of 
nasopharyngeal colonisation was observed in this experiment. It was found that the 
bacteraemia isolate was cleared from the nasopharynx of 100% of the mice by day 21, 
whilst 40% of the mice infected with the meningitis isolate were still carrying the 
bacteria, although at low density; however, no significant differences were observed 
between isolates when analysed using a two-way ANOVA test.    
 
 
Figure 42. Pneumococcal CFU per mg of nasopharyngeal tissue of MF1 mice infected with the 
bacteraemia (A42174) and meningitis (B13969) isolates at days 0, 1, 3, 7, 14 and 21 post-
infection shown as median (a) and the CFU of individual mice (b). Three mice were used for the 
day 0 control, and five mice were used for the rest of the time-points. No significant differences 
were observed when analysed using a two-way ANOVA. 
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In order to assess whether the presence of bacteria in the nasopharynx of mice infected 
with the meningitis isolate on day 21 post-infection was due to an improved adapted 
ability of those bacteria to colonise, the B13969 bacteria recovered after 21 days of 
carriage (highlighted in Figure 42) were re-tested in the nasopharyngeal carriage 
model for a further 14 days and compared to the original B13969 strain.  
 
 
Figure 43. Pneumococcal CFU per mg of nasopharyngeal tissue of MF1 mice infected with the 
meningitis isolate (B13969) and the same meningitis isolate after carrying for 21 days in the 
nasopharynx of a mouse (B13969 carried for 21 days) at days 0, 1, 3, 7 and 14 post-infection 
shown as median (a) and the CFU of individual mice (b). Three to five mice were used for the 
day 0 control, and five mice were used for the rest of the time-points. No significant differences 
were observed when analysed using a two-way ANOVA. 
 
 
As observed in Figure 43, the patterns of infection of both strains were very similar 
with the exception of day 14 where the bacterial numbers of the B13969 isolates that 
had been carried for 21 days were almost a log higher than the original B13969 isolate. 
However, the differences were not significant when analysed using a two-way 
ANOVA, due to the high variability observed between mice. 
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5.3. Cellular profiling and cytokine analysis during nasopharyngeal carriage 
There are two tissues that have been shown to be important in the regulation of 
pneumococcal nasopharyngeal carriage in mice: the nasal associated lymphoid tissue 
(NALT) and the cervical lymph nodes (CLN) [236]. The cellular profiling of these two 
tissues was studied by flow cytometry in order to study the immune response to 
pneumococcal nasopharyngeal carriage by serotype 1 in mice. Given that no 
differences were observed in the patterns of nasopharyngeal carriage of the three 
serotype 1 isolates studied, only the bacteraemia isolate was used for the study of host 
immune responses to nasopharyngeal carriage by serotype 1. The cytokine levels in 
nasopharyngeal homogenates were also studied to better understand the immune 
response to nasopharyngeal carriage. The bacterial numbers of the carriage experiment 
used for the cellular profiling and cytokine analysis during nasopharyngeal carriage 
with the bacteraemia isolate (A42174) are shown in Figure 44. 
 
 
Figure 44. Pneumococcal CFU per mg of nasopharyngeal tissue of MF1 mice infected with the 
bacteraemia (A42174) isolate at days 0, 1, 3, 7 and 14 post-infection shown as median (a) and the 
CFU of individual mice (b). Three mice were used for the day 0 control, and five mice were used 
for the rest of the time-points. No significant differences were observed when analysed using a 
two-way ANOVA. 
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5.3.1. Nasal associated lymphoid tissue (NALT) 
The nasal associated lymphoid tissue is located in the nasopharynx and has been shown 
to be important in the regulation of nasopharyngeal carriage in mice [236]. 
As observed in Figure 45a, the number of leukocytes in the NALT was approximately 
103 at the time of infection (day 0) and there was 0.5 log increase on days 1 and 3 post-
infection, although this increase remained outside statistical difference. The most 
abundant haematopoietic cell type in this tissue was found to be B cells which 
remained consistent throughout the duration of nasopharyngeal carriage at a level of 
approximately 103 (Figure 45b). 
T cells were found to also remain constant throughout the carriage period at a level of 
approximately 5x102 per whole tissue, with approximately 50% of those cells 
belonging to the T regulatory cell subtype (Figures 45c and 45d). No significant 
differences were observed in the number of T cells and T regulatory cells throughout 
the duration of carriage. 
The numbers of phagocytic cells studied in this experiment (neutrophils and 
macrophages) were very similar, both of them ranging between 102 and 103 throughout 
the carriage period (Figures 45e and 45f).  In both cases there was a small (but non-
significant) increase in the number of cells during days 1 and 3 post-infection. . 
A one-way ANOVA test was used to determine possible significant differences in the 
number of each cell type throughout the duration of carriage. 
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Figure 45. Mean ± SEM of a) leukocytes, b) B cells, c) T cells, d) T regulatory cells, e) 
neutrophils and f) macrophages in the nasal associated lymphoid tissue during nasopharyngeal 
carriage with the bacteraemia serotype 1 strain (A42174) in MF1 mice at days 0, 1, 3, 7 and 14 
post-infection. Three mice were used for the day 0 control, and five mice were used for the rest 
of the time-points. No significant differences were observed when analysed using a one-way 
ANOVA. 
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5.3.2. Cervical Lymph nodes 
The cervical lymph nodes analysed in this study were the mandibular lymph nodes and 
the superficial parotid lymph nodes, which are situated in the cervical area of mice. As 
with the nasal associated lymphoid tissue, these lymph nodes have previously been 
shown to play an important role in the regulation of nasopharyngeal carriage [236, 
315].  
As observed in Figure 46a, the number of leukocytes in the cervical lymph nodes was 
higher than in the nasal associated lymphoid tissue ranging between 105 and 107. Of 
these leukocytes, the most abundant cell type were the B cells and T cells, both ranging 
between 105 and 106 (Figures 46b and 46c). From the T cells, approximately 5x104 
were found to be T regulatory cells and no changes were observed in the number of 
these cells throughout the duration of carriage (Figure 46d). 
The number of neutrophils and macrophages was different in this tissue, with the 
neutrophils ranging between 103 and 105 and the macrophages ranging between 103 
and 104 (Figures 46e and 46f). Although the number of macrophages in the cervical 
lymph nodes was very consistent throughout mice and time-points, there was a higher 
variability in the number of neutrophils in mice on days 3 and 7 post-infection. The 
high variability in the number of neutrophils in the CLN was probably related to the 
variability in bacterial numbers found in the nasopharynx during these days. The 
bacterial number reached a peak three days post-infection, and the number of 
neutrophils in the CLN could be decreased in those mice that are clearing the infection 
at day 7 due to the migration of those neutrophils to the site of infection, the 
nasopharynx. 
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This data was analysed using a one-way ANOVA test to determine possible significant 
differences in the number of each cell type between time-points. 
 
Figure 46. Mean ± SEM of a) leukocytes, b) B cells, c) T cells, d) T regulatory cells, e) 
neutrophils and f) macrophages in the cervical lymph nodes during nasopharyngeal carriage 
with the bacteraemia serotype 1 strain (A42174) in MF1 mice at days 0, 1, 3, 7 and 14 post-
infection. Three mice were used for the day 0 control, and five mice were used for the rest of the 
time-points. No significant differences were observed when analysed using a one-way ANOVA. 
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5.3.3. Cytokine production during nasopharyngeal carriage 
Cytokines are small proteins secreted by host cells to communicate between each other 
allowing the recruitment and activation of other immune cells. There are some 
cytokines (i.e. IL-10 and TGF-β1) that have previously been shown to be important in 
maintenance of carriage, and others (i.e. IL-17 and IL-1β) that have been shown to be 
important for pneumococcal clearance during invasive disease [104, 386]. 
The concentration of cytokines in the nasopharynx during nasopharyngeal carriage by 
the bacteraemia serotype 1 isolate (A42174) was studied to determine possible 
explanations for the early clearance and low duration of carriage by serotype 1. The 
cytokines studied during nasopharyngeal carriage were IL-6, IL-10, KC, INF-γ, IL-1β, 
MIP-2, IL-17, TNF-α and active TGF-β1 based on their key roles in inflammation, 
protective immunity and regulation.  
IL-6 was not detected at any stage of serotype 1 strain A42174 carriage in the 
nasopharynx of mice (Figure 47a). The nasopharyngeal concentration of IL-10 ranged 
between 250 and 300pg/ml throughout the duration of carriage, with no significant 
differences observed between time-points (Figure 47b).  
As observed in Figures 47c to 47h, the rest of the cytokines analysed (INF-γ, IL-1β, 
MIP-2, IL-17, TNF-α, active TGF-β and KC) followed similar patterns throughout the 
nasopharyngeal carriage period starting at low concentrations at time 0 and either 
gradually increasing throughout the carriage period to reach its peak on day 14 post-
infection (INF-γ, MIP-2, IL-17, active TGF-β and KC) or increasing only on day 14 
post-infection (IL-1β and TNF-α). Previous studies with the serotype 2 strain D39 have 
shown that in order for pneumococcal nasopharyngeal carriage to be maintained, the 
pneumococcus has to induce the production of TGF-β1 in nasopharyngeal cells 
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resulting in an elevated concentration of TGF-β1 and a high number of T regulatory 
cells which allow carriage to be maintained [104]. However in these experiments, the 
induction of active TGF-β1 in mice carrying serotype 1 did not occur until day 14, 
when the pneumococcus had already been cleared from the nasopharynx suggesting 
that serotype 1 behaves differently to other pneumococcal serotypes. The lack of TGF-
β1 induction together with the lack of a T regulatory cell increase (Figures 45d and 
46d) during nasopharyngeal carriage with serotype 1 suggests that this serotype is not 
able to induce the production of TGF-β1 and T regulatory cells which results in an 
impaired maintenance and subsequent clearance of nasopharyngeal carriage. In the 
same study with the serotype 2 strain D39 it was observed that mice carrying the 
pneumococcus for a prolonged time had increased levels of IL-10 during the early 
stages of carriage [104], whilst in this study the levels of IL-10 were constant 
throughout the experimental time. IL-10 is a suppressive cytokine that has anti-
inflammatory properties, and like TGF-β1, can be a marker for immunomodulation 
and tolerance during carriage. Therefore, no variation in the levels of IL-10 in the 
nasopharynx of mice carrying serotype 1 may explain the early clearance of this 
serotype from the nasopharynx.  
In summary, the lack of induction of modulatory cytokines and T cells that regulate 
the inflammatory response may lead to the clearance of serotype 1 from the 
nasopharynx due to an increased number of phagocytes on days 1 and 3 post-infection 
(Figure 45) induced by tissue damage caused by the high levels of bacteria in the 
nasopharynx on day 1 and 3 (Figure 44). The lack of induction of modulatory 
cytokines, such as IL-10 and TGF-β1, lead to an increase of the pro-inflammatory 
cytokines MIP-2, IL-17, IL-1β, TNF-α and INF-γ which may lead to the clearance of 
serotype 1 [1, 2, 3, 4].  
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Figure 47. Mean ± SEM of a) IL-6, b) IL-10, c) INF-γ, d) IL-1β, e) MIP-2, f) IL-17, g) TNF-α, h) 
active TGF-β1 and h) KC in the nasopharynx of mice infected with the bacteraemia strain 
(A42174) during the nasopharyngeal carriage experiment at days 0, 1, 3, 7 and 14 post-infection. 
Three mice were used for the day 0 control, and five mice were used for the rest of the time-
points. *P-value<0.05 and **P-value<0.01 when analysed using a one-way ANOVA. 
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5.4. Antibody production during nasopharyngeal carriage 
The cellular profiling of the nasal associated lymphoid tissue and the cervical lymph 
nodes suggested that nasopharyngeal carriage by serotype 1 does not induce a strong 
host immune response. Considering the short duration of carriage of serotype 1 the 
concentration of IgA and IgG was determined from the nasopharynx and the serum 
respectively of mice carrying the serotype 1 strain A42174 to assess the induction of 
antibody production during carriage up to 28 days.  
 
5.4.1. IgA production 
IgA is the main immunoglobulin found in mucosal secretions [153], therefore the 
concentration of this immunoglobulin in the nasopharynx of mice carrying the 
bacteraemia isolate (Figure 44) was determined to assess the ability of serotype 1 to 
induce production of mucosal immunoglobulin.  
 
Figure 48. Concentration of IgA in the nasopharynx of MF1 mice carrying the bacteraemia 
isolate (A42174) at days 0, 1, 3, 7 and 14 post-infection shown as mean ± SEM. Three mice were 
used for the day 0 control and five mice were used for each of the experimental time-points. No 
significant differences were observed between time-points when analysed using a one-way 
ANOVA. 
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As observed in Figure 48, there were no detectable levels of IgA in the nasopharynx 
during the first 7 days of carriage. Subsequently, there was an increase from 0 to 
40ng/ml, 14 days post-infection in 40% of the mice infected with serotype 1, which 
were the mice still carrying the pneumococci 14 days post-infection. In previous 
studies it has been shown that an increase in IgA starts 3 days post-colonisation and 
peaks approximately 7 days into nasopharyngeal colonisation with the serotype 2 
strain D39 [238]. In contrast, induction of IgA production during carriage with 
serotype 1 is not observed until day 14 post-infection. Furthermore, IgA was only 
detected in the mice still carrying the pneumococcus by that day indicating that IgA 
production in serotype 1 is a late response during nasopharyngeal carriage and only 
occurs if the mouse has been carrying the isolates for approximately 14 days. 
 
5.4.2. Total IgG production 
IgG is the most abundant immunoglobulin found in serum and it can neutralise 
pathogens, activate complement pathways and effector cell functions leading to 
cytokine secretion and phagocytosis [316]. 
In this study total IgG levels were determined from the serum of mice carrying the 
serotype 1 strain A42174 and the Malawian serotype 6B strain D33275, which was 
used as a control. The 6B isolate was used as a control because it is a serotype 
commonly associated with carriage [317]. As observed in Figures 49a and 49b, the 6B 
strain D33275 was able to establish nasopharyngeal colonisation in mice for a longer 
period of time than the serotype 1 strain A42174, as it did not get completely cleared 
until 28 days post-infection. Furthermore, the levels of 6B bacteria colonising the 
nasopharynx was consistent throughout the study period, whilst the number of 
serotype 1 bacteria increased on day 3 post-infection, being significantly higher than 
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6B on that time-point when analysed using a two-way ANOVA (****P-value<0.001). 
When the levels of total IgG in serum were determined it was observed that, although 
not significant, there was an increase in IgG levels in mice infected with serotype 1 
when compared to mice infected with serotype 6B on days 7 and 14 post-infection 
(Figure 49c).   
 
Figure 49. Pneumococcal CFU per mg of nasopharyngeal tissue of MF1 mice infected with the 
bacteraemia (A42174) serotype 1 isolate and the serotype 6B strain D33275 at days 0, 3, 7, 14, 21 
and 28 post-infection shown as median (a),the CFU of individual mice (b) and the levels of total 
IgG in serum shown as mean mg/ml ± SEM (c). Five mice were used for each time-point. ****P-
value<0.001when comparing serotype 1 and serotype 6 in each time point using a two-way 
ANOVA. *P-value<0.05 when comparing the IgG levels for each serotype during different time 
points. 
 
In a previous study it was shown that an early increase in the levels of Anti-PspA IgG 
results in the early clearance of the pneumococcus from the nasopharynx of mice 
[238]. The increased levels of total IgG in mice infected with serotype 1 coincided 
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with the time when serotype 1 was getting cleared from the nasopharynx, hence these 
observations suggest that the increase in the levels of IgG in mice infected with 
serotype 1 could be associated with the earlier clearance from the nasopharynx of 
serotype 1 when compared to serotype 6B.   
 
5.4.3. Antibody functionality in vitro 
An increase in total IgG from serum of mice carrying the serotype 1 strain A42174 
was observed from 7-14 days post-infection. By 21 days post-infection, the 
concentration of total IgG in serum decreased to return to the same levels observed on 
day zero. In order to assess the functional activity of increased IgG in serum, an 
opsonophagocytic killing assay (OPKA) was performed opsonising the bacteria with 
either the serum from mice carrying the serotype 1 strain B13969 for 10 days or serum 
from naïve mice. Serum from mice infected with either the bacteraemia or the 
meningitis strains were going to be used for this experiment but the serum from the 
bacteraemia infected mice was accidentally destroyed during the heat inactivation 
process; therefore, only the serum from meningitis infected mice was used. In order to 
assess whether the IgG was serotype specific or even strain specific, three different 
strains were used in the OPK assay: the serotype 2 strain D39, the serotype 1 strain 
A42174 and the serotype 1 strain B13969. The serum used was a pool of 5 mice. 
As observed in Figure 50a, mice infected with the meningitis strain (B13969) had 
approximately double the amount of IgG in serum than naïve mice (*P-value<0.05). 
When compared to the levels of total IgG in mice infected with the bacteraemia strain 
(Figure 49b), the mice infected with the meningitis strain seemed to have a lower 
concentration of immunoglobulin in serum. Considering that the levels of IgG in naïve 
mice was also lower in this experiment when compared to the bacteraemia experiment 
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this observation was probably due to a technical problem during the heat inactivation 
of the serum or during the ELISA process. Nonetheless, an increase was observed in 
the levels of total IgG in mice carrying either the bacteraemia or the meningitis isolate. 
As observed in Figure 50b, when serum from naïve mice was used as opsonin there 
was no killing of any of the bacterial strains by HL-60-derived neutrophils. When sera 
from mice carrying the meningitis isolate for 10 days was used as opsonin there was 
approximately 40-50% killing of the bacteraemia serotype 1 strain (A42174) and 
approximately 30% killing of the meningitis serotype 1 strain (B13969) (**P-
value<0.01, ****P-value<0.001). Interestingly, no killing was observed in the 
serotype 2 strain D39 when opsonised using the same serum suggesting serotype 
specific antibody generation. These observations suggest that the increase in total IgG 
found in serum during nasopharyngeal carriage by serotype 1 is functional and that 
this functionality is serotype specific. 
 
 
Figure 50. a) Concentration of total IgG found in pooled serum from 5 naïve mice or 5 mice 
carrying the meningitis serotype 1 strain B13969 for 10 days. b) Percentage of killing by HL-60-
derived neutrophils of the serotype 2 strain D39, the bacteraemia serotype 1 strain A42174 and 
the meningitis serotype 1 strain B13969 after opsonisation with serum from naïve mice or from 
mice carrying the meningitis strain for 10 days. The OPKA was done in triplicates on three 
independent days. *P-value< 0.05, **P-value<0.01 and ****P-value<0.001 when analysed using 
a t-test and a two-way ANOVA respectively. 
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5.4.4. Assessment of memory responses in vivo 
The opsonophagocytic killing assay showed that the IgG produced during 
nasopharyngeal colonisation by serotype 1 is functional, and acts as an opsonin 
increasing the ability of phagocytes to kill pneumococci in a serotype-specific manner. 
In this section, the memory immune response in mice was tested in vivo by infecting 
MF1 mice with pneumococci of the bacteraemia serotype 1 strain (A42174) and re-
challenging the same mice with the same infective dose 21 days after the first infection. 
As previously observed (Figure 44), the serotype 1 strain A42174 carries at relatively 
high concentrations during the first 7 days of carriage but starts getting cleared after 
day 7 and is almost 100% cleared by day 21 post-infection. For that reason, the second 
infection was done on day 21 post-infection to ensure that no pneumococci from the 
first infection were still colonising the nasopharynx of the mice.  
 
 
Figure 51. Pneumococcal CFU per mg of nasopharyngeal tissue of MF1 naïve mice or pre-
challenged MF1 mice infected with bacteraemia isolate (A42174) at days 0, 1, 3 and 7 post-re-
infection shown as median (a) and range of the individual mice (b). Three to four mice were 
used for the day 0 control, and five mice were used for the rest of the time-points. No significant 
differences were observed when analysed using a two-way ANOVA. 
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As observed in Figure 51, naïve mice had a peak in pneumococcal numbers in the 
nasopharynx on day 3 post-infection. These bacterial numbers started declining after 
day 3 and by day 7 post-infection were approximately 5x101CFU/mg of tissue, hence 
equivalent to initial infective inoculum (see day zero). However, mice that had 
previously carried serotype 1 for 21 days (and had cleared them), started clearing the 
second infection by day 3 post re-challenge, and had completely cleared all 
pneumococci by day 7. This clearly shows that nasopharyngeal carriage with serotype 
1 induces an adaptive memory immune response upon re-challenge with the same 
serotype, which prevents future carriage events.  
 
5.5. Capsule switch in serotype 1 during nasopharyngeal carriage 
The pneumococcal capsule is an important virulence factor that has been shown to be 
a key determinant of invasiveness and prevalence; certain serotypes are more 
commonly associated with carriage and other serotypes are more commonly associated 
with invasive disease [28, 31, 69]. It has previously been observed that the 
pneumococcus has the ability to change the serotype of a single clone by altering or 
exchanging the cps locus, which encodes the capsular genes [66, 69]. As shown in this 
chapter, serotype 1 is able to establish nasopharyngeal colonisation, although for a 
shorter period of time when compared to other serotypes [238]. Since serotype 1 is 
rarely found in carriage it was hypothesised that serotype 1 could undergo capsular 
switching at high rates during nasopharyngeal colonisation therefore being under-
detected in the nasopharynx of healthy individuals. 
In order to identify possible capsular switching events mice were infected with the 
serotype 1 strain A42174 and after 3 days co-infected with the Malawian serotype 6B 
strain D33275, hence both serotypes were co-localised in the nasopharynx. Serotype 
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6B was chosen for the second infection because it is the fourth most common type 
found causing nasopharyngeal carriage in Malawian children [317]. The second 
infection was done on day 3 to ensure that the maximum density of serotype 1 isolates 
was found in the nasopharynx at the time of co-infection with 6B. A total of 310 single 
colonies were collected from different time-points: 10 colonies from day 3 before the 
6B co-infection which were used as controls, 100 isolates from day 4 (1 day post-co-
infection), 100 isolates from day 6 (3 days post-co-infection) and 100 isolates from 
day 10 (7 days post-co-infection). Phenotypic characterisation of the capsule was done 
by using a serotype 1 specific latex agglutination test. Genotypic characterisation was 
done by sequencing one of the seven house-keeping genes used for multi-locus 
sequencing. The housekeeping gene chosen for the genotypic analysis was the 
xanthine phosphoribosyltransferase (xpt) gene which has 6 allelic differences between 
serotype 1 and serotype 6B. 
146 isolates out of the total 310 isolates were tested using the latex agglutination test 
to determine whether they expressed a type 1 capsule or not.  47 of the isolates tested 
from days 1, 3 and 7 post-co-colonisation, as well as day 3 pre-co-colonisation as 
serotype 1 positive control, were sent to sequencing: 25 serotype 1 positives plus a 
serotype 1 control and 20 serotype 1 negatives (potentially serotype 6B) and a 6B 
control. 100% of the serotype 1 positive isolates were found to contain the serotype 1 
xpt gene and 100% of the serotype 1 negative isolates were found to contain the 
serotype 6 xpt gene. In conclusion, no capsule switch was observed during this 
experiment. Although no capsule switch was detected in this study, only 15% of the 
isolates collected were studied. In the future, it would be interesting to increase the 
number of isolates studied, as capsular switching is a rare event and a very high number 
of isolates might need to be studied to find a single capsular switching event. 
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The number of bacteria in the nasopharynx of mice infected with serotype 1 and 
serotype 6B for the detection of capsular switch can be found in Figure 52. Although 
the introduction of serotype 6B in the nasopharynx of mice already carrying serotype 
1 had no effect on the bacterial numbers of serotype 1, it was observed that the number 
of serotype 6B bacteria during co-colonisation was lower than in the nasopharynx of 
naïve mice (Figure 49a and 49b). This observation suggests that co-competition for 
the nasopharyngeal niche could have important effects on the pattern of carriage of 
different pneumococcal serotypes. For that reason, co-infection experiments were 
studied further.  
 
Figure 52. Pneumococcal CFU per mg of nasopharyngeal tissue of MF1 mice infected with the 
bacteraemia serotype 1 isolate (A42174) on day 0 and re-infected with the serotype 6B isolate 
D33275 shown as median (a) and range of the individual mice (b) at on days 0, 3 (pre-re-
infection), 3 (post-re-infection), 4, 5, 6, 10 and 17 post-infection. Four mice were used for the day 
0 control, and five mice were used for the rest of the time-points. ***P-value<0.005 when 
analysed using a two-way ANOVA. 
 
 
5.6. In vivo competition experiments between serotypes 
A recent study has shown that competitive interactions between different serotypes 
during host colonisation can alter the serotype distribution of nasopharyngeal carriage 
[318]. In the study by Trzciński et al., multiple serotypes were introduced at the same 
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time in the nasopharynx of mice and serotype ratios were determined at different stages 
of colonisation by quantitative PCR [318]. 
In this study however, the effect of multiple co-colonisation on carriage patterns of 
serotype 1 was determined by introducing one serotype on day zero and a second 
serotype 7 days after the first serotype was administered. It is realistic to accept that 
multiple colonisation events are likely to happen by acquisition of new serotypes 
through time, rather than by co-colonisation of different serotypes all at the same time; 
therefore, it was considered that this method was more representative of the clinical 
situation, than the one used by Trzciński et al. 
 
5.6.1. Co-infections with serotypes 1 and 6B 
As observed in Figure 52, when serotype 6B was introduced into the nasopharynx of 
mice already carrying serotype 1 for 3 days, no significant differences were observed 
in the nasopharyngeal carriage pattern of serotype 1. However, the carriage pattern of 
serotype 6B varied when compared to carriage in naïve mice (Figures 49a and 49b) 
suggesting that secondary colonisation of a niche already colonised by pneumococci 
significantly affects the newcomer. In this case serotype 6B was almost completely 
cleared from the nasopharynx by day 7 post-infection when it was introduced into a 
niche already carrying serotype 1, instead of by day 28 post-infection as it was 
observed in naïve mice.  
In order to determine whether this effect was just a reflection of the order of 
introduction of the serotypes, another experiment was done where serotype 6B was the 
one used to initially colonise the nasopharynx, and serotype 1 was the one used as the 
secondary infection. In this case the second infection was performed on day 7 post-
infection to allow the acclimatisation of the firstly introduced serotype. 
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Figure 53. Pneumococcal CFU per mg of nasopharyngeal tissue of MF1 mice infected with the 
serotype 6B isolate (D33275) on day 0 and re-infected with the bacteraemia serotype 1 isolate 
(A42174) on day 7 shown as median (a) and range of the individual mice (b) at on days 0, 3, 7 
(before re-infection), 8 (1 day post-re-infection), 10 (3 days post-re-infection), and 14 (7 days 
post-re-infection) post-infection. Five mice were used for each time-point. No significant 
differences were observed when analysed using a two-way ANOVA. 
 
 
 
As observed in Figure 53, no significant differences were observed in the numbers of 
6B bacteria in the nasopharynx of mice re-infected with serotype 1 when compared to 
mice carrying only 6B in the nasopharynx. However, a substantial difference was 
observed in the number of serotype 1 bacteria when compared to the bacterial numbers 
in mice only carrying serotype 1. The data was analysed using a two-way ANOVA. 
Although no significant differences were observed between the number of bacteria in 
the co-infection and the number of bacteria in naïve mice for each of the serotypes it 
was clear that when serotype 1 was introduced into the nasopharynx of mice already 
carrying other pneumococcal serotypes it was not able to establish colonisation at the 
same density or for the same period of time as it could in naïve mice. 
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5.6.2. Co-infections with serotypes 1 and 19F 
During the competition experiments with serotypes 1 and 6B, it was shown that when 
one serotype was already colonising the nasopharynx of mice, the introduction of a 
second serotype did not affect the nasopharyngeal carriage pattern of the original 
serotype. However, the carriage pattern of the second coloniser was considerably 
affected with reduced duration and density of colonisation. Hence, acquisition of a co-
coloniser would appear to detrimentally affect the ability of the second coloniser to 
compete in the same niche.  
In order to determine whether this observation could be applicable to other serotypes 
the same experiment was performed using serotype 1 and 19F, which has been shown 
to be the most common serotype in nasopharyngeal carriage in Malawian children 
[317]. In this experiment the second serotype was always introduced on day 7 to allow 
full comparison. 
As observed in Figures 54a and 54b, when serotype 19F was introduced 7 days after 
the introduction of serotype 1 no significant differences were observed in the bacterial 
numbers of serotype 1 in the nasopharynx of naïve mice or mice carrying both 
serotypes, although serotype 1 did not seem to clear as quickly during co-infection as 
it did during single colonisation. When 19F was introduced in the nasopharynx of mice 
already carrying serotype 1 the number of serotype 19F bacteria during the first 3 days 
was similar to those in single infected mice. However, 7 days post-re-infection the 
numbers of 19F bacteria in the nasopharynx were higher in naïve mice than in mice 
co-infected with serotype 1 and serotype 19F, which had mostly cleared 19F from the 
nasopharynx. 
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As observed in Figures 54c and 54d, when serotype 1 was introduced 7 days after the 
infection with serotype 19F, serotype 1 was not able to establish colonisation at the 
same density as when infecting naïve mice. Furthermore, the bacterial numbers of 
serotype 19F were significantly increased after introducing serotype 1 in the 
nasopharynx of mice already carrying serotype 19F (*P-value<0.05). This increase 
was only observed one day post-re-infection and the bacterial levels went back to the 
same levels observed in single infected mice. The data was analysed using a two-way 
ANOVA.  
In summary, these in vivo competition experiments clearly show that interactions 
between different serotypes during nasopharyngeal co-colonisation have clear effects 
on carriage density and duration. When serotype 1 is carried and a different serotype 
is subsequently introduced, no significant effect is observed on the carriage pattern of 
the original coloniser. However, when serotype 1 is acquired in mice already carrying 
a different serotype, the outcome on the carriage pattern of the original serotype varied 
amongst serotypes. Whilst there was no significant effect on the carriage pattern of 
serotype 6B, the introduction of serotype 1 significantly increased the density of 
serotype 19F. This observation suggests that the additional acquisition of serotype 1 
into the nasopharynx affects the pathogenicity of other pre-existing serotypes being 
carried. Interestingly, independently of the serotype, pneumococci acquired 
subsequently after the original carrier strain, were always less able to establish 
successful colonisation when compared to their single infections in naïve mice. 
Therefore, secondary acquisition is disadvantageous to the new incoming 
pneumococcal coloniser.  
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Figure 54. Pneumococcal CFU per mg of nasopharyngeal tissue of MF1 mice infected with either 
the bacteraemia serotype 1 strain (A42174) or the serotype 19F isolate and re-infected in on day 
7 with the serotype 19F isolate or the serotype 1 isolate, respectively. Data shown as median (a) 
and range of the individual mice (b) at on days 0, 3, 7 (before re-infection), 8 (1 day post-re-
infection), 10 (3 days post-re-infection), and 14 (7 days post-re-infection) post-infection. Five 
mice were used for each time-point. *P-value<0.05 when analysed using a two-way ANOVA. 
 
 
 
5.6.3. Host immune responses during co-colonisation 
In order to understand the mechanisms behind the different outcomes in the 
competition experiments the cellular profiling of the nasal associated lymphoid tissue 
(Figure 55) and the cervical lymph nodes (Figure 57) was analysed from mice that 
were colonised first with either serotype 6B (6B-1) or 19F (19F-1). 
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Figure 55. Mean percentage ± SEM of a) leukocytes, b) B cells, c) neutrophils and d) 
macrophages in the nasal associated lymphoid tissue of mice infected with serotype 1 after 
carrying serotype 6B (6B-1) or after carrying serotype 19F (19F-1). Five mice were used for 
each time-point. *P-value<0.05, **P-value<0.01, ***P-value<0.005 and ****P-value<0.001 when 
analysed using a two-way ANOVA. 
 
There was a significant difference between the two groups studied in the number of 
macrophages (Figure 55d) and B cells (Figure 55b) in the nasal associated lymphoid. 
The large variability in the number of macrophages made it difficult to draw any 
conclusions. However, there was a significant increase in the number of B cells in the 
6B-1 group when compared to the 19F-1 group which was already significant before 
the introduction of serotype 1, suggesting that 6B might induce B cells at a higher level 
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than 19F and therefore increase the number of antibodies, which might have an effect 
on the bacterial numbers in the nasopharynx after the introduction of serotype 1. In 
order to assess this theory the levels of total IgG in serum were assessed.  
 
 
Figure 56. Concentration of total IgG in pooled serum of five mice per time-point form the a) 
6B-1 co-infection experiment and the b) 19F-1 co-infection experiment shown as mean ± SEM. 
No significant differences were observed when analysed using a two-way ANOVA. 
 
As observed in Figure 56, the levels of total IgG in serum were higher in the 6B-1 
group than in the 19F-1 group although those differences were only present before the 
introduction of serotype 1. These observations suggest that the differences observed 
during competition experiments could be due to the difference in the immune response 
induced by the serotype that is already colonising the nasopharynx before the 
acquisition of the second serotype. 
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Figure 57. Mean percentage ± SEM of a) leukocytes, b) B cells, c) neutrophils and d) 
macrophages in the cervical lymph nodes of mice infected with serotype 1 after carrying 
serotype 6B (6B-1) or after carrying serotype 19F (19F-1). Five mice were used for each time-
point. *P-value<0.05, **P-value<0.01, ***P-value<0.005 and ****P-value<0.001 when analysed 
using a two-way ANOVA. 
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In the cervical lymph nodes there were significant differences in the numbers of T 
regulatory cells and macrophages one day after the re-infection. The number of T 
regulatory cells (Figure 57d) was higher in the 19F-1 infection when compared to the 
6B-1 infection, but there were already significant differences between groups before 
the introduction of serotype 1. This observation suggests that 19F was able to induce 
the production of T regulatory cells during single carriage which might help the 
maintenance of carriage. This increased number of T regulatory cells might later on 
help to control the induction of pro-inflammatory cytokines allowing the bacteria to 
grow even after the introduction of another serotype. Regarding the increased number 
of macrophages (Figure 57f) in the 6B-1 group when compared to the 19F-1 group, 
the high variability observed in the number of macrophages, even at time 0 post-
infection, makes it difficult to draw any conclusions. 
 
5.7. Conclusions 
There are different hypothesis to explain why serotype 1 is one of the major causes of 
invasive disease regardless of not being commonly found causing nasopharyngeal 
carriage:  
a) serotype 1 is carried but is undetected by the current methods of detection 
b) serotype 1 carries at low density and/or  
c) serotype 1 carries for a short period of time.  
A mouse model of nasopharyngeal carriage was used in this chapter to understand the 
patterns of nasopharyngeal carriage by serotype 1. 
The bacteraemia, meningitis and carriage strains were used in the in vivo 
nasopharyngeal carriage model to determine the duration and density of carriage of 
serotype 1, and to assess any possible differences in the carriage patterns of those 
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isolates. The three strains were able to establish nasopharyngeal colonisation in mice 
at a density of approximately 5x101 bacteria per mg of tissue. During the first three 
days of carriage the bacterial numbers increased until reaching their peak on day 3 
with a density of 5x102 to 103 bacteria per mg of tissue. After this point the bacterial 
density started declining until being almost cleared by day 14 post-infection. Although 
the three strains followed the same pattern during carriage, the carriage strain 
W004030 was carried at a higher density for most of the experiment suggesting that 
during colonisation serotype 1 is able to acquire certain adaptations allowing it to 
better colonise at a higher density. Although the density of the carriage strain was 
slightly higher when compared to the bacteraemia and the meningitis isolates there 
was no significant difference in the duration of carriage suggesting that the adaptive 
changes acquired during colonisation are not related to carriage duration. Indeed, when 
meningitis isolates that had been carrying in the mice for 21 days were used for a 
subsequent infection, the same results were found: the isolates were able to carry at a 
higher density than its wildtype but no significant differences were seen in the duration 
of carriage. These observations suggest that independently of the site of isolation, all 
serotype 1 ST217 strains are virtually the same isolate which occasionally is able to 
acquire adaptations to specific niches. These adaptations to specific niches can be 
permanent changes such as epigenetic changes which are genetic changes that are 
influenced by the environment, or single point mutations (SNPs) that can be acquired 
by random mutations. Alternatively, these changes can be transient by up-regulation 
or down-regulation of the expression of important metabolic pathways or specific 
virulence factors. Future experiments (i.e. whole genome sequencing) could be done 
to assess if these adaptations are permanent or transient.  
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The study of the host immune response to serotype 1 suggests that this pneumococcal 
serotype induces a late immune response in the nasopharynx which leads to the early 
clearance from the nasopharynx although it induces a serotype specific IgG production 
that contributes to protection against future colonisation events by the same serotype. 
It would be interesting to study the duration of this acquired protection; if this was a 
long lasting protection it would mean that individuals that had already been carrying 
serotype 1 would be protected from future carriage events, hence the low detection 
levels of serotype 1 causing nasopharyngeal carriage. 
Finally, it was observed that the bacterial density and the duration of carriage of 
different serotypes changed during co-infections. The introduction of a serotype in the 
nasopharynx of mice already carrying a different serotype resulted in a lower bacterial 
density in the nasopharynx of these mice and a much lower duration of carriage than 
in naïve mice.  In contrast, the density and duration of carriage of the serotype already 
colonising the nasopharynx varied depending on the serotype. Whilst the carriage 
pattern of serotypes 1 and 6B was not altered as a result of the introduction of another 
serotype, the introduction of serotype 1 induced a significant increase in the number 
of serotype 19F bacteria causing colonisation. These observations suggest that 
serotype 1 not only is highly able to cause invasive disease but it is also able to alter 
the pathogenicity of other serotypes during nasopharyngeal co-colonisation.  
In summary, it was found that serotype 1 carries for a shorter period of time than other 
serotypes and although it is not able to induce a strong immune response, it is able to 
induce the production of serotype specific antibodies that prevent future colonisation 
events by the same serotype. Therefore, the shorter duration of carriage by serotype 1 
and the protective effect of previous colonisation events suggest that serotype 1 is, as 
observed, likely to be less found causing nasopharyngeal carriage. Furthermore, as a 
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result of low carriage rates it is likely that if there is a new colonisation event this 
would happen in a nasopharynx that is already carrying a different serotype. In this 
case, the carriage density would be even lower and the duration of carriage would be 
even shorter therefore reducing the chances of further spreading through the 
community.  
In conclusion, although serotype 1 is a highly invasive pneumococcal serotype it is not 
a good coloniser, especially when other serotypes are already present. Considering that 
nasopharyngeal carriage is thought to be a pre-requisite for invasiveness, but serotype 
1 is not a good coloniser, this serotype might be an opportunistic invader. Unlike other 
serotypes, serotype 1 is known to cause invasive disease in young adults, which is the 
age group with lower pneumococcal carriage rates; this is possibly due to the fact that 
no competition in the nasopharynx with other serotypes leads to a better colonising 
ability and better chances of spreading and causing disease. Moreover, it was observed 
that the acquisition of serotype 1 in the nasopharynx of mice already carrying a 
different serotype was able to induce an increase in density of the original coloniser. 
Since carriage is a pre-requisite of invasiveness, a higher pneumococcal density may 
lead to an increased chance of translocation into lungs and therefore an increased 
chance of causing invasive disease. However, this was only observed in serotype 19F; 
as there was no effect on density when the original coloniser was serotype 6B. These 
observations suggest that the interaction of different serotypes in the nasopharynx may 
lead to different outcomes which might be driven by immune responses to different 
serotypes during single infection and during co-infection. 
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6. Identification of orthologous genes that are differentially 
expressed between serotype 1 and the serotype 2 strain D39 during 
in vitro growth 
 
 
6.1. Introduction 
Streptococcus pneumoniae has historically played an important role in molecular 
biology, being the bacteria studied in the experiments that led to the discovery of DNA 
as the genetic material [319, 320]. Since then, many studies have been performed to 
investigate the genome of the pneumococcus and its influence in virulence.  
Although the genomic variability between serotypes has been extensively studied, 
there is little information on the variability of gene expression between serotypes. The 
study of bacterial gene expression has been shown to be an important tool for the study 
of bacterial pathogenicity, by exposing bacterial adaptations to different conditions 
during infection [321]. At the same time, a comparative transcriptomic approach to 
compare closely related bacterial pathogens has been shown to be an important tool to 
understand pathogenic differences between closely related strains [322-324]. 
Comparative transcriptomics works on the basis that although strains may contain the 
same virulence and metabolic genes, the levels of expression of certain genes might 
be significantly different.  
Many studies have been done on the gene expression of a small selection of 
pneumococcal serotypes but little is known about the gene expression of serotype 1, 
especially of the serotype 1 isolates belonging to lineage B (i.e. ST217) [165, 169, 
325]. In this study it was hypothesised that the high virulence of serotype 1, when 
compared to other serotypes (i.e. serotype 2 strain D39), might be driven by the 
differential expression of orthologous genes involved in virulence and metabolism. 
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Orthologous genes are those genes from different strains that evolved from a common 
ancestor and share the same functions [308]. 
Most of the pneumococcal gene expression analysis done in the past has been done 
using either real time PCR or DNA microarrays. Although the microarray technology 
has greatly evolved since its discovery there are still limitations to the technique: 
microarrays are only available for the study of known genes since they require the 
synthesis of specific DNA probes, there is cross-hybridization between similar 
sequences and there is background noise introduced at different stages which limits 
the resolution of the technique [326, 327].  
In recent years, an alternative to microarrays has been developed that allows the 
quantification of gene expression by sequencing cDNA fragments which are 
consequently aligned to the chromosome and quantified, this technique is known as 
RNA-seq [326]. Although this technology is more expensive than microarrays, it 
overcomes some of the microarray-associated limitations: RNA-seq allows the 
quantification of non-annotated genes, and it can detect lower amounts of transcripts 
due to the absence of background noise [326, 327]. 
In order to identify differentially expressed genes between the serotype 1 strain 
A42174 and the serotype 2 strain D39, orthologous genes shared by the two strains 
were identified and the gene expression of those genes was compared by using the 
transcriptomic approach. 
In this study we compare the gene expression of the ST217 serotype 1 strain A42174 
and the serotype 2 strain D39 during five stages of in vitro growth using RNA-seq.  
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6. 2. In vitro growth phases  
In this study, the bacterial growth was divided into 5 different stages: early exponential 
phase (EEP), mid-exponential phase (MEP), late exponential phase (LEP), early 
stationary phase (ESP) and late stationary phase (LSP). During the three stages of 
exponential growth the bacteria are rapidly growing until they reach the early 
stationary phase. At that stage, there is a reduction of the bacterial metabolic rate 
caused by the decreased nutrient availability in the environment and by the stress 
caused by the accumulation of toxic metabolites. Finally, during the late stationary 
phase the metabolic activity stops and there is an activation of the resistance 
physiology [328]. Virulence genes have been shown to have growth-phase specific 
expression profiles in other bacterial pathogens such as Salmonella [308], for that 
reason the differential expression of A42174 and D39 was studied at five stages of 
growth. 
The growth curve with the five stages of growth for both A42174 and D39 can be seen 
in Figure 58. For A42174 the RNA was extracted as described in Section 2.19 when 
the bacterial cultures reached the following OD500 values: 0.130 (EEP), 0.550 (MEP), 
1.100 (LEP), 1.250 (ESP) and 5 hours after the early stationary phase (LSP). For D39 
the RNA was kindly extracted by Reham Yahya as described in Section 2.19 when the 
bacterial cultures reached the following OD500 values: 0.220 (EEP), 0.650 (MEP), 
1.200 (LEP), 1.400 (ESP) and 5 hours after the early stationary phase (LSP).  
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Figure 58. Growth curve of the serotype 1 strain A42174 (a) and the serotype 2 strain D39 (b) in 
BHI broth (OD550) showing the five distinct growth phases at which bacterial RNA was 
extracted: early exponential phase (EEP), mid-exponential phase (MEP), late exponential phase 
(LEP), early stationary phase (ESP) and late exponential phase (LEP). 
 
6. 3. Details of mapping of RNA-seq reads 
RNA-seq was performed by Vertis Biotechnologie AG and annotated by Chrispin 
Chaguza as described in Section 2.20. The mapping of the RNA-Seq reads against the 
annotated genomes to infer transcripts was done by Dr. Karsten Hokamp at Trinity 
College, Dublin, as previously described [328]. Finally, the expression analysis of the 
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transcriptome was done in collaboration with Prof. Jay Hinton (University of 
Liverpool) using the GeneSpring 7.3 software (Agilent Technologies).  
 
Strain Growth 
phase 
Total number 
of reads 
sequenced 
Number of 
Uniquely 
Mapped reads 
(%) 
Number of 
Multi-
Mapped reads 
(%) 
Number of 
Un-Mapped 
reads 
(%) 
A42174 EEP 13,337,636 12,560,732 
(94.2%) 
484,212 
(3.6%) 
292692 
(2.2%) 
A42174 MEP 13,164,697 12,582,060 
(95.6%) 
334,810 
(2.5%) 
247827 
(1.9%) 
A42174 LEP 12,430,448 11,875,633 
(95.5%) 
327,528 
(2.6%) 
227287 
(1.8%) 
A42174 ESP 9,245,968 8,585,510 
(92.9%) 
449,433 
(4.9%) 
211025 
(2.3%) 
A42174 LSP 7,880,688 6,850,848 
(86.9%) 
786,438 
(10%) 
243402 
(3.1%) 
D39 EEP 29,929,671 6,807,453 
(22.7%) 
20,924,228 
(69.9%) 
2,197,990 
(7.3%) 
D39 MEP 37,829,397 9,045,311 
(23.9%) 
24,561,956 
(64.9%) 
4,222,130 
(11.2%) 
D39 LEP 44,567,392 2,763,509 
(6.2%) 
37,641,096 
(84.5%) 
4,162,787 
(9.3%) 
D39 ESP 38,795,356 2,154,055 
(5.6%) 
31,435,865 
(81%) 
5,205,436 
(13.4%) 
D39 LSP 36,137,954 2,481,893 
(6.9%) 
30,383,210 
(84.1%) 
3,272,851 
(9.1%) 
Table 10. Sequencing depth of the A42174 and D39 samples from different growth phases. 
 
 
It has been previously shown that a sequencing depth of 5 to 10 million non-rRNA 
fragments is needed for optimal bacterial transcriptome profiling of Salmonella; since 
the pneumococcal genome is half the size of the Salmonella genome, a sequencing 
depth of 2 to 5 million non rRNA fragments are needed for optimal pneumococcal 
transcriptome profiling [329]. As observed in Table 10, the sequencing depth of the 
A42174 and the D39 samples was high enough to provide optimal analysis of the 
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transcriptomes: the total number of reads sequenced was above 2 million. There was a 
high percentage of uniquely mapped reads (above 85% in the serotype 1 isolate 
A42174) which are reads that are mapped to only one location in the genome. The 
transcriptome analysis in this study was done using only the uniquely mapped reads to 
assemble a high-quality gene expression dataset. 
 
6. 4. Gene expression of A42174 and D39 at different stages of growth 
The study of differential gene expression between different strains is an important tool 
to understand differences in pathogenicity between different strains, therefore the 
differential gene expression of A42174 and D39 was done in this study. 
A pair-wise comparison of the expression of 2069 orthologous genes was done by 
normalising the expression of A42174 in each growth phase to the expression of D39 
in the same growth stage (Figure 59). The data were filtered by only taking into 
account TPM (transcript per million) values greater than 10 and fold changes greater 
than 2. In previous studies it was considered that a gene was expressed when the TPM 
value was higher than 10 [328]. This cut-off was selected after analysing the 
expression of a gene essential for the degradation of myo-inositol by Salmonella. In 
the absence of the sugar the expression of the gene involved in its degradation was 
approximately TPM = 4, therefore a conservative cut-off of 10 is used to ensure that 
the gene is expressed. 
As observed in Figure 59, the pair-wise comparison of the expression of orthologous 
genes between A42174 and D39 showed broadly similar levels of gene expression 
between the three exponential phases, whilst the two stationary phases followed a 
different pattern of expression. 
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Figure 59. Differential gene expression between strains A42174 and D39 at five stages of growth 
(EEP: Early Exponential Phase, MEP: Mid Exponential Phase, LEP: Late Exponential Phase, 
ESP: Early Stationary Phase, LSP: Late Stationary Phase). The 2069 orthologous genes genes 
were included in this analysis. TPM>10 and >2-fold change. Down-regulated genes in A42174 
when compared to D39 are shown in blue, up-regulated genes A42174 when compared to D39 
are shown in red, and not differentially expressed genes between the two strains are shown in 
white. 
 
 
As observed in Table 11, between 26% and 39% of the orthologous genes were 
differentially expressed in A4217 compared to D39, with a higher proportion of those 
being down-regulated than up-regulated.  
 
Growth 
phase 
N° Up-regulated 
genes (%) 
N° Down-regulated 
genes (%) 
Total N° of differentially 
expressed genes (%) 
EEP 168 (8.12%) 375 (18.13%) 543 (26.24%) 
MEP 231 (11.16%) 315 (15.22%) 546 (26.39%) 
LEP 232 (11.21%) 514 (24.84%) 746 (36.06%) 
ESP 329 (15.90%) 390 (18.85%) 719 (34.75%) 
LSP 283 (13.68%) 508 (24.55%) 791 (38.23%) 
Table 11. Number and percentage of genes differentially expressed in A42174 during the 5 
growth phases when compared to D39. 2069 orthologous genes were included in this analysis 
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6.5. Functional category analysis during the five phases of growth 
6.5.1. Selection of functional categories 
KEGG (Kyoto Encyclopedia of Genes and Genomes) is a bioinformatic resource that 
integrates current knowledge on molecular interaction networks such as metabolic 
pathways [329]. This resource allows the prediction of cellular processes and organism 
behaviour by classifying genes into different functional categories. The study of 
functional categories provides the possibility of studying cellular complex processes 
that are essential for the survival of the pathogen [329]. 
The functional category analysis of the two pneumococcal strains was done using the 
information obtained from the KEGG database using DAVID Bioinformatics 
Resources 6.7 (https://david.ncifcrf.gov/). The hypothetical genes were excluded from the 
functional category analysis reducing the number of orthologous genes analysed from 
2069 to 466. A total of 57 functional categories were categorised by KEGG.  
Since the number of genes included in the functional categories obtained from the 
KEGG database was less than 25% of the whole genome used in the pair-wise 
comparison of A42174 and D39 (Figure 59), a new pair-wise comparison was done 
with the reduced set of genes to determine any changes in the proportion of 
differentially expressed genes for each growth phase. After reducing the number of 
genes used in the analysis from 2069 to 466 the same patterns of expression were still 
observed (Figure 60); the gene expression followed broadly similar patterns 
throughout the three exponential phases, which were distinct from the genes 
expression patterns seen in the stationary phases. 
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Figure 60. Differential gene expression between strains A42174 and D39 at five stages of growth 
(EEP: Early Exponential Phase, MEP: Mid Exponential Phase, LEP: Late Exponential Phase, 
ESP: Early Stationary Phase, LSP: Late Stationary Phase). The 466 genes categorised in the 
KEGG database were included in this analysis. TPM>10 and >2-fold change. Down-regulated 
genes in A42174 when compared to D39 are shown in blue, up-regulated genes A42174 when 
compared to D39 are shown in red, and not differentially expressed genes between the two 
strains are shown in white. 
 
As observed in Table 12, when the analysis only included the 466 genes detected by 
the KEGG database there were still more genes that were down-regulated than up-
regulated in A42174 when compared to D39 in all phases except early stationary 
phase. In this analysis the number of differentially-expressed genes varied from 
28.11% in the mid exponential phase to 39.06% in the late stationary phase. In 
summary, although the percentage of genes that were differentially-expressed in 
A42174 varied when the set of genes used in the analysis is reduced, the percentage 
still ranged between approximately 25% and 40%. 
Growth 
phase 
N° Up-regulated 
genes (%) 
N° Down-regulated 
genes (%) 
Total N° of differentially 
expressed genes (%) 
EEP 42 (9.01%) 96 (20.60%) 138 (29.61%) 
MEP 63 (13.52%) 68 (14.59%) 131 (28.11%) 
LEP 74 (15.88%) 83 (17.81%) 157 (33.69%) 
ESP 91 (19.53%) 76 (16.31%) 167 (35.84%) 
LSP 90 (19.53%) 92 (19.74%) 182 (39.06%) 
Table 12. Number and percentage of genes differentially expressed in A42174 during the 5 
growth phases when compared to D39. The 466 genes detected in the KEGG database were 
included in this analysis.  
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For this study, a selection of 11 functional categories was chosen for deep investigation 
based on their effect on growth and virulence. Nonetheless, the percentage of up-
regulated and down-regulated genes in each of the 57 functional categories for each 
growth phase can be found in Section 9.2. 
The categories selected for further investigation were selected based on their 
importance in virulence and fitness of the pneumococcus (Table 13).  
 
Functional categories Genes 
ABC transporters cbiO, cbiO1, adcC, adcB, adcA, malD, malC, 
malX, pstB, pstA, pstC, pstS, rafE, rafF, rafG, 
amiA, amiC, amiD, amiE, amiF, proWX, psaC, 
psaB, aliB, potA, potC, potD, lmb, ftsX, ftsE, 
livF, livG, livM, livH, livJ, aliA 
Bacterial secretion system yajC-2, secAm ffh, ftsY, secG, yajC-1, secY 
Fatty acid biosynthesis accA, accD, accC, fabZ, accB, fabF, fabD, fabK, 
fabH 
Fructose and mannose 
metabolism 
fucl, scrK, tpiA, pgm, rpml, pfkA, fba, manL, 
manM 
Galactose metabolism galU, nagA, aga, galK, galT-2, scrB, galE-1, 
lacA, lacB, lacC, lacD, lacF-2, lacE-2, lacG-2, 
pfkA, bgaA, lacE-1, lacG-1, lacF-1, agaS, bgaC 
Glucolysis / gluconeogenesis pgi, gap, tpiA, ldg, acoA, lpdA, eno, gapN, celA, 
pyk, pfkA, exp5, gki, fba, pgk, galM 
Peptidoglycan biosynthesis pbp1B, pbp2A, penA, ddlA, murF, murE, murC, 
murB, dacC,  
murG, murD, fibB, bacA, pbp1A, mraY, pbpX 
Phosphotransferase system 
(PTS) 
lacF-2, lacE-2, ptsl, celB, lacE-1, lacF-1, manL, 
manM 
Pyruvate metabolism ackA, ldh, acoA, lpdA, ppc, gloA, nspC, pyk, 
spxB, pflB, accA, accD, accC, accB 
Starch and sucrose 
metabolism 
malP, galU, pgi, gtfA, scrB, scrK, amy, glgA, 
glgD, glgC, glgB, pulA, bglA-2, bglA-1 
Two-component system pgi, tkt, trpE, zwf, pfkA, deoC, deoB, rpiA, fba, 
grpE, gnd, eda, talC, prsA 
Table 13. Functional categories selected for the study and genes included in each category. 
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Given the limitations of the KEGG databases the genes in Table 13 are not the only 
genes involved in these pathways, but are the only ones recognised by the KEGG 
database and therefore the only ones used for this analysis. 
Figure 61 shows the variation during the five stages of growth of the proportion of 
differentially expressed genes for each functional category. Each functional category 
was analysed in detail (Figures 62-74).  
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6.5.2. Transport mechanisms 
6.5.2.1. Bacterial secretion system 
In bacteria, proteins need to be transported, secreted and/or inserted into membranes 
and this process occurs via the secretion system (Sec), formed by Sec protein 
conducting channels. The two main subunits forming the Sec machinery in S. 
pneumoniae are secA and secY [330, 331]. 
In the pneumococcus, most virulence factors and some proteins involved in cell 
division are transported to the cell surface by the Sec system, and it has previously 
been observed that mutations in cardiolipin synthase (responsible to promote the 
associations of the different components of the Sec pathway) lead to growth 
impairment and fragility of pneumococcal chains [331].  
 
Figure 62. Differential expression of the genes involved in bacterial secretion shown as 
percentage of up-regulated (red) and down-regulated (blue) genes in A42174 compared to D39. 
 
During all growth phases it was observed that the genes involved in this pathway were 
mainly up-regulated, although some genes were down-regulated at the later stages of 
growth (Figure 62). These results may suggest that serotype 1 requires up-regulation 
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of protein transport genes during growth to compensate the down-regulation of other 
transport pathways. 
 
6.5.2.2. ABC transporter 
The ATP-binding cassette (ABC) transporters are transmembrane proteins that use 
adenosine triphosphate (ATP) for the translocation of substances across the 
cytoplasmatic membrane. A critical requirement for the pneumococcus to be able to 
colonise the nasopharynx and cause invasive disease is to have an efficient nutrient 
acquisition system; the ABC transporters have been shown to be involved in the 
transport of a wide range of substances such as cations, sugars, aminoacids, 
oligopeptides, polyamines, and minerals [332-334]. In previous studies an increase in 
the expression of genes involved in the ABC transporter system was associated with 
antibiotic resistant pneumococcal strains [335, 336].  
 
Figure 63. Differential expression of the genes involved in the ABC transporter pathway shown 
as percentage of up-regulated (red) and down-regulated (blue) genes in A42174 compared to 
D39. 
 
 
More ABC transporters genes were down-regulated in A42174 throughout the 
different growth phases than up-regulated (Figure 63). During exponential growth the 
Chapter 6: Transcriptomics 
167 
 
percentage of genes down-regulated was higher than the up-regulated ones, but this 
observation changed in the last two phases of growth. The growth phases in which the 
pneumococcus is growing and dividing are the three exponential phases. Down-
regulation of the ABC transporters in serotype 1 during these phases may lead to 
reduced acquisition of nutrients and therefore reduced growth. 
 
6.5.2.3. Phosphotransferase system 
There are two main transport systems in the pneumococcus used for the transport of 
carbohydrates: the phosphoenolpyruvate phosphotransferase system (PTS) and the 
ATP-binding cassette (ABC) transporters [332]. The PTS transports sugars and can be 
classified into 6 different families: glucose- and sucrose-PTS, mannitol- and fructose-
PTS, lactose- and cellobiose-PTS, mannose-PTS, glucitol-PTS, and galactitol-PTS 
[337, 338]. Although the PTS is mainly known for its role in sugar phosphorylation, it 
also regulates a wide variety of metabolic processes and controls the expression of 
numerous genes [339]. 
Approximately 38% of the genes involved in the phosphotransferase system were 
down-regulated in serotype 1 during the early exponential phase (Figure 64). For other 
growth phases there was a high percentage of differentially expressed genes: 20-60% 
of the genes were up-regulated and 12-25% of the genes were down-regulated genes 
in this pathway. As previously mentioned, different types of PTS families are involved 
in the transport of different types of sugars. The high variability in the gene expression 
of the PTS genes by serotype 1 may suggest that this serotype might be more 
successful at using only certain types of sugars, which could be a strategy by serotype 
1 to compensate for the down-regulation of other genes involved in the pathway. 
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Although the main known function of the PTS pathway is sugar transport, it is also 
involved in other processes in the bacterium. Given the diverse functionality of the 
pathway it is difficult to know the exact repercussions of the up-regulation or down-
regulation of the genes from this pathway without looking into the differential 
expression of individual genes. 
 
Figure 64. Differential expression of the genes involved in the phosphotransferase system 
pathway shown as percentage of up-regulated (red) and down-regulated (blue) genes in A42174 
compared to D39. 
 
6.5.3. Metabolism of carbohydrates 
S. pneumoniae is a strictly fermentative bacterium that relies on glycolytic metabolism 
to obtain energy; this makes the ability to uptake and metabolise sugars a crucial factor 
for the fitness of the pneumococcus [340]. Glucose is the preferred source of carbon 
of the pneumococcus, but the concentration of this sugar in the nasopharynx is low, 
which makes glycoproteins, such as mucin, good candidates as alternative carbon 
sources [340, 341]. The pneumococcal surface contains a number of glycosidases, such 
as NanA, which break down the glycosidic bonds releasing free sugars into the 
environment [342]. The attenuation of these glycosidases in the pneumococcus leads 
to a reduced colonisation ability [127, 343].The following figure shows the pathways 
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proposed by Paixão et.al. for the decomposition of monosaccharides originated from 
the deglycosilation of host glycans by the Streptococcus pneumoniae strain D39 [340]. 
 
 
Figure 65. Proposed pathways for the decomposition of monosaccharides originated from the 
deglycolysation of host glycans by the Streptococcus pneumoniae strain D39 [340]. 
 
 
6.5.3.1. Fructose and mannose metabolism 
Between 10% and 30% of the genes involved in the metabolism of fructose and 
mannose were down-regulated in A42174 when compared to D39, with only 10% of 
the genes being up-regulated in all growth phases with the exception of the late 
stationary phase where the percentage of up-regulated genes increased to 
approximately 30% (Figure 66). These observations may suggest that serotype 1 is less 
able to use fructose and mannose as a source of carbon throughout all the growth 
phases and therefore less efficient in the uptaking of sugar which would be detrimental 
in an environment with sugar limitations. 
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Figure 26. Differential expression of the genes involved in the metabolism of fructose and 
mannose shown as percentage of up-regulated (red) and down-regulated (blue) genes in A42174 
compared to D39. 
 
 
6.5.3.2. Galactose metabolism 
Galactose is the main sugar involved in pneumococcal metabolism [340]. A high 
proportion (20-80%) of genes involved in metabolism were found to be significantly 
down-regulated in serotype 1 when compared to D39 in all growth phases except the 
early stationary phase (Figure 67). These observations may suggest that, as well as 
mannose and fructose, galactose is not easily metabolised by serotype 1. 
 
Figure 67. Differential expression of the genes involved in the metabolism of galactose shown as 
percentage of up-regulated (red) and down-regulated (blue) genes in A42174 compared to D39. 
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6.5.3.3. Starch and sucrose metabolism 
Similar patterns of differential expression were observed in the starch and sucrose 
metabolism pathway, where a big proportion of genes (10-50%) were down-regulated 
throughout most of the stages of growth (Figure 68).  
 
Figure 68. Differential expression of the genes involved in the metabolism of starch and sucrose 
shown as percentage of up-regulated (red) and down-regulated (blue) genes in A42174 
compared to D39. 
 
The late exponential phase showed the lowest percentage of down-regulated genes 
involved in the starch and sucrose metabolism which may suggest that serotype 1 is 
more capable of metabolising starch and sucrose during the late exponential phase. A 
high percentage of genes involved in the metabolism of starch and sucrose 
(approximately 40%) were up-regulated in the late stationary phase probably induced 
by an increase in sugar release during the death of bacteria in this phase. 
 
6.5.3.4. Glycolysis and gluconeogenesis 
Finally, the gene expression of genes involved in the glycolysis and gluconeogenesis 
pathways was studied. As observed in Figure 69, the gene expression pattern of this 
pathway showed an important down-regulation of genes throughout all stages of 
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growth (10-35%) and a consistent up-regulation of approximately 12% of the genes 
throughout all the stages of growth. 
 
Figure 69. Differential expression of the genes involved in glycolysis and gluconeogenesis shown 
as percentage of up-regulated (red) and down-regulated (blue) genes in A42174 compared to 
D39. 
 
In summary, the analysis of the expression of genes involved in the metabolism of 
sugars shows a high percentage of down-regulated genes during exponential growth. 
These observations may suggest that serotype 1 could be less capable of causing 
nasopharyngeal colonisation due to the reduced ability of the bacterium to metabolise 
the sugars present in the human nasopharynx [342]. Since the concentration of sugars 
in blood has been reported to be up to 6 times higher and 12 times higher than in nasal 
secretions and in lower airway secretions respectively, this reduced expression of 
genes involved in the metabolism of sugar might not have an effect on the growth of 
serotype 1 in blood [341]. 
 
6.5.3.5. Pyruvate metabolism 
The absorption of sugars is an essential process for the growth and survival of the 
pneumococcus. Sugars are uptaken through different transport mechanisms (i.e. 
Chapter 6: Transcriptomics 
173 
 
phosphotransferase system) and metabolised by the classical Embden-Meyerhof-
Parnas pathway which produces pyruvate and NADH and a net gain of 2 ATP 
molecules per mole of glucose [344]. Lactic acid is the main metabolic end product of 
this pathway (Figure 70) [344].  
 
Figure 70. Schematic representation of the metabolism of sugar by S. pneumoniae [344]. 
 
Figure 71. Differential expression of the genes involved in the metabolism of pyruvate shown as 
percentage of up-regulated (red) and down-regulated (blue) genes in A42174 compared to D39. 
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As observed in Figure 71, approximately 20% of the genes from this pathway were 
down-regulated in the first two growth phases. On the contrary, there was a higher 
proportion of up-regulated genes in serotype 1 during the last three phases of growth. 
As previously observed, the transport of sugars by serotype 1 is less efficient than in 
D39 which is detrimental for the growth of the bacterium. In serotype 1, the up-
regulated genes in the pyruvate metabolism pathway might be an effort from the 
bacterium to overcome the reduced income of sugars by metabolising those sugars 
more efficiently. 
 
6.5.4. Biosynthesis 
6.5.4.1. Fatty acid biosynthesis 
There are different genes involved in the biosynthesis of fatty acids, and the fatty acid 
composition of the pneumococcal membrane is closely regulated by the fab gene 
cluster [345]. It has been observed in previous studies that up-regulation of the fab 
gene cluster causes changes in the membranes which makes the bacteria more sensitive 
to low pH [345].  
 
Figure 72. Differential expression of the genes involved in the biosynthesis of fatty acids shown 
as percentage of up-regulated (red) and down-regulated (blue) genes in A42174 compared to 
D39. 
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As observed in Figure 72, the genes in the fatty acid pathway were mostly up-regulated 
in the serotype 1 strain A42174 throughout all the growth phases, compared to D39. 
As previously mentioned, up-regulation of the fab gene cluster leads to higher 
sensitivity to low pH which means that serotype 1 is likely to be more sensitive in low 
pH environments. Previous publications report that the pH of the human nasopharynx 
is approximately 6.2, whilst the pH of blood is approximately 7.4 [346, 347]. 
Therefore, up-regulation of the fab gene cluster in serotype 1 may explain why 
serotype 1 is not very efficient during nasopharyngeal colonisation but commonly 
causes invasive disease.  
 
6.5.4.2. Peptidoglycan biosynthesis 
Peptidoglycan, also known as murein, is an essential and specific component of the 
bacterial cell wall that provides protection to the bacterium; degradation or inhibition 
of its biosynthesis results in the lysis of the bacterium [348]. In the pneumococcus 
there are mainly two groups of genes that are responsible for the cell wall synthesis: 
the mur genes which encode enzymes that are involved in the synthesis of 
peptidoglycan precursors, and the pbp genes which encode peptidoglycan synthases 
[349-351].  
As observed in Figure 73, approximately 10-30% of the genes involved in this pathway 
were down-regulated in serotype 1, when compared to D39, except in the early 
stationary phase where 30-40% of the genes were up-regulated. Since peptidoglycan 
is an essential component of the pneumococcal cell wall these observations may 
suggest that the growth rates of serotype 1 could be reduced when compared to D39 
in all phases except in the early stationary phase. 
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Figure 73. Differential expression of the genes involved in the biosynthesis of peptidoglycan 
shown as percentage of up-regulated (red) and down-regulated (blue) genes in A42174 
compared to D39. 
 
6.5.5. Two-component system 
The two-component systems, also known as two-component signal transduction 
systems, are an important mechanism through which bacteria are able to perceive and 
respond to environmental stimuli [352]. The two-component systems are composed of 
two proteins: a membrane associated sensor which receives the stimuli from the 
outside and a cytoplasmatic cognate response regulator which initiates the cell 
response to the stimuli [353]. There are 13 known two-component systems in the 
pneumococcus, and previous studies have shown that some of them have a key role in 
virulence [353-355]. It is believed that two-component systems may regulate the 
expression of pneumococcal virulence factors depending on the external stimuli [356, 
357]. 
The genes involved in the two-component system pathways were significantly down-
regulated in serotype 1 when compared to D39 and this observation was consistent 
throughout all the stages of growth (Figure 74). These observations may suggest that 
serotype 1 might be less effective at responding to external stimuli than D39 which 
could explain its lower ability to cause nasopharyngeal colonisation. The nasopharynx 
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is a complex system where different species co-exist and compete for the niche, 
therefore the reduced ability of serotype 1 to quickly respond to environmental stimuli 
might result in out-competition by other serotypes or species. 
 
 
Figure 74. Differential expression of the genes involved in the two-component systems pathways 
shown as percentage of up-regulated (red) and down-regulated (blue) genes in A42174 
compared to D39. 
 
6.6. Analysis of gene expression of virulence factors in A42174 compared to D39 
 
There are a great number of pneumococcal genes that are required for the virulence of 
the pneumococcus; the products of these genes are known as virulence factors [12]. 
Absence of certain virulence factors in the pneumococcus has been associated with 
reduced virulence [12]. Nonetheless, although the presence or absence of these genes 
might determine the level of virulence, it has previously been reported that differential 
expression of virulence factors is an important tool to understand differences in 
virulence between different strains or serotypes [322]. A list of well-characterised 
virulence factors was selected for this analysis based on their reported role in 
nasopharyngeal carriage and/or invasive disease (Table 14) [12, 36]. 
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Gene 
name 
D39 
identifier 
A42174 
identifier 
Gene Product 
bgaA SPD_0562 SPQ_00804 Beta-galactosidase 
cbpA SPD_2017 SPQ_00113 Choline binding protein A 
cbpC SPD_0345 SPQ_00583 Choline binding protein C 
cbpD SPD_2028 SPQ_00123 Choline binding protein D 
cbpE SPD_0821 SPQ_00865 Choline binding protein E 
cbpF SPD_0357  Choline binding protein F 
cbpG SPD_0356 SPQ_00593 Choline binding protein G 
cps2A SPD_0315 SPQ_00548 Integral membrane regulatory protein 
cps2B SPD_0316 SPH_0456 Tyrosine-protein phosphatase 
cps2C SPD_0317  Chain length determinant protein/polysaccharide export 
protein, MPA1 family protein 
cps2D SPD_0318  Tyrosine-protein kinase Cps2D cytosolic ATPase 
cps2E SPD_0319  Undecaprenylphosphate glucosephosphotransferase 
Cps2E 
cps2F SPD_0321  Glycosyl transferase family protein 
cps2G SPD_0322  Glycoside hydrolase family protein 
cps2I SPD_0324  Glycoside hydrolase family protein 
cps2K SPD_0326 SPQ_00559 UDP-glucose 6-dehydrogenase 
cps2L SPD_0328  Glucose-1-phosphate thymidylyltransferase 
cps2P SPD_0327  UDP-galactopyranose mutase 
cps2T SPD_0320  Glycoside hydrolase family protein 
cps2H SPD_0323  Polysaccharide polymerase 
eno SPD_1012 SPQ_01975 Binds to plasminogen/phosphopyruvate hydratase 
hyl SPD_0287 SPQ_00521 Breaks down hyaluronan-containing extracellular matrix 
components 
igA SPD_1018 SPQ_01969 Cleaves human IgA1 
lytA SPD_1737 SPQ_01440 Autolysin - digests the cell wall 
nanA SPD_1504 SPD_1504 Sialidase A 
nanB SPD_1499 SPQ_01320 Sialidase B 
pavA SPD_0854 SPQ_00899 Binds to fibronectin /adherence and virulence protein A 
pcpA SPD_1965  Choline binding protein PcpA 
ply SPD_1726 SPQ_01427 Pneumolysin 
psaA  SPQ_01284 Component of the ABC transport system 
psaB SPD_1461 SPQ_01282 Manganese ABC transporter ATP-binding protein 
psaC SPD_1462 SPQ_01283 Manganese ABC transporter permease 
pspA SPD_0126 SPQ_00349 Surface protein - prevents binding of C3 onto 
pneumococcal surface 
spxA SPD_0178 SPQ_00409 Transcriptional regulator Spx 
spxB SPD_0636 SPQ_01798 Pyruvate oxidase 
srtA SPD_1076 SPQ_01907 Sortase 
strH SPD_0063 SPQ_00287 Beta-N-acetylhexosaminidase - adherence 
Table 14. Virulence factors selected for gene expression analysis. Genes in red are genes that 
were not detected during the annotation process in either A42174 or D39. 
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6.6.1. Differential expression of virulence factors between A42174 and D39 
The level of expression of each of the virulence factors at different growth phases is 
shown in Figure 75, and the absolute levels of expression for both D39 and A42174 
can be found in Section 9.3. The data were normalised to the levels of expression of 
D39 for each time point. 
 
 
Figure 75. Virulence factors that are differentially expressed in A42174 compared to D39.  
TPM>10 and >2-fold change. Red is >2-fold up-regulation, yellow is no differential expression 
and blue is >2-fold down-regulation. 
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As shown in Table 15, more genes were down-regulated than up-regulated in A42174 
compared to D39. In summary, the growth phases with a higher number of 
differentially-expressed genes were the late exponential phase, the early stationary 
phase and the late stationary phase. The gene expression of each virulence factor was 
analysed in detail (Figures 76-86). 
 
 EEP MEP LEP ESP LSP 
Number of down-regulated genes 5 7 8 6 9 
Number of up-regulated genes 0 1 6 8 7 
Number of differentially expressed genes 5 8 14 14 16 
Table 15. Number of virulence genes that are down-regulated and up-regulated in A42174 when 
compared to D39 in the different stages of growth. 
 
 
6.6.2. Capsule genes: cps2A, cps2B and cps2K. 
The polysaccharide capsule is known to be the major pathogenicity determinant in the 
pneumococcus. All virulent strains express capsule and there are over 90 different 
capsular types. In serotype 2 there is a series of capsule genes which are called the 
cps2 genes [358]. Genes cps2A to cps2J share a high similarity with those of other 
serotypes, as well as cps2K which shares 89% similarity with serotype 1 [358]. Due to 
the variation between the capsule genes of serotype 2 and serotype 1, only the ones 
with high similarity were found in the annotation process and therefore analysed. 
Those genes were cps2A, cps2B and cps2K. 
As observed in Figure 76, the three capsule genes analysed in this study were up-
regulated throughout the whole growth of A42174 when compared to D39, although 
only significantly in the last three stages of growth. Previous studies have shown that 
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up-regulation of capsule genes in vitro is linked to invasiveness and is inversely 
proportional to the percentage of carriage prevalence [359]. This finding is consistent 
with the fact that serotype 1 is, compared to D39, more capable of causing disease but 
less able to cause nasopharyngeal carriage. 
 
 
Figure 76. Differential expression of the capsule genes cps2A, cps2B and cps2K in A42174 
compared to D39. Data shown as fold change after filtering for TPM values greater than 10. 
Red = up-regulation, blue = down-regulation and yellow = not significant differential 
expression. 
 
6.6.3. Pneumolysin 
Together with the capsule, pneumolysin is the most studied virulence factor of the 
pneumococcus [360]. This CDC is not actively secreted by the bacterium, but is 
released after the lysis of the bacterium by either autolysis or lysis induced by external 
factors such as antibiotics causing the lysis of eukaryotic cells by forming pores on 
their membrane [360]. Pneumolysin is able to induce inflammation which aids 
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bacterial survival and dissemination [360]. Previous studies have shown that increased 
levels of pneumolysin are linked to increased virulence [361]. 
As observed in Figure 77, the expression of pneumolysin was significantly up-
regulated in serotype 1 during the late exponential phase, the early stationary phase 
and the late stationary phase. These observations may suggest that up-regulation of 
pneumolysin might induce inflammation in the nasopharynx leading to its early 
clearance. On the contrary, during invasive disease the up-regulation of pneumolysin 
might cause major damage in the tissues leading to increased virulence and spreading 
of the bacteria. 
 
Figure 77. Differential expression of the pneumolysin gene in A42174 compared to D39. Data shown as fold 
change after filtering for TPM values greater than 10. Red = up-regulation, blue = down-regulation and 
yellow = not significant differential expression. 
 
6.6.4. Surface proteins 
6.6.4.1. Choline binding proteins: CbpA, CbpC, CbpD, CbpE, CbpG, PspA and 
LytA. 
The choline binding proteins are a family of approximately 15 surface proteins that 
bind to choline residues of lipoteichoic acid and teichoic acid present in the cell wall 
making the pneumococcus able to interact with host cellular receptors [362, 363].  As 
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observed in Figure 78, the expression of the relevant protein coding genes was quite 
variable. 
 
Figure 78. Differential expression of the choline binding proteins genes cbpA, cbpC, cbpD, cbpE, 
cbpG and pspA in A42174 compared to D39. Data shown as fold change after filtering for TPM 
values greater than 10. Red = up-regulation, blue = down-regulation and yellow = not significant 
differential expression. 
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CbpA has been reported to bind to factor H preventing C3b deposition and therefore 
preventing opsonisation of the bacterium [363, 12]. CbpA has also been shown to bind 
to the polymeric immunoglobulin receptor, usually responsible for the secretion of 
IgA, suggesting that CbpA might be a key protein in the translocation of the 
pneumococcus through tissues. [12]. The expression of CbpA was up-regulated in 
A42174 during the mid-exponential phase and the late exponential phase, but down-
regulated during the stationary phases of growth (Figure 78). The variability of 
expression of CbpA during the different growth phases suggests that in vivo, the 
expression of this gene might be determined by environmental conditions given that 
the nutrient availability during the stationary phases is considerably lower than during 
the exponential phases. 
Similarly to CbpA there was a high variability in the expression of CbpD throughout 
the different growth phases, making it hard to draw any conclusions from these data 
(Figure 78).  
The cbpC, cbpE, cbpG and pspA genes were seen to be mainly down-regulated in 
serotype 1 (Figure 78). These proteins have been shown to be important in adherence 
having a direct effect on nasopharyngeal carriage and virulence. These observations 
suggest that the low ability of serotype 1 to carry could be due to the down-regulation 
of these adherence proteins [108].  
Finally, LytA is an amidase responsible for the cleavage of the N-acetylmuramoyl-L-
alanine bond of the pneumococcal peptidoglycan, consequently LytA causes the 
autolysis of the pneumococcus [12]. As observed in Figure 78, no significant 
differences were observed in the expression of this protein between the serotype 1 
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strain A42174 and the serotype 2 strain D39. These observations may suggest that 
LytA might not be involved in the increased virulence of serotype 1. 
6.6.4.2. Pneumococcal surface adhesins: PsaB and PsaC. 
The pneumococcal surface adhesins PsaB and PsaC are members of the ABC 
transporter family and have been shown to be involved in adhesion, which is probably 
linked to the acquisition of nutrients through the ABC transporter system [12, 152, 
222, 364]. The study of the gene expression of psaB and psaC showed a significant 
down-regulation of the expression of these proteins in serotype 1 during the late 
exponential phase, the early stationary phase and the late stationary phase (Figure 79). 
These observations raise the possibility that serotype 1 might be less capable of 
adhering and acquiring nutrients than serotype 2 which could have a negative effect 
on its growth and therefore virulence. 
 
Figure 79. Differential expression of the pneumococcal surface proteins genes psaB and psaC in 
A42174 compared to D39. Data shown as fold change after filtering for TPM values greater 
than 10. Red = up-regulation, blue = down-regulation and yellow = not significant differential 
expression. 
 
6.6.4.3. Surface exoglycosidases: NanA, NanB, BgaA and StrH. 
The nasopharynx is usually the first host niche that the pneumococcus encounters 
during infection. The concentration of sugars, the main nutrient for the pneumococcus, 
is low in the nasopharynx hence the pneumococcus needs a mechanism to efficiently 
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use the sugars available in the environment [340, 341]. The pneumococcus expresses 
proteins responsible for cleaving extracellular sugars and making the sugars more 
available for the bacterium; these proteins are the exoglycosidases [342, 365, 366]. 
The gene expression of the exoglycosidases NanA, NanB, BgaA and StrH is shown in 
Figure 80.  
 
Figure 80. Differential expression of the surface exoglycosidases genes nanA, nanB, bgaA and 
strH in A42174 compared to D39. Data shown as fold change after filtering for TPM values 
greater than 10. Red = up-regulation, blue = down-regulation and yellow = not significant 
differential expression. 
 
The expression of the exoglycosidase genes tended to be down-regulated in the first 
three stages of growth and up-regulated in the stationary phases, with the exception of 
NanA which was mainly down-regulated throughout all the growth phases. These 
observations may suggest a lower ability of serotype 1 to break down the sugars of the 
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environment and therefore a reduced ability to survive in nutritionally poor 
environments such as the nasopharynx.  
6.6.4.4. Enolase 
Enolase is a pneumococcal protein that allows the pneumococcus to bind to human 
plasminogen [136]. It is believed that enolases bind to plasminogen leading to an 
increased production of plasmin, which is responsible for the degradation of the 
extracellular matrix [367]. For this reason, enolases promote the adhesion of the 
pneumococcus to the extracellular matrix in the host inducing its degradation [367, 
368]. As shown in Figure 81, eno was not differentially-expressed in serotype 1, except 
for the mid-exponential phase. Down-regulation of enolases in the pneumococcus may 
suggest a reduction in adherence and therefore virulence, although the expression of 
enolases could be induced by host factors during colonisation which might help the 
bacterium become invasive. 
 
Figure 81. Differential expression of the enolase gene in A42174 compared to D39. Data shown 
as fold change after filtering for TPM values greater than 10. Red = up-regulation, blue = down-
regulation and yellow = not significant differential expression. 
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6.6.4.5. Hyaluronidase lyase 
Hyaluronidase lyase is a surface protein that degrades hyaluronic acid, which is found 
in mammalian connective tissue and in the extracellular matrix [85]. The degradation 
of hyaluronic acid by hyaluronidase lyase increases the permeability of mammalian 
tissues, hence playing an important role in the translocation of the pneumococcus 
between tissues [36, 85, 152, 369]. As observed in Figure 82, no differential expression 
was observed during the exponential phases of growth. In contrast, the expression of 
hyl was increased during the stationary phases, especially in the late stationary phase. 
An increase in the expression of hyaluronidase lyase might play an important role in 
the increased virulence of serotype 1. 
 
Figure 82. Differential expression of the hyaluronidase lyase gene in A42174 compared to D39. 
Data shown as fold change after filtering for TPM values greater than 10. Red = up-regulation, 
blue = down-regulation and yellow = not significant differential expression. 
 
6.6.4.6. Pneumococcal adherence and virulence factor A: PavA 
PavA is a pneumococcal protein known to bind to fibronectin and is associated with 
adherence and virulence in the pneumococcus [132, 370]. Despite binding to 
fibronectin, it is believed that this protein is not the only pneumococcal protein able to 
bind to fibronectin since PavA-deficient pneumococci were able to retain 50% of their 
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fibronectin binding ability [132, 133, 370]. The pathogen-fibronectin interaction 
mediates the attachment of the pneumococcus to host cells and it has been shown that 
PavA mutants have a decreased ability to adhere and cause invasive disease [133, 136, 
370]. Furthermore, PavA has been shown to protect against recognition and 
phagocytosis by dendritic cells [133, 370]. 
As observed in Figure 83, the expression of pavA in serotype 1 is down-regulated 
throughout all the stages of growth. This observation may suggest that down-
regulation of pavA may reduce the ability of serotype 1 to adhere to epithelial cells 
during nasopharyngeal colonisation. Nonetheless, PavA-deficiencies have been shown 
to be important during invasiveness therefore pavA might be down-regulated in 
serotype 1 during nasopharyngeal carriage and an external stimuli could induce the 
expression of the gene encoding for PavA allowing the bacteria to become invasive. 
In other words, the expression of pavA could be dependent on external host factors.  
 
Figure 83. Differential expression of the pavA gene in A42174 compared to D39. Data shown as 
fold change after filtering for TPM values greater than 10. Red = up-regulation, blue = down-
regulation and yellow = not significant differential expression. 
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6.6.5. Sortase A 
SrtA is a highly conserved pneumococcal transpeptidase enzyme, also known as 
sortase A, responsible for the connection of the pneumococcal pili and other specific 
proteins to the cell wall [132, 371]. The effect of SrtA in colonisation and pathogenesis 
of the pneumococcus has been previously studied, showing that SrtA contributes to 
adherence of the pneumococcus to human cells but has no important effect on 
pathogenesis [372-375]. As observed in Figure 84, sortase A was only up-regulated in 
early stationary phase of the serotype 1 growth. The up-regulation of this protein in 
only one growth phase makes it difficult to draw any conclusions on the possible effect 
of this protein in the virulence of serotype 1.  
 
Figure 84. Differential expression of the sortase A gene in A42174 compared to D39. Data shown 
as fold change after filtering for TPM values greater than 10. Red = up-regulation, blue = down-
regulation and yellow = not significant differential expression. 
 
6.6.6. IgA protease 
IgA is a pneumococcal protease that specifically cleaves human IgA1 antibodies [136, 
377]. Human IgA1 is present in blood at low concentrations, but it is the main antibody 
present in human mucosal surfaces such as the nasopharynx [376]. The activity of 
IgA1 proteases lead to the inactivation of the antibodies in the nasopharynx therefore 
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aiding colonisation of the nasopharynx [377]. As observed in Figure 85, the expression 
of igA in serotype 1 is up-regulated when compared to D39 during the late exponential 
phase and the early stationary phase. This observation may suggest that serotype 1 
clearance might be strongly mediated by the innate immune system and not the 
acquired immune system. 
 
Figure 85. Differential expression of the IgA protease gene in A42174 compared to D39. Data 
shown as fold change after filtering for TPM values greater than 10. Red = up-regulation, blue = 
down-regulation and yellow = not significant differential expression. 
 
6.6.7. Pyruvate oxidases 
SpxB is a pyruvate oxidase involved in the metabolism of sugar by decarboxylating 
pyruvate and producing acetyl-phosphate [378]. This process produces oxygen 
peroxide (H2O2) in quantities high enough to kill other members of the nasopharyngeal 
flora [378].  
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Figure 86. . Differential expression of the pyruvate oxidase spxB and its regulator spxA in 
A42174 compared to D39. Data shown as fold change after filtering for TPM values greater 
than 10. Red = up-regulation, blue = down-regulation and yellow = not significant differential 
expression. 
 
As observed in Figure 86 the levels of expression of spxB were not significantly 
different from those in D39. On the contrary, spxA, the transcription regulator of spxB, 
was significantly differentially-expressed and was down-regulated in the mid and late-
exponential phases in serotype 1 when compared to serotype 2. The down-regulation 
of the transcription regulator of spxB did not translate into a down-regulator of the 
pyruvate oxidase SpxB.  
 
6.7. Conclusions 
The in vitro analysis of the gene expression of the serotype 1 strain A42174 in 
comparison to the serotype 2 strain D39 showed that 25-40% of the genes were 
differentially expressed in the two strains. The patterns of expression were different 
between growth phases but there were two clear sub-groups: the three exponential 
phases shared similar patterns of expression, as well as the two stationary phases, 
which also shared similar patterns of expression.  
Chapter 6: Transcriptomics 
193 
 
The differential expression of different functional categories was studied to understand 
possible differences in the important cellular functions leading to differences in 
virulence and survival of the two strains studied. 
A high percentage of genes involved in the ABC transporter were down-regulated in 
A42174 when compared to D39, as well as the genes involved in the metabolism of 
carbohydrates such as starch, sucrose and galactose. These observations suggest that 
serotype 1 might be less capable of metabolising sugars than serotype 2. On the 
contrary, there was a high percentage of up-regulated genes involved in the 
phosphotransferase system in the A42174 strain, which would be consistent with a 
mechanism of the bacteria to compensate the down-regulation of the ABC transporter. 
Moreover, the genes involved in the metabolism of pyruvate were considerably up-
regulated in A42174 when compared to D39. Pyruvate is one of the metabolites from 
the acid lactic biosynthesis pathway, therefore, an increase in the pyruvate pathway 
could be a mechanism of serotype 1 to compensate for the low sugar intake due to the 
down-regulation of the ABC transporter genes and the sugar metabolism pathway 
genes.  
The biosynthesis of peptidoglycan was also down-regulated in serotype 1, supporting 
the idea of a lower growth ability by serotype 1 when compared to serotype 2.  
Additionally, there was an up-regulation of the genes involved in the biosynthesis of 
fatty acids in A42174, which may increase the sensitivity of the pneumococcus to 
environments with low pH. The pH in the nasopharynx is known to be lower than in 
the blood, hence serotype 1 is probably more capable of growing in blood than in the 
nasopharynx, which could explain why it is rarely found in carriage but commonly 
found causing invasive disease. Furthermore, there was a down-regulation in the genes 
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involved in the two-component systems which helps the pneumococcus to respond to 
external stimuli. The nasopharynx is a complex system with a high diversity of species 
found causing asymptomatic colonisation [13]. As observed in Chapter 5, the 
interaction between different species or strains in the nasopharynx can have a high 
impact in the nasopharyngeal carriage patterns of the pneumococcus. Therefore, the 
down-regulation of genes involved in the ability to respond to external stimuli could 
be detrimental for serotype 1 reducing the ability of this serotype to cause successful 
nasopharyngeal carriage. 
The differential expression of 24 important pneumococcal virulence factors was 
analysed in the A42174 and the D39 strains. The number of differentially-expressed 
genes varied between growth phases, ranging between 5 and 16 differentially 
expressed genes. The majority of differentially expressed genes were down-regulated 
in A42174 when compared to D39, although the number of up-regulated genes 
increased in the last stages of growth. 
The analysis of differentially expressed genes in the A42174 and D39 strains showed 
that the expression of genes involved in invasive disease (i.e. capsule genes, 
pneumolysin and hyaluronidase lyase) were up-regulated in A42174 when compared 
to D39. On the other hand, the genes involved in adherence and colonisation (i.e. 
choline binding proteins, pneumococcal surface adhesins, pyruvate oxidase, 
pneumococcal adherence and virulence factor A and enolases) were found to be down-
regulated in A42174 when compared to D39. These observations suggest that serotype 
1 might be more adapted to cause invasive disease than nasopharyngeal carriage. Since 
nasopharyngeal carriage is a pre-requisite for invasive disease, the reduced ability of 
serotype 1 to adhere and cause asymptomatic colonisation suggests that serotype 1 
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might be an opportunistic pathogen that is not good at colonisation but has evolved to 
be successful during invasive disease. Therefore to compensate the reduced expression 
of adherence and colonisation related genes, serotype 1 may increase the expression 
of genes involved in increased invasiveness in the pneumococcus to ensure successful 
invasiveness. 
Although there is a pattern of down-regulation of genes involved in nasopharyngeal 
colonisation and up-regulation in genes involved in invasiveness it is important to 
consider that some of the proteins previously mentioned are often involved in both 
carriage and invasive disease.  
In the future, the findings from this study should be validated by analysing the 
proteomic profile of serotype 1 compared to D39. Furthermore, the in vivo analysis of 
the differential gene expression of A42174 and D39 should be done from bacteria 
obtained during nasopharyngeal colonisation or form invasive disease to understand 
the progression of infection and the pathogenic mechanisms of serotype 1.   
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7. Discussion 
 
7.1. Introduction 
Streptococcus pneumonaie is a human pathogen that causes severe invasive diseases 
such as pneumonia, septicaemia and meningitis, as well as less serious non-invasive 
diseases such as otitis media, bronchitis and sinusitis [379]. The World Health 
Organisation (WHO) estimates that the pneumococcus accounts for 15% of all deaths 
of children under 5 years old, killing an estimated 922,000 children in 2015 [2]. 
Nonetheless, the cases of pneumococcal disease are believed to be underestimated 
because the incidence statistics are largely based on bacteraemic infections, as it has 
been estimated that for every bacteraemic infection caused by S. pneumoniae there are 
three non-bacteraemic infections caused by the same pathogen [379]. The high 
incidence of pneumococcal disease and the high mortality and morbidity associated 
with this pathogen results in a significant burden for the healthcare systems of both 
developed and developing countries [5].  
Serotype 1 is a highly invasive serotype that is rarely found during nasopharyngeal 
carriage [269-272]. This serotype is however responsible for approximately 10% of 
invasive pneumococcal disease cases globally, increasing to up to 30% in some 
developing countries [200]. Despite the addition of this capsular type to the 
pneumococcal conjugate vaccine formulation, it has been observed that vaccine 
efficacy against serotype 1 is limited [192, 294]. For that reason, studying the 
mechanisms involved in the pathogenicity of pneumococcal serotype 1 is of key 
importance, to understand how, despite the low carriage rates observed for this 
serotype, it is still one of the leading causes of invasive pneumococcal disease. 
Understanding the mechanisms of pathogenesis of serotype 1 will help elucidate how 
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serotype 1 transmission occurs and may lead to the development of more efficient 
vaccines against this highly invasive serotype. 
In this study, the pathogenesis of African serotype 1 isolates belonging to sequence 
type 217 (the most common sequence type in Africa), was investigated due to the high 
incidence of invasive disease in Sub-Saharan Africa caused by serotype 1. 
 
7.2. In vitro characterisation of serotype 1 
The first approach to understanding the pathogenicity of serotype 1 was to study 
different aspects of the pneumococcus in vitro that have been shown to have an impact 
on pathogenesis, such as: haemolytic activity, ability to adhere to and invade epithelial 
cells, capsule thickness, ability to evade phagocytosis and complement deposition.  
 
7.2.1. Haemolytic activity 
Pneumolysin is a cholesterol-binding cytolysin that is produced by the pneumococcus 
causing, at high concentrations, the disruption of mammalian cell membranes leading 
to the lysis of the cell [74, 75]. Pneumolysin is produced by all clinical isolates, and 
its haemolytic activity has been shown to be a key factor in immune activation, pro-
inflammation and disease progression. Hence, the haemolytic activity of the African 
ST217 serotype 1 isolates was determined to assess the levels of haemolytic activity 
in this sequence type as compared to other serotypes. Out of the 20 isolates tested, only 
the C9741 strain (which was isolated from the cerebro-spinal fluid of a child), was 
found to have a significantly lower haemolytic activity than the control serotype 2, 
D39 strain, used as the comparator strain. Considering that the haemolytic activity of 
the majority of isolates was similar to that of D39, it was considered that ST217 
serotype 1 isolates have a fully-functioning pneumolysin, and any variation in the 
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haemolytic activity between strains is due to inter-strain variation. Moreover, the 
similar levels of haemolysis observed in the pneumolysin produced by the D39 strain 
and the serotype 1 strains used in this study suggest that pneumolysin by itself may 
have little influence on the increased virulence of the ST217 serotype 1 isolates.  
 
7.2.2. Adhesion and invasion 
The pneumococcus is able to adhere to and invade epithelial and endothelial cells 
[133]. Many pneumococcal virulence factors have been shown to be involved in 
adherence and invasion: CbpA (binds to glycoconjugates from human cells and is 
involved in translocation between tissues by binding to the IgA receptor), hyaluronate 
lyase (breaks down the extracellular matrix increasing tissue permeabilisation), 
neuraminidases (cleaves terminal sugars from host surfaces revealing receptors for 
adherence), PavA (binds to fibronectin from the extracellular matrix), enolase (binds 
to human plasminogen), PsaA (acts as an adhesion) and pili (adheres to human cells) 
amongst others. The absence of any of these virulence factors have been shown to 
reduce the ability of the pneumococcus to adhere and therefore to become invasive 
[380, 381]. Since the ability to adhere is a determinant of the success of the 
pneumococcus to cause colonisation and to eventually cause invasive disease, the 
adhesion of three serotype 1 ST217 isolates (an isolate from a bacteraemia patient, an 
isolate from the cerebro-spinal fluid of a meningitis patient, and an isolate form the 
nasopharynx of a healthy individual) was compared to adhesion and invasion by the 
well-characterised serotype 2, D39 strain, and a non-typeable clinical isolate. The non-
typeable isolate used in this study was unencapsulated, and lack of capsule has 
previously been associated with increased adherence to epithelial surfaces given the 
increased exposure of adhesins [60, 61]. Human nasopharyngeal epithelial cells and 
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human broncho-alveolar epithelial cells were used in this study to assess the ability of 
the serotype 1 isolates to adhere to tissue in comparison to other serotypes and to assess 
possible differences between the different serotype 1 isolates. No differences were 
observed in the ability of the different serotype 1 isolates to adhere to nasopharyngeal 
epithelial cells. Furthermore, the ability to adhere to these cells was similar in serotype 
1 isolates and the D39 strain, although significantly lower than the non-typeable strain. 
However, there was a significant difference in their ability to invade nasopharyngeal 
epithelial cells, with the meningitis isolate being the only one able to cause invasion. 
Although invasion was only seen in one of the three repeats done for the experiment, 
these observations suggested that the meningitis isolate may be better at invading host 
cells and therefore could be better adapted to translocate between tissues. Although 
invasion was also observed for the non-typeable strain, the numbers of invading 
bacteria for this strain were very low when compared to the number of adhered 
bacteria. Whilst 14% of the adhered meningitis bacteria were able to invade the 
nasopharyngeal epithelial cells, only 0.04% of the adhered non-typeable bacteria were 
able to cause invasion. Considering that the levels of adhesion were similar in all of 
the encapsulated strains, the increased ability of the meningitis isolate to invade is most 
likely to be an adapted characteristic particular to this strain and clearly associated with 
enhanced invasiveness, a potential key factor in its ability to translocate through the 
brain-blood barrier. The genetic changes leading to this acquired characteristic, remain 
to be determined. 
In broncho-alveolar epithelial cells no adhesion or invasion was observed for any of 
the encapsulated isolates, the exception being the non-typeable isolate, which was the 
only strain able to adhere and invade in those cells. Previous studies have shown that 
the pneumococcus is able to adhere to broncho-epithelial cells; however, the 
Chapter 7: Discussion 
201 
 
bacteria:cell ratio in the published experiments was different from the ratio used in this 
study, a variable that has previously been show to influence the adhesion and invasion 
rates in vitro [313, 382].  
 
7.2.3. Capsule thickness 
An important virulence factor that has been shown to have an impact in the adherence 
of the pneumococcus is the capsule. The exposure of adhesins and other surface 
molecules is increased in the absence of capsule, therefore, unencapsulated isolates are 
more able to adhere to epithelial cells. Furthermore, the ability to modify capsule 
thickness in encapsulated isolates has been shown to be an adaptation of the 
pneumococcus to increase adherence to host surfaces (by reducing capsule) or to evade 
the host immune system during invasiveness (by increasing capsule) [56, 58, 60, 61]. 
Nonetheless, the thickness of the capsule is not the only variable having an effect on 
adherence and invasiveness since it has been shown that capsular type also determines 
the interaction of pneumococcal surface proteins and adhesins with the host surfaces 
[70, 71]. Furthermore, capsular type influences the levels of C3 deposition on the 
bacterial surface and determines the vulnerability of the pneumococcus to 
phagocytosis [71]. It has been proposed that the biochemical structure of the different 
capsular types influence the accessibility and functionality of surface proteins; 
therefore, differential expression of surface proteins might be altered to overcome 
these differences [70-72].  
The capsule thickness, the vulnerability to phagocytosis and the levels of complement 
deposition were determined in the three serotype 1 isolates and compared to the 
serotype 2 strain D39. It was observed that the capsule thickness of the bacteraemia 
and the meningitis isolates was similar to D39, nonetheless, the capsule of the carriage 
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serotype 1 isolate was significantly thicker than the bacteraemia and the meningitis 
serotype 1 isolates as well as the serotype 2 strain D39. These observations contradict 
the current dogma that suggests that carriage isolates reduce the expression of their 
capsule to increase their ability to adhere to host surfaces. Since the variation of 
capsule thickness is a transient adaptation to a specific niche, it is likely that the 
differences in capsule thickness are only temporary and not reproducible in vitro. In 
order to compare the capsule thickness of the different isolates it would be interesting 
to determine and compare the thickness of the capsule in the different niches in vivo 
and at different stages of infection, which might also have an effect on polysaccharide 
production. 
 
7.2.4. Opsonophagocytic killing assay 
During an opsonophagocytic killing assay where the bacteria were opsonised using 
commercial intra-venous IgG, it was observed that the serotype 1 strains were more 
resistant to phagocytosis by HL-60 neutrophils than the serotype 2 strain. However, 
no differences were observed between the two serotype 1 isolates used in the OPKA 
experiments; the bacteraemia and the meningitis isolates. Since no differences were 
observed between the capsule thickness of the meningitis and bacteraemia serotype 1 
isolates and the serotype 2 strain, the levels of C3 deposition were determined to 
elucidate the mechanisms through which the serotype 1 isolates were more resistant to 
phagocytosis by HL-60-derived neutrophils than the serotype 2 strain. 
 
7.2.5. Complement deposition 
The C3 deposition on the surface of the different isolates showed that the three 
serotype 1 isolates (meningitis, bacteraemia and carriage) had a lower deposition of 
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the complement protein C3 on their surface when compared to the serotype 2 strain. 
No differences were observed between the serotype 1 isolates suggesting that the 
overall biochemical structure of the type 1 capsule might have an effect on the binding 
of complement proteins to the bacterial surface. Whilst most pneumococcal serotypes 
have a neutral or a negatively charged capsule, the serotype 1 capsule contains both 
negative and positive charges [383]. The positive charges found in the serotype 1 
capsule is due to the presence of amino groups (NH3
+) which have previously been 
linked to reduced complement deposition [384,385].  
 
In summary, in vitro characterisation of serotype 1 isolates showed that the capsule of 
serotype 1 may have a role in reducing the levels of surface binding by complement 
proteins resulting in reduced phagocytosis by the host, therefore making this serotype 
more resistant to host killing and hence more virulent. Moreover, it was observed that 
the meningitis isolate was the only encapsulated isolate able to invade nasopharyngeal 
epithelial cells, although only at very low rates. This observation suggests that this 
isolate might have developed mechanisms to be more invasive by increasing its ability 
to translocate between tissues. For that reason, in vivo models of invasive disease and 
nasopharyngeal carriage were used to determine possible differences in the virulence 
of the different serotype 1 isolates.   
 
7.3. Serotype 1 during invasive disease 
7.3.1. Progression of infection 
The virulence of the different serotype 1 isolates was determined using a well-
established in vivo model of invasive pneumonia in mice [254]. When serotype 2 strain 
D39 is used in this model, mice start showing signs of disease approximately 24h post-
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infection and become moribund by 48h post-infection with only up to 10-20% 
surviving the infection. In this study, when the serotype 1 isolates were used in this 
same infection model, there was also a final survival of approximately 10-20%. 
However, the progression of disease in serotype 1 infected mice was substantially 
faster than in mice infected with the serotype 2 strain; approximately 80-100% of the 
mice succumbed to the infection between 24h and 48h post-infection [254].    
When the different serotype 1 isolates were compared, it was observed that the 
meningitis isolate was significantly more virulent than the bacteraemia and the 
carriage isolates. However, when the progression of infection was analysed using a 
timecourse experiment, no significant differences were observed in the bacterial load 
in the tissues analysed in mice infected with the bacteraemia and the meningitis 
serotype 1 isolates.  
Pneumococcal meningitis is believed to occur by either translocation of bacteria from 
blood to the meninges through the blood-brain barrier, or through direct translocation 
from the nasopharynx and the middle ear to the meninges during asymptomatic 
carriage or during otitis media [13]. The mechanisms that determine whether the 
pneumococcus is able to translocate from the blood or the nasopharynx to the 
meninges are, however, unclear [380]. A recent genome comparison of pneumococcal 
isolates collected from the blood of bacteraemia patients or from the CSF of meningitis 
patients has concluded that presence or absence of disease associated genes alone does 
not explain why some isolates are able to reach the meninges and others are not [380]. 
Nonetheless, in this study it was observed that the bacteraemia serotype 1 isolate 
tended to be able to translocate into blood quicker than the meningitis isolate, and that 
the meningitis isolate tended to be present in the brain at higher rates than the 
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bacteraemia isolate 24h post-infection, even though the bacterial numbers in blood 
were lower on that specific time-point for the meningitis isolate than for the 
bacteraemia isolate. Although these observations were not significant, they correlate 
with the invasion patterns observed in nasopharyngeal epithelial cells, where the 
meningitis isolate was the only encapsulated isolate able to cause invasion. For that 
reason, it would be interesting to study possible single nucleotide polymorphisms 
(SNPs) differences between the bacteraemia and the meningitis isolate, as well as 
possible differences in the gene expression of key virulence factors in vivo which may 
explain the increased invasiveness of the meningitis isolate when compared to other 
serotype 1 isolates. 
 
7.3.2. Host immune responses against invasive pneumococcal disease 
The host immune response against serotype 1 invasive disease in mice was studied and 
it was observed that mice succumbed to infection before the adaptive immunity could 
be effective. Therefore, the mechanisms activated in mice to fight against infection 
were those associated with innate immunity. However, although innate, it was a 
delayed response which failed to clear the infection.  
In the lung, there was an increase in the levels of IL-17 6h post-infection, which started 
the recruitment of neutrophils to the site of infection. This was followed by an increase 
of TNF-α and IL-6 24h post-infection, which are key markers of inflammation and the 
recruitment of neutrophils, respectively. These observations suggest that by 24h post-
infection it was highly likely that there was tissue damage, which would correlate with 
an increase of bacteria in the lung. In other serotypes such as serotype 2, D39 strain, 
there is an increase in T regulatory cells during invasive disease, but this study shows 
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that serotype 1 is not able to induce an increase of T regulatory cells, which may 
explain increased tissue damage caused by uncontrolled inflammation [386]. 
In blood, there was also an increase in the number of neutrophils in the last stages of 
infection which correlates with the increase observed in levels of IL-6, TNF-α and 
MIP-2, 24h post-infection. Similarly to lungs, there was an increase in the levels of 
IL-17, 6h post-infection, after which the number of neutrophils started increasing. The 
percentage of T regulatory cells in blood significantly increased throughout the course 
of infection; however, the percentage of T cells was reduced.  
In the brain, a low level of inflammation was observed with the levels of most 
cytokines remaining constant throughout the course of infection. Although, 
pneumococci started seeding into blood as soon as 3h post-infection, there was no 
translocation into the brain until 12h to 24h post-infection. These observations suggest 
that the brain is kept clear of pneumococcal infection (at least until the infection 
becomes systemic by 24hrs) in order to avoid inflammation, which clearly can be 
significantly detrimental for the survival of the individual [314]. 
 
In summary, serotype 1 is a highly invasive serotype that has been shown to be more 
virulent than the serotype 2 strain used in this study. Intra-serotype virulence 
differences were observed, with the meningitis isolate being significantly more 
invasive than the bacteraemia and the carriage isolates, which correlates with the 
increased levels of invasion previously observed with the meningitis isolate. 
Furthermore, unlike other serotypes, serotype 1 induces a delayed innate immune 
response in mice during invasive pneumococcal disease, which also fails to clear the 
infection and eventually leads to their death through lack of control of infection in 
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lungs and seeding of pneumococci into blood, causing uncontrollable systemic 
disease. Moreover, unlike other serotypes, serotype 1 fails to induce T regulatory cells 
which is likely to lead to uncontrolled inflammation resulting in increased host tissue 
barrier damage and therefore increased spread and invasiveness of the pneumococcus. 
 
7.4. Serotype 1 during nasopharyngeal carriage 
7.4.1. Bacterial progression 
Serotype 1 is rarely found during nasopharyngeal carriage [269, 270]. Since 
nasopharyngeal carriage is a pre-requisite for invasive disease, it is key to understand 
the patterns of infection by serotype 1 to understand how it is transmitted and therefore, 
possibly reduce the incidence of disease caused by this serotype. 
The three serotype 1 isolates were tested in a well-characterised in vivo model of long 
term nasopharyngeal carriage in mice to determine the pattern of colonisation of 
serotype 1 and to determine possible differences between the isolates from different 
host niches. The serotype 2 strain D39 is able to colonise the nasopharynx of mice for 
a minimum of 28 days at a relatively stable density [238]; however, the serotype 1 
isolates were only able to establish colonisation for an average of 14 days. Other 
serotypes were tested in this study such as 6B and 19F which are serotypes highly 
associated with nasopharyngeal carriage [29]. Similarly to serotype 2, 6B and 19F 
isolates were able to establish stable colonisation at a constant density of 102 to 103 
bacteria/mg of nasopharynx throughout the duration of carriage which varies for each 
serotype (28 days for serotype 2, 21 days for serotype 6B and a minimum of 14 days 
for serotype 19F): however, the density of serotype 1 was highly variable throughout 
the same colonisation period. Initially, serotype 1 colonised at a density of 101 to 102 
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bacteria per mg of nasopharyngeal tissue, which increased up to 103 during the first 
three days post-infection, only to start declining until eventually cleared, by 14 - 21 
days post-infection. No significant differences were observed in the patterns of 
nasopharyngeal carriage of the three serotype 1 isolates suggesting that, independently 
of the site of isolation, ST217 serotype 1 isolates might behave similarly during 
nasopharyngeal colonisation in vivo. In summary, serotype 1 is able to establish 
nasopharyngeal colonisation, but for a shorter period of time and at lower bacterial 
density than other serotypes (2, 6B and 19F). 
 
7.4.2. Host immune responses to pneumococcal nasopharyngeal colonisation 
Detailed host immune responses during nasopharyngeal carriage have been previously 
studied, leading to the conclusion that the induction of immuno-modulatory cytokines 
such as IL-10 and TGF-β1 by the pneumococcus, as well as an increased numbers of 
T regulatory cells, leads to the longer term maintenance of pneumococcal carriage 
[104]. However, if immune-regulatory responses are not instigated the pneumococcus 
can be cleared from the nasopharynx by pro-inflammatory responses instead. In this 
study it was observed that serotype 1 failed to induce immune-regulatory responses, 
and increases in cytokines associated with pneumococcal clearance was observed 
which correlated with a decline in bacterial numbers in the nasopharynx. Hence, these 
observations suggest that serotype 1 is not able to induce the production of immune-
modulatory cytokines or T regulatory cells and instead drives an increase of pro-
inflammatory cytokines involved in pneumococcal clearance. However, previous 
studies have shown that purified serotype 1 capsule can activate CD4+ T cells after 
intra-peritoneal injection inducing IL-10 and TGF-β, which provide immune tolerance 
[296, 297]. This contradictory result can be explained by the different experimental 
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protocols used. The studies that suggest induction of T regulatory cells and IL-10 and 
TGF-β1 cytokines were done using injected purified capsule, and it has been shown 
that although capsular type has an important effect on the host immune response 
against the pneumococcus, the interaction of the capsule with bacterial surface proteins 
anchored to the cell wall can alter the host immune response [70, 71]. The 
pneumococcus produces many virulence factors that have been shown to have an effect 
on immune activation, pro-inflammation and disease progression; moreover, there are 
differences in presence and absence of certain virulence factors and in the expression 
of those. Therefore, studying the effect of purified capsule in vivo might not be 
reflective of the host immune responses to intact bacteria.   
As previously mentioned, serotype 1 is able to establish nasopharyngeal carriage but 
for a shorter period of time and at a lower density than other serotypes. However, it 
was still able to induce serotype-specific IgG in mice between days 7 and 14 post-
infection. During carriage with the serotype 6B there was also an increase in IgG 
between days 7 and 14 post-infection, but the levels of IgG were not as high as in mice 
carrying serotype 1. The levels of IgG in serum returned to base-line levels by day 21 
post-infection suggesting that independently of serotype, the production of IgG occurs 
between days 7 and 14 post-infection. The increased IgG production in serotype 1-
carrying mice was probably due to the increased nasopharyngeal pneumococcal 
density when compared to serotype 6B. Therefore, IgG is always produced during the 
first 2 weeks of carriage, independently of serotype, and is likely to be proportional to 
the density of carriage. Nonetheless, the levels of IgG are in every case reduced back 
to initial levels. Although the levels of IgG in serotype 1-carrying mice was reduced 
in the last stages of carriage, re-infected mice were able to clear a newly-acquired 
serotype 1 infection much earlier than naïve mice, indicating that the IgG produced 
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during serotype 1 carriage is protective against future colonisation events. IgG 
generated during pneumococcal nasopharyngeal carriage has been proven to also be 
protective against invasive disease; however, this needs to be proven for serotype 1 
[238].   
An increase in nasopharyngeal IgA by day 14 was observed only in the mice still 
carrying the bacteria at that stage, suggesting that production of IgA in serotype 1 is a 
later immune response. Hence, it was observed than nasopharyngeal carriage with 
serotype 1 induces an adaptive memory response which prevents from further 
colonisation events. However, the long-term duration of this protection was not 
assessed in this study. 
 
7.4.3. Serotype 1 during nasopharyngeal co-colonisation with other serotypes 
Many studies have investigated the effect of inter-species nasopharyngeal co-
colonisation on the density, duration and serotype distribution of pneumococcal 
carriage [214, 381, 387, 388]. In addition, co-colonisation with multiple pneumococcal 
serotypes is also considered an important factor which affects progression into 
invasive disease, horizontal gene transfer and host-to-host transmission [389-391]. 
However, the incidence of multiple pneumococcal carriage is considered to be 
underestimated, with a study suggesting that the incidence of multiple carriage in 
Bangladesh can range from 3% when using the WHO recommended detection method, 
to 22% when using a novel molecular technique [392]. In sub-Saharan Africa, up to 
40% of the infants studied carried two or more serotypes at the sampling time [317, 
277].  
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Co-colonisation is believed to have an effect on acquisition of new serotypes, rather 
than in clearance of carriage [393]. However, in this study it was observed that 
although acquisition of a new serotype during co-colonisation is reduced, the 
acquisition of a new serotype can also change the carriage patterns of serotypes already 
colonising the nasopharynx. These observations were serotype-specific, given that 
only the density of serotype 19F increased with the acquisition of serotype 1 whilst 
this acquisition had no effect on the density of serotype 6B when this was the already 
pre-colonising serotype. 
In this study, it was observed that serotype 1 is able to colonise the nasopharynx of 
mice for a shorter period of time and at a lower density than other serotypes; it is likely 
therefore, that the transmission of serotype 1 occurs during the early stages of 
colonisation and is also likely to be acquired when a different serotype is already 
present in the nasopharynx. As the co-infection experiments suggest, if serotype 1 is 
acquired when another serotype is already colonising the nasopharynx, the duration 
and density of carriage by serotype 1 is even lower than during single-serotype 
colonisation suggesting that serotype 1 might be more successful at colonisation when 
no other serotypes are present in the nasopharynx. Considering that there is a high 
incidence of pneumococcal carriage in infants and the elderly, serotype 1 should be 
able to be more efficient during nasopharyngeal carriage in individuals that are not 
carrying the pneumococcus, i.e. young adults [8]. These observations may explain why 
the incidence of invasive pneumococcal disease caused by serotype 1 is higher in this 
age group, as opposed to other serotypes that affect mainly infants and the elderly [270, 
271, 272].  
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The limited carriage ability of serotype 1 is likely to reduce transmission; however, its 
high virulence results in high incidence of invasive disease by serotype 1 despite the 
low carriage rates. If the carriage rates of serotype 1 increased, this would lead to an 
even higher incidence of invasive disease caused by serotype 1. Since PCV13 has been 
shown to have limited efficacy against serotype 1 it is important to consider how the 
effect of the vaccine in the carriage incidence of other serotypes might lead to an 
increase of serotype 1 carriage and therefore, an overall increase in invasive disease 
cause by this serotype. These observations highlight the importance to develop a more 
efficient vaccine against serotype 1. 
 
7.5. Gene expression of serotype 1 
Differential gene expression is a relatively new technique that allows the comparison 
of levels of expression of genes that are key for virulence or for the metabolism of 
bacteria [164]. Some studies have been performed on the differential gene expression 
of a limited number of virulence factors in serotype 1 compared to other serotypes; 
however, a more extensive analysis was done in this study. The in vitro gene 
expression in serotype 1 of 24 key pneumococcal virulence factors and 11 pathways 
involved in metabolism was studied and compared to the in vitro gene expression in 
the serotype 2 strain D39. In the mouse models used in this study it was observed that 
serotype 1 is more virulent than serotype 2, but is less efficient at nasopharyngeal 
carriage; however, differential gene expression between these two serotypes was 
studied in vitro due to difficulties in extracting intact RNA from mouse. 
Between 25% and 40% of the orthologue genes were differentially expressed between 
the two serotypes, with a general down-regulation of pathways related to bacterial 
growth such as the metabolisms of sucrose, starch and galactose. It has previously been 
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shown that increased growth is linked to increased prevalence of carriage; therefore, 
the down-regulation of mechanisms involved in growth might explain the reduced 
ability of serotype 1 to carry [305].  
It was also observed that the biosynthesis of fatty acids is up-regulated in serotype 1 
when compared to serotype 2. Previous studies show that up-regulation of this 
metabolic pathway can increase the sensitivity of the pneumococcus to external low 
pH. The pH varies in different parts of the body; whilst the nasopharynx has a pH of 
approximately 6.2, the pH in blood is closer to 7.4. Therefore, the up-regulation 
observed in the biosynthesis of fatty acids in serotype 1 can increase the sensitivity of 
the pneumococcus in the nasopharynx when compared to blood, suggesting that for 
this serotype, the nasopharynx is a more hostile environment than blood. Moreover, a 
down-regulation was observed in genes involved in two-component systems, which 
are an important mechanism through which the pneumococcus is able to perceive and 
respond to environmental stimuli. Considering that the nasopharynx is a host niche 
where a variety of species are present, it is important to have an efficient mechanism 
to be able to respond to the constant external stimuli produced by other commensals 
of the nasopharynx. Therefore, the down-regulation of two-component systems in 
serotype 1 may reduce the ability of this serotype to change and adapt to the constant 
external stimuli present in the nasopharynx. These observations suggest that serotype 
1 is likely to survive more comfortably in a stable niche such as blood, instead of the 
nasopharynx where there is constant competition with other pneumococcal serotypes 
as well as other species. 
The analysis of the differential expression of the 24 virulence factors showed that 
virulence factors that are associated with carriage (i.e. choline binding proteins, 
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pneumococcal surface adhesins, pyruvate oxidase, pneumococcal adherence and 
virulence factor A and enolases) are down-regulated in serotype 1 when compared to 
serotype 2. In contrast, virulence factors associated with invasiveness, such as 
pneumolysin, capsule and hyaluronidase lyase, were found to be up-regulated in 
serotype 1 when compared to serotype 2.  
These observations suggest that serotype 1 is less adapted to colonisation and 
adherence to nasopharyngeal cells and is more likely to be successful at surviving in 
blood than in the nasopharynx, which is a more dynamic environment. Therefore, not 
only does serotype 1 increase the expression of genes encoding key virulence factors 
that are involved in invasiveness and protective against host immunity (such as 
pneumolysin and capsule) but it also decreases the expression of those genes related 
to adherence and nasopharyngeal carriage, adapting itself to conditions more 
favourable to survival in blood for example than in the nasopharynx.  
 
7.6. Summary 
This study shows that serotype 1 is a highly invasive serotype that is able to cause 
nasopharyngeal colonisation but for a shorter period of time and at a lower density 
than other serotypes. The zwiterionic capsule it has, exhibits both negative and positive 
charges and these positive charges might prevent the deposition of the complement 
protein C3b on the surface of the bacteria therefore reducing its susceptibility to 
phagocytosis and therefore increasing its virulence. 
Moreover, differential gene expression of serotype 1 and serotype 2 showed that those 
virulence factors involved in nasopharyngeal carriage were down-regulated in 
serotype 1, whilst virulence factors involved in invasiveness were up-regulated when 
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compared to serotype 2. These observations suggest that serotype 1 is not adapted to 
be a successful coloniser, for which it has had to develop mechanisms to overcome the 
reduced spreading opportunities. Nasopharyngeal carriage is the main reservoir for the 
pneumococcus and therefore essential for transmission; however, the pneumococcus 
is also able to transmit during pneumonia. Given the reduced ability to establish 
nasopharyngeal carriage, serotype 1 may have developed mechanisms to transmit 
during pneumonia episodes instead of during asymptomatic colonisation. Pneumonic 
spread of bacteria has been shown to be more virulent than carriage spread, probably 
due to the up-regulation during invasiveness of key virulence factors [394]. Although 
the mechanisms leading to this increased virulence remains unclear, it is likely to be a 
consequence of increased expression of major virulence factors during pneumonia; 
when the pneumococcus is then transmitted during coughing or sputum it is already 
highly virulent and is therefore ready to invade. This theory may explain why serotype 
1 is a major cause of disease outbreaks and is commonly isolated from communities 
where a recent outbreak occurred [269].  
Additionally, it was observed that the three ST217 serotype 1 isolates used in this study 
showed no differences during adherence in vitro and during nasopharyngeal carriage 
in vivo; however, significant differences were observed in invasiveness, both in vitro 
and in vivo. These observations suggest that the ability to cause nasopharyngeal 
carriage in serotype 1 might be determined by capsule whilst the ability to cause 
invasive disease might be determined by other non-capsular determinants such as 
pneumolysin, IgA protease, neuraminidases, hyaluronidase lyase or the pneumococcal 
adherence and virulence factor PavA. 
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7.7. Research limitations 
Although the aims of this study were accomplished, there were some limitations that 
need to be taken into account. First, only one isolate form each collection site (i.e. 
blood, CSF, nasopharynx) was used for investigation; a bigger sample size would have 
been more representative. There was also a limitation in the number of mice that could 
be used for each in vivo experiment. According to the principle of the 3Rs, animal 
work should be replaced when possible, the number of animals should be reduced 
when possible, and the methods used during animal work should be refined to 
minimise animal suffering. For that reason, a small number of animals were used for 
these experiments which compromised, in some cases, the statistical analysis of the 
results. Finally, financial limitations lead to reduced in-depth studies of the gene 
expression of serotype 1 by limiting the transcriptomic study to only the bacteraemia 
isolate.   
 
7.8. Future work 
In this study it was found that the host immune responses to ST217 serotype 1 isolates 
are different from those to other serotypes, although, the mechanisms leading to these 
different responses are still unknown. For that reason, further study is needed to 
understand the mechanisms that lead to the differential induction of host immunity in 
this serotype compared to other clinical serotypes. 
It was observed that nasopharyngeal co-colonisation had an effect on the carriage 
patterns of the pre-colonising serotype and also on the carriage patterns of the newly-
acquired serotype; however, this effect was different depending on the serotype 
combinations used during co-colonisation. A deeper investigation is needed on the 
interaction of serotypes and their effect on carriage and invasiveness, for that reason a 
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wider range of serotypes should be studied in co-colonisation studies to further 
understand the mechanisms that lead one serotype to enhance the density of one 
serotype but not others.   
The in vitro study of the differential gene expression of the bacteraemia serotype 1 
isolate compared to the serotype 2 reference strain D39 showed important differences 
in the metabolism and the expression of virulence factors of those isolates.  
It would be interesting to study the differential genes expression of serotype 1 and 
serotype 2 in vivo; however, there are currently limitations in the process of extraction 
of good quality and importantly quantity of RNA from tissue to be able to undertake 
RNAseq analysis. When the extraction of RNA from tissue is optimised it would be 
interesting to do the analysis of gene expression of serotype 1 in vivo at different stages 
of infection and using bacteria collected from different sites of infection (nasopharynx, 
lung, blood and brain). Moreover, considering the findings of this study it would be 
interesting to study the gene expression of the meningitis isolate to understand the 
mechanisms that make this isolate more invasive than the bacteraemia and the carriage 
isolates.  
In summary, the unique nature of the capsule of serotype 1 is likely to influence its 
inability to maintain longer periods of nasopharyngeal colonisation; however, this 
inability may also have allowed serotype 1 to develop other mechanisms of survival, 
such as causation of invasive disease, with the progression of pneumonia acting as an 
alternative method of transmission for this serotype. 
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9. Appendix 
 
9.1. Appendix 1: Nasopharyngeal carriage by the serotype 1 strain C9174 
 
 
 
Figure 87. Pneumococcal CFU per mg of nasopharyngeal tissue of MF1 mice infected with the 
low haemolytic serotype 1 isolate (C9471), the bacteraemia (A42174), the meningitis (B13969) 
and the carriage (W004030) isolates at days 0, 1, 3 and 7 post-infection shown as median value 
(a) and CFU of individual mice (b). Three mice were used for the day 0 control, and five mice 
were used for the rest of the time-points. No significant differences were observed when 
analysed using a two-way ANOVA. 
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9.2. Appendix 2: Functional category analysis of the different growth phases 
 
Figure 88. Pairwise comparison showing the percentage of genes in each pathway that are up or 
down-regulated in A42174 when compared to D39 during the Early Exponential Phase 
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Figure 8927. Pairwise comparison showing the percentage of genes in each pathway that are up 
or down-regulated in A42174 when compared to D39 during the Mid Exponential Phase 
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Figure 9028. Pairwise comparison showing the percentage of genes in each pathway that are up 
or down-regulated in A42174 when compared to D39 during the Late Exponential Phase 
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Figure 91. Pairwise comparison showing the percentage of genes in each pathway that are up or 
down-regulated in A42174 when compared to D39 during the Early Stationary Phase 
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Figure 92. Pairwise comparison showing the percentage of genes in each pathway that are up or 
down-regulated in A42174 when compared to D39 during the Late Stationary Phase 
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9.3. Appendix 3: Absolute expression of virulence factors in D39 and A42174.  
 
 
 
 
 
 
 
Figure 9329. Absolute expression values of bgaA in D39 and A42174. 
 
 
 
 
 
 
Figure 94. Absolute expression values of cbpA in D39 and A42174. 
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Figure 95. Absolute expression values of cbpC in D39 and A42174. 
 
 
 
 
 
 
Figure 96. Absolute expression values of cbpD in D39 and A42174. 
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Figure 97. Absolute expression values of cbpE in D39 and A42174. 
 
 
 
 
 
 
 
Figure 98. Absolute expression values of cbpG in D39 and A42174. 
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Figure 9930. Absolute expression values of cps2A in D39 and A42174. 
 
 
 
 
 
 
Figure 100. Absolute expression values of cps2B in D39 and A42174. 
 
 
 
 
 
 
 
Appendix 
262 
 
 
 
 
 
 
 
Figure 10131. Absolute expression values of cps2K in D39 and A42174. 
 
 
 
 
 
 
 
Figure 10232. Absolute expression values of eno in D39 and A42174. 
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Figure 103. Absolute expression values of hyl in D39 and A42174. 
 
 
 
 
 
 
Figure 10433. Absolute expression values of igA in D39 and A42174. 
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Figure 105. Absolute expression values of lytA in D39 and A42174. 
 
 
 
 
 
 
 
Figure 106. Absolute expression values of nanA in D39 and A42174. 
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Figure 10734. Absolute expression values of nanB in D39 and A42174. 
 
 
 
 
 
 
 
Figure 10835. Absolute expression values of pavA in D39 and A42174. 
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Figure 109. Absolute expression values of ply in D39 and A42174. 
 
 
 
 
 
 
 
Figure 110. Absolute expression values of psaB in D39 and A42174. 
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Figure 11136. Absolute expression values of psaC in D39 and A42174. 
 
 
 
 
 
 
 
Figure 112. Absolute expression values of pspA in D39 and A42174. 
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Figure 113. Absolute expression values of spxA in D39 and A42174. 
 
 
 
 
 
 
 
Figure 11437. Absolute expression values of spxB in D39 and A42174. 
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Figure 115. Absolute expression values of srtA in D39 and A42174. 
 
 
 
 
 
 
 
Figure 116. Absolute expression values of strH in D39 and A42174. 
  
 
 
 
 
 
 
